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One in four adults aged 65 years and older in the United States has diabetes. For diabetes 
patients, adherence to diabetes medications is essential to preventing negative health outcomes 
related to poor blood glucose control. In the elderly, the high costs of medication have been 
identified as a major barrier to medication adherence. The purpose of this study is to identify 
independent determinants (patient, health system, provider factors) of medication adherence in 
adults with diabetes (Aim 1), and to examine whether Medicare Part D (a recent policy effort to 
reduce the financial burden of prescription drugs for the elderly) effectively decreases the 
proportion of out-of-pocket pharmacy costs for elderly diabetes patients (Aim 2). To answer 
these aims, the author analyzed data from the Medical Expenditure Panel Survey, which enables 
the generation of national- and regional-level estimates of health care use and expenditures for 
non-institutionalized U.S. civilians. 
A cross-sectional design was employed for Aim 1. Medication adherence, the outcome 
variable for Aim 1, was defined as a Proportion of Days Covered (PDC) ≥ 80% over a 1-year 
period using pharmacy refill data. First, to compare the characteristics of adherent and non-
adherent patients, Wald chi-square tests and simple logistic regression analyses were performed 
for categorical and continuous variables, respectively (Aim 1-1). Second, multivariate logistic 
regression analyses were also used to identify independent factors related to medication 
 
adherence in adults with diabetes (Aim 1-2). Nine hundred and ninety-two adults with diabetes 
(833 adherent, 159 non-adherent) were included in these analyses. 
For Aim 2, a segmented regression of an interrupted time series design was employed 
(Aim 2-1) and difference-in-difference analyses were used (Aim 2-2) to evaluate whether 
Medicare Part D was effective at decreasing the proportion of out-of-pocket pharmacy costs for 
elderly patients with diabetes. For these analyses, 8,176 adults with diabetes [4,717 aged ≥ 65 
years; 1,933 pre-Part D and 2,784 post-Part D (1,558 beneficiaries; 1,226 non-beneficiaries) and 
3,459 aged 50‒60 years (comparison group)] were used. 
In the analyses for Aim 1-1, the following eight variables were statistically different 
between adherent and non-adherent patients: age, gender, race/ethnicity, diabetes duration, 
HbA1c test, type of health insurance, proportion of out-of-pocket costs for prescription drugs, 
and provider communication. Of the 11 variables studied [8 variables from Aim 1-1, and 3 
variables from the literature review (family support, depressive symptoms, and diabetes self-
efficacy)] that met criteria for inclusion in the multivariate models, 4 factors (age ≥ 65 years, 
male gender, non-Hispanic white race and provider communication) independently predicted 
medication adherence among adults with diabetes (Aim 1-2). Provider communication was a 
facilitator of medication adherence whereas younger age, female gender, non-Hispanic black and 
Hispanic race/ethnicity were associated with poor adherence to diabetes medication. 
Following Medicare Part D implementation, elderly patients with diabetes, including Part 
D beneficiaries and non-beneficiaries, had a 13.5% decrease (SE = 2.2%, p < .0001) in the level 
of the proportion of out-of-pocket costs for prescribed drugs compared to before (years 2000‒
2005), with 5.5% lower (SE = 1.2%, p < .0001) out-of-pocket prescription drug costs for 
beneficiaries compared to non-beneficiaries on average. Controlling for potential confounding 
 
factors using the comparison group, Medicare Part D decreased out-of-pocket pharmacy costs by 
16.2% (SE=1.6%, p < .0001) among elderly adults with diabetes. However, the proportion of 
Part D beneficiaries with diabetes who exceeded the initial coverage limit, where beneficiaries 
were responsible for 100% of total prescription drug costs, increased from 58.1% (2006) to 
72.1% (2011). This is significantly higher than the rate reported in prior studies, which showed 
that approximately 25% of Medicare Part D beneficiaries with diabetes enter the coverage gap. 
Improved patient-provider communication is essential to improved medication 
adherence. Healthcare providers need to understand the circumstances of patients’ medication 
non-adherence. Furthermore, to minimize gender and racial/ethnic disparities in medication 
adherence, legislation efforts are needed to increase health care access, coverage and utilization 
among gender and racial/ethnic minorities. This study lends support to current efforts to both 
maintain and improve Part D policy with the goal of removing cost-related barriers to adherence 
in the elderly. However, further research is crucial to understanding the effect of current policy 
efforts through the Affordable Care Act (2010) to eliminate the Medicare Part D coverage gap 
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Impact of Out-of-pocket Pharmacy Costs and Medicare Part D 
on Medication Adherence among Adults with Diabetes 
Chapter I: Introduction 
 This chapter presents the significance of out-of-pocket costs for medication adherence in 
elderly diabetes patients and background information on Medicare Part D and its coverage gap, 
known as the donut hole. Then, the specific aims and hypotheses of this study are introduced. 
Background 
Diabetes mellitus is a leading cause of morbidity and mortality as well as excessive 
healthcare costs among the elderly in the United States (Centers for Disease Control and 
Prevention, 2011a, 2011b). Diabetes may lead to severe and irreversible complications such as 
kidney failure, blindness, non-traumatic lower limb amputation, and even death (Centers for 
Disease Control and Prevention, 2011b). In addition, total medical costs for diabetes patients are 
twice as high as those for people without diabetes (Centers for Disease Control and Prevention, 
2011b). The total estimated medical expenses for diabetes in the U.S. (2007) have reached 
almost $174 billion (Centers for Disease Control and Prevention, 2011b). 
Although lifestyle modification is a first step in managing diabetes, regular use of 
medication is an essential treatment strategy for both type 1 and 2 diabetes (American Diabetes 
Association, 2013b). Poor treatment adherence leads to almost twice higher risk of 
hospitalization [OR=2.5, 95% CI (1.4, 4.6)] (Lau, 2004) and mortality [OR=1.8, 95% CI (1.5, 
2.2)] (Ho, 2006) as adherent diabetes patients. 
Problem Statement 




26.9% of the adults aged 65 years and older in the U.S. have diabetes. The proportion of the 
elderly affected by diabetes is the largest among all age groups; the prevalence of diabetes in the 
elderly is from two to seven times higher compared to other age groups (20–44 years: 3.7%; 45–
64years: 13.7%) (Centers for Disease Control and Prevention, 2011b). 
 Non-adherence to medication increases with age, and is generally higher in the elderly 
compared to younger patients (Bardel, Wallander, & Svardsudd, 2007; Briesacher, Gurwitz, & 
Soumerai, 2007; Ekedahl & Mansson, 2004; Kennedy & Morgan, 2009; Kennedy, Tuleu, & 
Mackay, 2008). The elderly experience cognition decline as a natural result of the aging process, 
and may forget to take their medication as prescribed (Gadkari & McHorney, 2012). In addition, 
recent studies have shown that diabetes can increase the effects of aging on cognition decline and 
improved blood glucose control may delay cognitive decline (Logroscino, Kang, & Grodstein, 
2004; Luchsinger et al., 2011; Wessels et al., 2011; Yaffe et al., 2012). Although lifestyle 
modification is strongly recommended for elderly diabetes patients (Wannamethee, Shaper, & 
Whincup, 2006), elderly people generally perceive changing past diet and exercise patterns to be 
difficult (Dye, Haley-Zitlin, & Willoughby, 2003) and lifestyle modification is not compelling 
for the elderly since they often believe that it is too late to change old habits going forward 
(Polly, 1992). 
 Since medication non-adherence is a complex behavior determined by complicated 
relationships among various factors (Bardel et al., 2007; Kennedy et al., 2008) that increases risk 
for severe health outcomes for patients with chronic disease, identifying determinants of 






 Among elderly diabetes patients, one of the most frequently discussed reasons for non-
adherence to diabetes medication is due to their high cost (Vijan et al., 2005). Diabetes 
management requires long-term and consistent financial commitment (American Diabetes 
Association, 2013a); however, poor or retired elderly patients have difficulty purchasing their 
prescribed medications due to high out-of-pocket costs (Briesacher et al., 2007; Kennedy et al., 
2008; T. Lynch, 2006). Khan and Kaestner (2009) found that medication utilization is positively 
related to prescription drug coverage. However, approximately 10% of the elderly still don’t 
have any drug coverage (Kaiser Family Foundation, 2012). 
According to Wick (2011)’s study, elderly patients often discontinue their prescribed 
medication because the financial burden of obtaining their medications is greater than the 
perceived benefit of taking them. Most elderly people have retired from their work and rely on 
fixed incomes; patients with chronic illnesses often feel discouraged from taking prescribed 
medications because of financial burdens (Briesacher et al., 2007; Kennedy et al., 2008; T. 
Lynch, 2006). 
In order to decrease these financial burdens and enhance prescription medication 
coverage for the elderly, Medicare Part D, a government health insurance program, went into 
effect on January 1, 2006 as part of the Medicare Prescription Drug, Improvement, and 
Modernization Act of 2003 (O'Sullivan, 2008). This program supports the costs of prescription 
medications for Medicare beneficiaries in the United States (O'Sullivan, 2008). 
Although Medicare Part D went into effect in 2006, 15% of beneficiaries discontinued 
their medications when they fell into the coverage gap, also called the Medicare donut hole 




program, however, Medicare Part D has a coverage gap, which lies between the initial coverage 
limit and the program’s catastrophic threshold (O'Sullivan, 2008). Figure 1.1 illustrates the 
structure of Medicare Part D design and how the coverage gap and catastrophic coverage are 
defined according to the deductible, initial coverage limit, and catastrophic threshold. 
 
 Catastrophic coverage 
 









Initial coverage limit→ 
 







Out-of-pocket costs  
(100%)  
 
Figure 1.1. Medicare Part D plan design: Coverage gap and catastrophic coverage. 
 
Before Medicare Part D enrollees reach the initial coverage limit, they are responsible for 
paying 25% of the cost of the prescribed drugs (O'Sullivan, 2008). However, during the coverage 
gap, beneficiaries must pay 100% of prescribed medication cost until reaching the catastrophic 
threshold level (O'Sullivan, 2008). In 2006, approximately 25% of individual Medicare 
Advantage Prescription drug plan beneficiaries entered the donut hole and 4% reached the 
catastrophic threshold (Y. Zhang, Donohue, Newhouse, & Lave, 2009). The U.S. Department of 




discontinue taking their drugs as prescribed due to the burden of cost when they reach the donut 
hole. 
With the Patient Protection and Affordable Care Act of 2010, people who entered the 
coverage gap in 2010 received a $250 rebate from the Centers for Medicare and Medicaid 
Services (Kaiser Family Foundation, 2013). Beginning in 2011, the coverage gap will be 
gradually reduced and the gap will be completely eliminated by the year 2020 (Kaiser Family 
Foundation, 2013). Evidence is lacking regarding the effect of Medicare Part D on out-of-pocket 
pharmacy costs and medication adherence in elderly diabetes patients. 
 Increased understanding of the factors that influence non-adherence to medications 
through this study will enhance the understandings of health care professionals and policy 
makers and enable them to develop more effective policy strategies to reduce healthcare costs 
and improve medication adherence in elderly diabetes patients. 
Specific Aims and Hypotheses 
Research question 1: What factors predict medication adherence in adult patients1 with 
diabetes? 
The target population for Aims 1-1 and 1-2 was non-institutionalized U.S. residents aged 
19 years and older who reported a diagnosis of diabetes and had at least two prescription records 
of diabetes medication(s)2. Medication adherence, the outcome variable for Aims 1-1 and 1-2 
was calculated using Proportion of Days Covered (PDC) over a 1-year period. Patients who had 
a PDC ≥ 80% were defined as adherent to medications. 
                                                 
1 The sample for Aims 1-1 and 1-2 was not limited to the elderly (≥ 65 years) as limiting the data to the elderly 
reduced the sample size and the power to detect a significant statistical effect. 
2 To calculate medication adherence, at least two prescription records were needed to determine the period that the 




Aim 1-1: To compare the characteristics of adult diabetes patients who are adherent to 
those of patients who are non-adherent to diabetes medications. 
Hypothesis 1-1: The patient, health system, and provider characteristics of 
adherent (annual PDC ≥ 80%) adults (≥ 19 years) with diabetes are statistically 
different from those of non-adherent adult diabetes patients. 
Aim 1-2: To identify the independent barriers to and facilitators of adherence to diabetes 
medications among adult patients with diabetes. 
Hypothesis 1-2: Patient factors [demographics (age < 65 years, female gender, 
black/African American race, fewer years of formal education, living alone, 
poverty), coexisting illnesses (depressive symptoms, higher number of major 
comorbid conditions, longer duration of time with diabetes), diminished cognitive 
function, and negative illness representation (less confidence in diabetes self-
care), poorly perceived health status (poor physical and mental health status), 
negative health behaviors (smoking, less diabetes-related routine check-ups, fewer 
other preventive efforts)] are negatively associated with adherence to diabetes 
medication (annual PDC ≥ 80%) in adult patients (≥ 19 years) with diabetes. 
Hypothesis 1-3: Health system factors (higher out-of-pocket pharmacy costs, 
uninsured, and difficulty having timely usual care) are negatively associated with 
adherence to diabetes medication (annual PDC ≥ 80%) in adult (≥ 19 years) 
diabetes patients. 
Hypothesis 1-4: Provider factors (lower patient satisfaction with providers) are 
negatively associated with adherence to diabetes medication (annual PDC ≥ 80%) 




Research question 2: Has the implementation of the Medicare Part D program decreased the 
proportion of out-of-pocket pharmacy costs for the elderly who have diabetes? 
The target population for Aims 2-1 and 2-2 was non-institutionalized U.S. residents aged 
65 years and older who reported a diagnosis of diabetes and had been prescribed at least one 
diabetes medication. The outcome variable for Aims 2-1 and 2-2 was the proportion of out-of-
pocket costs for prescription drugs and defined as out-of-pocket costs at pharmacies divided by 
total pharmacy expenses. Out-of-pocket pharmacy costs were directly reported by pharmacists 
and measured as actual dollar values of the amount of payments by patients or family for 
prescription drugs received. 
Aim 2-1: To compare the trend of the proportion of out-of-pocket pharmacy expenditures 
from 2000 to 2011, including prior to (2000–2005) and subsequent to (2006–2011) the 
implementation of Medicare Part D, between elderly (including Part D beneficiaries and 
non-beneficiaries) and non-elderly adults with diabetes. 
Hypothesis 2-1: Subsequent to the implementation of Medicare Part D, the 
proportion of out-of-pocket pharmacy costs decreased over time for elderly adults 
(≥ 65 years) with diabetes compared to the non-elderly adults (50–60 years) with 
diabetes. 
Hypothesis 2-2: Subsequent to the implementation of Medicare Part D, among 
elderly adults (≥ 65 years) with diabetes, the proportion of out-of-pocket 
pharmacy costs decreased over time for the Medicare Part D beneficiaries with 





Aim 2-2: To examine the effect of the implementation of Medicare Part D on the 
proportion of out-of-pocket pharmacy expenditures for the elderly (≥ 65 years) 
with diabetes.Hypothesis 2-3: After the implementation of Medicare Part D, 
elderly adults (≥ 65 years) with diabetes had a greater decrease in the proportion 





Chapter II: Literature Review 
 This chapter summarizes current knowledge that has informed the methodology and 
hypotheses for the proposed study. First, this chapter reviews and compares measurement of 
adherence using patient self-report, pharmacy refill records, and electronic lid measures. Second, 
prescription refill measurement is examined through a literature review to determine the best 
approach to calculation of adherence using these types of data, and the most common benchmark 
for pharmacy refill adherence. Third, a systematic review is conducted to identify barriers to 
and/or facilitators of medication adherence in diabetes patients. Fourth, this chapter will review 
the previous studies that focused on the impact of Medicare Part D and its coverage gap on out-
of-pocket pharmacy expenditures and medication adherence. Lastly, current gaps in knowledge 
that this study will examine are identified. 
Measurement of Medication Adherence 
 Medication adherence is defined as “the extent to which patients take medications as 
prescribed by their health care providers” (Osterberg & Blaschke, 2005). There are three main 
methods used to measure medication adherence: use of electronic lids on medication containers, 
patient self-reports, and prescription refill records. 
Electronic lids on medication containers. 
Electronic lid adherence is measured using the Medication Event Monitoring System 
(MEMS), a medication container that records the time and date of each bottle opening (van den 
Boogaard, Lyimo, Boeree, Kibiki, & Aarnoutse, 2011). This measure is considered the gold 
standard for the measurement of medication adherence (Hansen et al., 2009; van den Boogaard et 
al., 2011); however, it is rarely used in research because the devices are expensive and 





 Patient self-report is a commonly used method in research because it is easy to 
administer—it often does not require additional explanation or training—and cost-effective. 
However, self-report also has a high risk of bias. Since self-report solely depends on the patient’s 
memory, it may lead to a recall bias where patients may over- or under-report their adherence. In 
addition, because of social desirability, patients may over-report their adherence. 
 Diabetes medication adherence is commonly measured by one of two patient self-report 
measures: the Morisky scale and the Summary of Diabetes Self-Care Activities (SDSCA) scale. 
 The original Morisky Medication Adherence Scale (MMAS-4) (Morisky, Green, & Levine, 
1986) consists of four items (“Yes” = 0 and “No” = 1) with scores ranges from 0 to 4. The 
Morisky 8-item Medication Adherence Scale (MMAS-8) (Morisky, Ang, Krousel-Wood, & 
Ward, 2008) was developed in 2008 by adding four items to the MMAS-4 and modifying others. 
All questions require yes/no responses except for the last item, which uses a 5-point Likert 
response (Morisky et al., 2008). 
 The MMAS-8 showed good convergent and known-group validity among type 2 diabetes 
patients; the MMAS-8 was highly associated with the original Morisky scale (r = 0.8; p < .01), 
and there was a relationship between the MMAS-8 and blood glucose control (p < .05) 
(Sakthong, Chabunthom, & Charoenvisuthiwongs, 2009). The reliability of the MMAS-8 is 
greater (α = 0.8) (Morisky et al., 2008) than that of the MMAS-4 (α = 0.6) (Morisky et al., 1986).  
 The Summary of Diabetes Self-Care Activities scale (SDSCA), which originally developed 
in 1994, measures five aspects of self-care: general diet, specific diet, exercise, medication 
taking, and blood-glucose monitoring. The scale demonstrates high inter-item reliability and 




SDSCA subscales was supported by comparing correlations with other measures of diet and 
exercise (Toobert et al., 2000). The revised SDSCA scale (2000) consists of 11 core items and 14 
additional questions regarding six domains: diet, medication, exercise, blood glucose testing, 
foot care, and smoking (Toobert et al., 2000). Three questions are used to measure medication 
adherence: (1) On how many of the last seven days did you take your recommended diabetes 
medication?; (2) On how many of the last seven days did you take your recommended insulin 
injections?; (3) On how many of the last seven days did you take your recommended number of 
diabetes pills? (Toobert et al., 2000). The revised SDSCA (2000) has been translated and adapted 
to various cultural contexts and has acceptable reliability and validity (Choi et al., 2011; 
Jalaludin, Fuziah, Hong, Mohamad, & Jamaiyah, 2012; Vincent, McEwen, & Pasvogel, 2008). 
Prescription refill records. 
Compared to self-report, pharmacy refill records are an objective measure that cannot be 
influenced by patient perceptions. Although “refilling” does not guarantee the act of consuming 
medicine, pharmacy refill record adherence is widely used because it is possible to calculate 
medication adherence for large samples using simple formulas. 
According to Hansen et al. (2009), pharmacy refill adherence (ρ3 = 0.5) demonstrated 
better congruence with electronic lid adherence, the gold standard, compared to self-report 
(ρ=0.3) in all age groups in two similarly designed randomized controlled trials. Especially for 
the elderly aged ≥ 65 years, pharmacy refill adherence had a moderate positive linear correlation 
(ρ = 0.3) with the electronic measure whereas self-reports had a weak positive linear relationship 
(ρ = 0.1) with pharmacy refill adherence (Hansen et al., 2009). This finding supports use of the 
                                                 
3 ρ (rho), also known as Spearman’s rank correlation coefficient, is a non-parametric measure of correlation between 




pharmacy refill method for measuring medication adherence in an elderly population. Self-report 
measures of adherence may be unreliable in elderly subjects because comprehension and 
memory function declines with aging or due to cognitive impairment such as dementia 
(Campbell et al., 2012). 
Numerous approaches to measurement of medication adherence when using pharmacy 
refill data are available to the researcher: medication proportion ratio (MPR), medication refill 
adherence (MRA), continuous measure of medication acquisition (CMA), proportion of days 
covered (PDC), refill compliance rate (RCR), days between fills adherence rate (DBR), 
compliance ratio (CR), medication proportion ratio, modified (MPRm), continuous measure of 
medication gaps (CMG), continuous multiple interval measure of oversupply (CMOS), and 
continuous, single-interval measure of medication acquisition (CSA). However, the literature can 
be confusing as researchers may use different terms for the same pharmacy measure. In addition, 
when the formula to calculate adherence is presented, it may not be consistent with the named 
measure. 
Hess, Raebel, Conner, and Malone (2006) compared the formulas for 11 existing 
pharmacy refill adherence measures and found that only 8 of the measures were unique. MPR is 
equivalent to both CMA and MRA; in addition, RCR and DBR are numerically identical (Karve 
et al., 2008). Of these measures, PDC and CMG are reported to have the highest validity in 
predicting any cause of diabetes-related hospitalizations among diabetes patients (Karve et al., 





Eight Formulas for Eleven Pharmacy Refill Medication Adherence Measures 
Medication Adherence Measure Formula 
Medication possession ratio (MPR) 
Medication refill adherence (MRA) 
Continuous measure of medication 
acquisition (CMA) 
 
Number of days' supply in index period
Number of days in the study period
 ×100 
 
Proportion of days covered (PDC) Number of days covered in index period
Number of days in the study period
 × 100 capped at 1 
Refill compliance rate (RCR) 
Days between fills adherence rate (DBR) 
Number of days' supply
Last claim date-Index date
 × 100 
Compliance ratio (CR) Number of days' supply in the index period- Last days' supply
Last claim date-Index date
 
Medication possession ratio, modified 
(MPRm) 
Number of days' supply
Last claim date- Index date + Last days' supply
 × 100 
Continuous measure of medication gaps 
(CMG) 
Total days of treatment gaps
Total days to next fill or end of observation period
  
Continuous multiple interval measure of 
oversupply (CMOS) 
Total days of treatment gaps (+) of surplus (-)
Total days to next fill or end of observation period
  
Continuous, single interval measure of 
medication acquisition (CSA) 
Days' supply obtained at the beginning of the interval
Days in interval
  
Note. Eight formulas adapted from “An Empirical Basis for Standardizing Adherence Measures 
derived from Administrative Claims Data among Diabetic Patients,” by S. Karve, M. A. Cleves, 
M. Helm, T. J. Hudson, D. S. West, and B. C. Martin, 2008, Medical Care, 46, p. 1127. 





Systematic Review 1: Definitions and Measurements of Pharmacy Refill Medication 
Adherence 
A systematic review was conducted on the studies that utilized pharmacy claims data to 
measure medication adherence to identify the most preferred measure of calculating medication 
adherence when using pharmacy claims data, the standard for defining adherence as well as the 
best time interval appropriate for measuring pharmacy claims-based medication adherence. The 
following are the questions that guided the review. 
Review question 1: How have researchers measured and calculated medication 
adherence using pharmacy refill records? 
Review question 2: What cut-off points have been used to define adherence? 
Search strategy. 
The initial PubMed and MEDLINE searches were conducted in October 2012 and 
updated in March 2013. For this review, “medication adherence” was used in the “title and 
abstract fields”. The similar search terms, including “pharmacy records,” “pharmacy refill,” and 
“pharmacy claim,” were combined with “OR” and then applied to the “all fields”. The results 
were retrieved from a combination of the search phrases by using “AND.” Additional limits—
“human” and “English”—were applied to the retrieved results. The complete strategies 
conducted on PubMed and MEDLINE are displayed in Appendix B. 
Study selection. 
The reference lists were collected, and duplicates were excluded using EndNote X5. In 
order to identify studies for this review, both 1) title and abstract screening and 2) full-text 





An article was included if (1) the study used pharmacy refill records to measure 
medication adherence and (2) the target population was those with chronic diseases. In addition, 
the included studies were (3) original studies and (4) published in the English language. Studies 
were excluded if any of the following criteria were satisfied: (1) medication adherence was not 
measured; (2) the study measured medication adherence other than using pharmacy claims data; 
(3) the formula to calculate medication adherence was unclear or not described; (4) the purpose 
of the study was protocol or scale development. Studies concerning (5) HIV/AIDS patients were 
also excluded because HIV/AIDS treatments often require a strict and rigid adherence standard 
(e.g., 95–100%) to prevent the development of drug resistance against their antiretroviral 
medicines, which is different from other chronic diseases. 
Data extraction. 
The following information was extracted from the included studies: authors; publication 
year; chronic disease population studied; calculation formulas; pharmacy refill measure terms 
used by the authors; cut-off points of medication adherence; and the time intervals of the 
pharmacy refill measures. 
Results of study selection. 
Figure 2.1 demonstrates the study selection process. Through electronic searching, 170 
and 73 studies were found from PubMed and MEDLINE, respectively. A total of 171 studies 
were retrieved after excluding 72 duplicates. From the title and abstract assessments, 67 studies 
were excluded, in accordance with inclusion and exclusion criteria. After full-text assessments, 
10 studies were excluded because the calculation formula was unclear or not described. As a 





Figure 2.1. Flow diagram of the process of study selection for systematic review 1. 
243 records identified through 
 
PubMed: n = 170 
MEDLINE: n = 73 
Titles and abstracts 
screened (n =171) 
Records excluded, with reasons 
(n = 67) 
 Medication adherence not measured: 9 
 Not a prescription refill measure: 7 
 Formula unclear or not described: 6 
 Not an original study (including a review paper): 11 
 Protocol or scale development: 18 
 HIV/AIDS population studied: 16 
 
Full-text articles assessed 
for eligibility 
(n = 104) 
Full-text articles excluded, with reasons 
(n = 10) 
 Formula unclear or not described: 10 
Studies included in 
synthesis 
(n = 94) 
Duplicates 




Characteristics of included studies. 
A total of 94 studies were reviewed. Tables 2.2 and 2.3 summarize the characteristics of 
the 94 studies included; Table 2.2 presents 33 studies concerning diabetes patients and Table 2.3 
describes 61 studies of patients with other diagnoses. Eleven studies that consist of studies of 
patients with both diabetes and other diagnoses are displayed in Table 2.2 and not included in 
Table 2.3. 
All included studies were published after 2000 and included patients with chronic 
diseases. The most common condition for the study samples was diabetes (n = 33; 35.1%) 
(Adeyemi, Rascati, Lawson, & Strassels, 2012; Barner, 2011; Bryson et al., 2008; Cheong, 
Barner, Lawson, & Johnsrud, 2008; Christensen et al., 2010; Cook, Wade, Martin, & Perri, 2005; 
Devine, Vlahiotis, & Sundar, 2010; Farley, Wansink, Lindquist, Parker, & Maciejewski, 2012; 
R. Grant et al., 2007; Gu, Zeng, Patel, & Tripoli, 2010; Hou et al., 2012; Hunt, Rozenfeld, & 
Shenolikar, 2009; Joyce, Carrera, Goldman, & Sood, 2011; Khanna et al., 2012; Kilbourne, 
Reynolds, et al., 2005; Lawrence, Ragucci, Long, Parris, & Helfer, 2006; W. C. Lee, Balu, 
Cobden, Joshi, & Pashos, 2006; Lin et al., 2006; Lin et al., 2004; Mabotuwana, Warren, 
Harrison, & Kenealy, 2009; Melikian, White, Vanderplas, Dezii, & Chang, 2002; Mullan et al., 
2009; Oladapo, Barner, Rascati, & Strassels, 2012; Pladevall et al., 2004; Raebel, Carroll, Ellis, 
Schroeder, & Bayliss, 2011; Roebuck, Liberman, Gemmill-Toyama, & Brennan, 2011; 
Rozenfeld, Hunt, Plauschinat, & Wong, 2008; Sharma & Taylor, 2012; Shenolikar, Balkrishnan, 
Camacho, Whitmire, & Anderson, 2006b; Vanderpoel, Hussein, Watson-Heidari, & Perry, 2004; 
Yang et al., 2009; Yeaw, Benner, Walt, Sian, & Smith, 2009; L. Zhang et al., 2011), followed by 
hypertension (n = 24; 25.5%) (J. E. Bailey, Wan, Tang, Ghani, & Cushman, 2010; Bramley, 




et al., 2005; Farley et al., 2012; R. W. Grant, Singer, & Meigs, 2005; Heisler et al., 2008; Hou et 
al., 2012; Joyce et al., 2011; Khanna et al., 2012; W. D. Lynch, Markosyan, Melkonian, Pesa, & 
Kleinman, 2009; Mabotuwana et al., 2009; Nabi et al., 2008; Pittman, Tao, Chen, & Stettin, 
2010; Raebel et al., 2011; Roebuck et al., 2011; Schneider, Murphy, & Pedersen, 2008; Shin et 
al., 2010; Siegel, Lopez, & Meier, 2007; Vincze et al., 2008; Wu et al., 2010; Yeaw et al., 2009; 
Zedler, Joyce, Murrelle, Kakad, & Harpe, 2011). 
Results of the included studies. 
Of a total of 94 studies reviewed, 21 studies (22.3%) lacked agreement between the 
formulas described and the measurement terms used by the authors (Bautista, Graham, & 
Mukardamwala, 2011; Bautista & Rundle-Gonzalez, 2012; Bender, Pedan, & Varasteh, 2006; 
Cook et al., 2005; Cross & Finkelstein, 2009; Devine et al., 2010; Dunlay, Eveleth, Shah, 
McNallan, & Roger, 2011; Evans et al., 2009; Gilmer et al., 2009; R. Grant et al., 2007; Hope, 
Wu, Tu, Young, & Murray, 2004; S. Kane, Huo, Aikens, & Hanauer, 2003; Khanna et al., 2012; 
Koneru et al., 2008; Mullan et al., 2009; Nabi et al., 2008; Oliva-Hemker, Abadom, Cuffari, & 
Thompson, 2007; Patel, Chang, Shenolikar, & Balkrishnan, 2010; Rozenfeld et al., 2008; Ting et 
al., 2012; Trivedi, Bryson, Udris, & Au, 2012). The discrepancies between the terms based on 
the formulas presented and the measurement terms used by the authors were observed in the 
majority of the studies (n = 50; 53.2%), and only 23 studies (24.5%) showed consistency 
between measurement term used by the authors and formula described (Adeyemi et al., 2012; 
Burton, Chen, Schultz, & Edington, 2010; Cecere et al., 2012; Christensen et al., 2010; Foreman 
et al., 2012; Heisler et al., 2008; Hunt et al., 2009; Ivanova et al., 2012; Joyce et al., 2011; Jung, 
Pickard, Salmon, Bartle, & Lee, 2009; Lambert-Kerzner et al., 2012; Lawrence et al., 2006; A. 




Muir et al., 2012; Pladevall et al., 2004; Raebel et al., 2011; Sun, Ye, Lee, Dupclay, & 
Plauschinat, 2008; Warren et al., 2011; Woltmann et al., 2007; Yeaw et al., 2009). For example, 
among the studies mentioning the term MPR (n = 49), only one-third (n = 16; 32.7%) used the 
term correctly based on the formula presented (Adeyemi et al., 2012; Burton et al., 2010; Cecere 
et al., 2012; Christensen et al., 2010; Hunt et al., 2009; Ivanova et al., 2012; Joyce et al., 2011; 
Jung et al., 2009; Lambert-Kerzner et al., 2012; Lawrence et al., 2006; A. Lee et al., 2011; 
Mabotuwana et al., 2009; Muir et al., 2012; Sun et al., 2008; Warren et al., 2011; Woltmann et 
al., 2007). 
The majority of studies (n = 88; 93.6%) measured adherence rather than non-adherence 
(Adeyemi et al., 2012; J. E. Bailey et al., 2010; Balkrishnan, Bhosle, Camacho, & Anderson, 
2006; Barner, 2011; Bautista et al., 2011; Bautista & Rundle-Gonzalez, 2012; Bender et al., 
2006; Bramley et al., 2006; Bryson et al., 2008; Burton et al., 2010; Cecere et al., 2012; Chang, 
Desai, Solomon, & Winkelmayer, 2011; Cheong et al., 2008; Christensen et al., 2010; Cook et 
al., 2005; Cross & Finkelstein, 2009; Devine et al., 2010; Dunlay et al., 2011; Eakin, Bilderback, 
Boyle, Mogayzel, & Riekert, 2011; Evans et al., 2009; Farley et al., 2012; Foreman et al., 2012; 
Gazmararian, Jacobson, Pan, Schmotzer, & Kripalani, 2010; Gianfrancesco, Sajatovic, 
Rajagopalan, & Wang, 2008; Gilmer et al., 2009; R. Grant et al., 2007; R. W. Grant et al., 2005; 
Gu et al., 2010; Hankin et al., 2012; Hope et al., 2004; Hou et al., 2012; Hunt et al., 2009; Huser, 
Evans, & Berger, 2005; Ivanova et al., 2012; Joyce et al., 2011; Jung et al., 2009; S. Kane et al., 
2012; S. Kane et al., 2003; S. V. Kane, Cohen, Aikens, & Hanauer, 2001; Khanna et al., 2012; 
Kilbourne, Reynolds, et al., 2005; Koneru et al., 2008; Koneru et al., 2007; Lambert-Kerzner et 
al., 2012; Lawrence et al., 2006; A. Lee et al., 2011; W. C. Lee et al., 2006; Loeppke et al., 2011; 




2008; Muir et al., 2012; Mullan et al., 2009; Nabi et al., 2008; Oladapo et al., 2012; Oliva-
Hemker et al., 2007; Park, Rascati, Prasla, & McBayne, 2012; Patel et al., 2010; Patterson, 
Blalock, Smith, & Murray, 2011; Pittman et al., 2010; Raebel et al., 2011; Roebuck et al., 2011; 
Rozenfeld et al., 2008; Schneider et al., 2008; Sears, Lewis, Noel, Albright, & Fischer, 2010; 
Sharma & Taylor, 2012; Shenolikar et al., 2006b; Shin et al., 2010; Siegel et al., 2007; Stacy, 
Schwartz, Ershoff, & Shreve, 2009; Karen M. Stockl et al., 2010; K. M. Stockl et al., 2010; Sun 
et al., 2008; Ting et al., 2012; Trivedi et al., 2012; Vanderpoel et al., 2004; Villar, Izuel, Carrizo, 
Vicente, & Marin, 2009; Vincze et al., 2008; Wade et al., 2012; Warren et al., 2011; Wiegand, 
McCombs, & Wang, 2012; Woltmann et al., 2007; Wu et al., 2010; Yang et al., 2009; Yeaw et 
al., 2009; Zedler et al., 2011; L. Zhang et al., 2011; Zillich et al., 2012). Based on the best 
interpretation of the formula described, MPR was the most commonly used measure (n = 39; 
41.5%) (Adeyemi et al., 2012; Bender et al., 2006; Bryson et al., 2008; Burton et al., 2010; 
Cecere et al., 2012; Chang et al., 2011; Christensen et al., 2010; Evans et al., 2009; R. Grant et 
al., 2007; Gu et al., 2010; Hou et al., 2012; Hunt et al., 2009; Ivanova et al., 2012; Joyce et al., 
2011; Jung et al., 2009; Khanna et al., 2012; Koneru et al., 2007; Lambert-Kerzner et al., 2012; 
Lawrence et al., 2006; A. Lee et al., 2011; Mabotuwana et al., 2009; Menckeberg et al., 2008; 
Muir et al., 2012; Mullan et al., 2009; Nabi et al., 2008; Oliva-Hemker et al., 2007; Park et al., 
2012; Sharma & Taylor, 2012; Stacy et al., 2009; K. M. Stockl et al., 2010; Sun et al., 2008; 
Trivedi et al., 2012; Warren et al., 2011; Wiegand et al., 2012; Woltmann et al., 2007; Wu et al., 
2010; Yang et al., 2009; Zedler et al., 2011; L. Zhang et al., 2011), followed by PDC (n = 16; 
17.0%) (Bramley et al., 2006; Eakin et al., 2011; Farley et al., 2012; Foreman et al., 2012; 
Gianfrancesco et al., 2008; Huser et al., 2005; W. D. Lynch et al., 2009; Melikian et al., 2002; 




al., 2011; Wade et al., 2012; Yeaw et al., 2009; Zillich et al., 2012), RCR (n = 8; 8.5%) 
(Balkrishnan et al., 2006; Cook et al., 2005; S. Kane et al., 2012; S. Kane et al., 2003; S. V. Kane 
et al., 2001; Kilbourne, Reynolds, et al., 2005; Loeppke et al., 2011; Shenolikar et al., 2006b), 
CR (n = 8; 8.5%) (R. W. Grant et al., 2005; Hope et al., 2004; Rozenfeld et al., 2008; Schneider 
et al., 2008; Sears et al., 2010; Shin et al., 2010; Siegel et al., 2007; Zedler et al., 2011), MPRm 
truncated at 1 (n = 4; 4.3%) (Cheong et al., 2008; W. C. Lee et al., 2006; Vanderpoel et al., 2004; 
Villar et al., 2009), and MPRm (n = 3; 3.2%) (Barner, 2011; Hankin et al., 2012; Karen M. 
Stockl et al., 2010). Measures of non-adherence that count medication gaps, such as CMG and 
CMOS, were rarely used (n = 6; 6.4%) (Dolder, Lacro, Dunn, & Jeste, 2002; Gazmararian et al., 
2010; Heisler et al., 2008; Lin et al., 2006; Lin et al., 2004; Pladevall et al., 2004). 
Almost two-thirds of the included studies treated medication adherence as a dichotomous 
variable (n = 62; 66.0%) (Adeyemi et al., 2012; J. E. Bailey et al., 2010; Barner, 2011; Bramley et 
al., 2006; Bryson et al., 2008; Burton et al., 2010; Cecere et al., 2012; Chang et al., 2011; 
Cheong et al., 2008; Cross & Finkelstein, 2009; Dolder et al., 2002; Dunlay et al., 2011; Evans et 
al., 2009; Farley et al., 2012; Gazmararian et al., 2010; Gilmer et al., 2009; R. Grant et al., 2007; 
Gu et al., 2010; Heisler et al., 2008; Hope et al., 2004; Hou et al., 2012; Hunt et al., 2009; 
Ivanova et al., 2012; S. Kane et al., 2012; S. Kane et al., 2003; S. V. Kane et al., 2001; Koneru et 
al., 2008; Koneru et al., 2007; Lambert-Kerzner et al., 2012; A. Lee et al., 2011; W. C. Lee et al., 
2006; Loeppke et al., 2011; Mabotuwana et al., 2009; Nabi et al., 2008; Oladapo et al., 2012; 
Oliva-Hemker et al., 2007; Park et al., 2012; Patterson et al., 2011; Pittman et al., 2010; 
Pladevall et al., 2004; Raebel et al., 2011; Roebuck et al., 2011; Rozenfeld et al., 2008; Sears et 
al., 2010; Shin et al., 2010; Siegel et al., 2007; Stacy et al., 2009; Sun et al., 2008; Ting et al., 




al., 2012; Woltmann et al., 2007; Wu et al., 2010; Yang et al., 2009; Yeaw et al., 2009; Zedler et 
al., 2011; L. Zhang et al., 2011; Zillich et al., 2012) and used a cut-off point for adherence, while 
the rest considered adherence to be a continuous variable (n = 32; 34.0%) (Balkrishnan et al., 
2006; Bautista et al., 2011; Bautista & Rundle-Gonzalez, 2012; Bender et al., 2006; Christensen 
et al., 2010; Cook et al., 2005; Devine et al., 2010; Eakin et al., 2011; Foreman et al., 2012; 
Gianfrancesco et al., 2008; R. W. Grant et al., 2005; Hankin et al., 2012; Huser et al., 2005; 
Joyce et al., 2011; Jung et al., 2009; Kilbourne, Reynolds, et al., 2005; Lawrence et al., 2006; Lin 
et al., 2006; Lin et al., 2004; W. D. Lynch et al., 2009; Melikian et al., 2002; Menckeberg et al., 
2008; Muir et al., 2012; Mullan et al., 2009; Patel et al., 2010; Schneider et al., 2008; Sharma & 
Taylor, 2012; Shenolikar et al., 2006b; Karen M. Stockl et al., 2010; K. M. Stockl et al., 2010; 
Vanderpoel et al., 2004; Vincze et al., 2008). The ranges of adherence varied and included 20–
120%, ≥ 80%, 80–100%, 80–120% and others. The majority (n = 56; 59.6%) utilized an 80% 
cut-off point, including ≥ 80%, 80–100%, and 80–120% (Adeyemi et al., 2012; J. E. Bailey et 
al., 2010; Barner, 2011; Bramley et al., 2006; Bryson et al., 2008; Burton et al., 2010; Cecere et 
al., 2012; Chang et al., 2011; Cheong et al., 2008; Cross & Finkelstein, 2009; Dunlay et al., 
2011; Evans et al., 2009; Farley et al., 2012; Gilmer et al., 2009; Gu et al., 2010; Hope et al., 
2004; Hou et al., 2012; Hunt et al., 2009; Ivanova et al., 2012; S. Kane et al., 2012; S. Kane et 
al., 2003; S. V. Kane et al., 2001; Koneru et al., 2008; Koneru et al., 2007; Lambert-Kerzner et 
al., 2012; A. Lee et al., 2011; W. C. Lee et al., 2006; Loeppke et al., 2011; Mabotuwana et al., 
2009; Oladapo et al., 2012; Oliva-Hemker et al., 2007; Park et al., 2012; Patterson et al., 2011; 
Pittman et al., 2010; Raebel et al., 2011; Roebuck et al., 2011; Rozenfeld et al., 2008; Sears et 
al., 2010; Shin et al., 2010; Siegel et al., 2007; Stacy et al., 2009; Sun et al., 2008; Ting et al., 




al., 2012; Woltmann et al., 2007; Wu et al., 2010; Yang et al., 2009; Yeaw et al., 2009; Zedler et 
al., 2011; L. Zhang et al., 2011; Zillich et al., 2012). Studies that used non-adherence measures 
such as CMG and CMOS had a cut-off point of 20% or less, which has essentially the same 
meaning as a cut-off point of 80% or greater for adherence (Gazmararian et al., 2010; Heisler et 
al., 2008; Pladevall et al., 2004). 
For the time interval of measurement using pharmacy refill adherence, the most 
frequently utilized time period was “at least 1 year,” (n = 32; 34.0%) (Adeyemi et al., 2012; 
Balkrishnan et al., 2006; Bender et al., 2006; Burton et al., 2010; Cross & Finkelstein, 2009; 
Dolder et al., 2002; Evans et al., 2009; Farley et al., 2012; Gilmer et al., 2009; Heisler et al., 
2008; Hou et al., 2012; Hunt et al., 2009; Jung et al., 2009; Khanna et al., 2012; Kilbourne, 
Reynolds, et al., 2005; Lambert-Kerzner et al., 2012; Lin et al., 2006; Loeppke et al., 2011; W. 
D. Lynch et al., 2009; Nabi et al., 2008; Park et al., 2012; Patel et al., 2010; Pittman et al., 2010; 
Roebuck et al., 2011; Sharma & Taylor, 2012; Sun et al., 2008; Wade et al., 2012; Warren et al., 
2011; Wiegand et al., 2012; Woltmann et al., 2007; L. Zhang et al., 2011; Zillich et al., 2012) 
followed by an “at least a 6-month” period (n = 20; 21.3%) (J. E. Bailey et al., 2010; Dunlay et 
al., 2011; Gazmararian et al., 2010; Gianfrancesco et al., 2008; R. Grant et al., 2007; Hankin et 
al., 2012; Hope et al., 2004; Joyce et al., 2011; S. Kane et al., 2003; S. V. Kane et al., 2001; A. 
Lee et al., 2011; W. C. Lee et al., 2006; Melikian et al., 2002; Muir et al., 2012; Mullan et al., 
2009; Oladapo et al., 2012; Oliva-Hemker et al., 2007; Raebel et al., 2011; Stacy et al., 2009; 
Vanderpoel et al., 2004). 
The most preferred methods of calculating and defining medication adherence assessed 
by pharmacy claims data, as well as the period for measuring claims-based medication 




(Adeyemi et al., 2012; Bryson et al., 2008; Christensen et al., 2010; R. Grant et al., 2007; Gu et 
al., 2010; Hou et al., 2012; Hunt et al., 2009; Joyce et al., 2011; Khanna et al., 2012; Lawrence et 
al., 2006; Mabotuwana et al., 2009; Mullan et al., 2009; Sharma & Taylor, 2012; Yang et al., 
2009; L. Zhang et al., 2011) was the most preferred measure, followed by PDC (n = 6; 18.2%) 
(Farley et al., 2012; Melikian et al., 2002; Oladapo et al., 2012; Raebel et al., 2011; Roebuck et 
al., 2011; Yeaw et al., 2009), MPRm truncated at 1 (n = 3; 9.1%) (Cheong et al., 2008; W. C. 
Lee et al., 2006; Vanderpoel et al., 2004), and continuous measure of medication gaps (n = 3; 
9.1%) (Lin et al., 2006; Lin et al., 2004; Pladevall et al., 2004). The cut-off point of 80% (n = 18; 
54.5%) including ≥ 80% (n = 11) and 80–100%, (n = 7) was the most common for diabetes 
patients (Adeyemi et al., 2012; Barner, 2011; Bryson et al., 2008; Cheong et al., 2008; Farley et 
al., 2012; Gu et al., 2010; Hou et al., 2012; Hunt et al., 2009; Khanna et al., 2012; W. C. Lee et 
al., 2006; Mabotuwana et al., 2009; Oladapo et al., 2012; Raebel et al., 2011; Roebuck et al., 
2011; Rozenfeld et al., 2008; Yang et al., 2009; Yeaw et al., 2009; L. Zhang et al., 2011); 
another half of studies treated adherence as a continuous variable (n = 12; 36.4%) (Christensen et 
al., 2010; Cook et al., 2005; Joyce et al., 2011; Kilbourne, Reynolds, et al., 2005; Lawrence et 
al., 2006; Lin et al., 2006; Lin et al., 2004; Melikian et al., 2002; Mullan et al., 2009; Sharma & 
Taylor, 2012; Shenolikar et al., 2006b; Vanderpoel et al., 2004). The 1-year period was the most 
common time interval of measuring adherence as well (n = 10; 30.3%) (Adeyemi et al., 2012; 
Farley et al., 2012; Hou et al., 2012; Hunt et al., 2009; Khanna et al., 2012; Kilbourne, Reynolds, 
et al., 2005; Lin et al., 2006; Roebuck et al., 2011; Sharma & Taylor, 2012; L. Zhang et al., 
2011), followed by a period of at least 6 months (n = 8; 24.2%) (R. Grant et al., 2007; Joyce et 
al., 2011; W. C. Lee et al., 2006; Melikian et al., 2002; Mullan et al., 2009; Oladapo et al., 2012; 





In order to determine the most appropriate method for this study measuring medication 
adherence using pharmacy claims data, a systematic review was conducted. A total of 94 studies 
that utilized pharmacy claims were included for this review, including 33 studies specifically 
concerning diabetes patients. MPR and PDC were the most commonly used methods of 
determining medication adherence measured by prescription refill records. Over half of the 
included studies used an 80% threshold to classify adherence. Most studies measured medication 
adherence using at least a 1-year period of pharmacy claims data, while the others used at least 6 
months of data. These findings were consistent across the 33 studies of patients with diabetes. 
However, almost a quarter of the included studies revealed discrepancies between the 
formulas described and the terminology. Consensus on standardized measurement, terminology, 
and formulas of claims-based adherence measures is crucial in order to foster consistency across 







Summary of 33 Included Studies concerning Diabetes Patients: Formulas, Terms, Definitions of Pharmacy Refill Medication Adherence 
and Measurement interval 





Formula that the authors 
used 
Term  Term based 
on formula 
presented 
Melikian et al. 
(2002) 
Diabetes (Sum of the days’ supply of 
medication obtained by the 
patient during the follow-up 
period/total number of days 
in the designated follow-up 
period) truncated at 1 
MPR PDC Continuous 6-month 
Lin et al. (2004) Diabetes Total number of non-
adherent days in the prior 
year/ total number of days 
prescribed oral diabetes 











Continuous Not reported 
Pladevall et al. 
(2004) 
Diabetes Proportion of days with 
gaps in medication refills 










< 20% Not reported 
Vanderpoel et al. 
(2004) 
Diabetes [Total days’ supply 
obtained/(Date of last claim-
date of first claim +days’ 
supply of last claim)] 
truncated at 1 
MPR MPRm 












Formula that the authors 
used 
Term  Term based 
on formula 
presented 













Not reported Refill 
Compliance 
Rate (RCR) 
Continuous Not reported 
Kilbourne, 
Reynolds, et al. 
(2005) 
Diabetes (Day’s supply/number of 










Lawrence et al. 
(2006) 
Diabetes Total days’ supply of 
medication that was 
dispensed/number of days in 
the evaluation period 
(allows >1) 
MPR MPR Continuous 9-month 
W. C. Lee et al. 
(2006) 
Diabetes [Sum of the days’ supply of 
medication/(number of days 
between the first fill and the 
last refill +days’ supply of 
the last refill] truncated at 1 
MPR MPRm 
truncated at 1 











Formula that the authors 
used 
Term  Term based 
on formula 
presented 
Lin et al. (2006) Diabetes (Total number of non-
adherent days in the 
previous year/the total 
number of days the patient 
was prescribed medications, 


















Shenolikar et al. 
(2006b) 
Diabetes Days of prescription supply 
dispensed/number of days 
between these prescription 
refills 









R. Grant et al. 
(2007) 
Diabetes Medication dispensed (from 
pharmacy 
records)/medication days 
prescribed (as documented 
in the medical record) for 
the first prescribed drug 







Bryson et al. (2008) Diabetes, 
hypertension 
hyperlipidemia, 
Number of days during the 
observation period that 
medication was available 
PDC MPR ≥ 80% ≥ 3-month 
Cheong et al. 
(2008) 
Diabetes [Sum of total days’ supply 
for all fills/(number of days 
between the first and last 
fills +days’ supply of the 
last fill)] truncated at 1 
MPR MPRm 












Formula that the authors 
used 
Term  Term based 
on formula 
presented 
Rozenfeld et al. 
(2008) 
Diabetes =[(Sum of the days’ supply 
from the index prescription 
date to the last fill date-
days’ supply that was 
dispensed at the final 
prescription fill)/duration of 
therapy] 
Not reported Compliance 
Ratio (CR) 
≥ 80% Not reported 
Hunt et al. (2009) Diabetes Sum of days’ supply of 
medication that a patient 
received during the 12-
month follow-up period/ 
365 days 
MPR MPR ≥ 80% 1-year 





(Number of days’ supply 
held during evaluation 
period/number of days 
between first dispensing 
date and end of evaluation 
period)×100 
MPR MPR ≥ 80% 15-month 
Mullan et al. (2009) Diabetes Proportion of days covered 
during the 180 days after the 
visit, crediting overlapping 
supply 
Not reported MPR Continuous 6-month 
Yang et al. (2009) Diabetes Number of days with 
medication on hand/ number 
of days in the specified time 
interval 











Formula that the authors 
used 
Term  Term based 
on formula 
presented 







(Patients’ total days 
supplied of index class 
medications for the 360-day 
period following the index 
date/360) truncated at 1 
PDC PDC 80–100% 360-day 




Number of days with drug/ 
number of days in the index 
period 
MPR MPR Continuous 13-month 
Devine et al. (2010) Diabetes Number of days a patient 
was in possession of the 
medication after the 
beginning of the 
period/(total number of days 
in the period +days’ supply 
between two pharmacy 
claims for a medication) 
MPR Unable to 
determine 
Continuous Not reported 
Gu et al. (2010) Diabetes Number of days covered by 
at least 1 medication in a 
certain period of time/ 
number of days in that 
period 
PDC MPR ≥ 80% Not reported 
Barner (2011) Diabetes [Sum of days’ supply in 
interval/(total number of 
days in interval between 
first and last fill +supply of 
last fill)] 











Formula that the authors 
used 
Term  Term based 
on formula 
presented 




Number of days’ supply of a 
medication over the 6 
months following the initial 
prescription 
MPR MPR Continuous 6-month  




(Total days’ supply 
dispensed/ 180 days in the 
observation period) 
truncated at 1 
PDC PDC 80–100% 6-month  







Number of days during the 
year when the patient had 
medication/ number of days 
in the year 
(MPR values ranged from 0 
to 1) 
MPR PDC 80–100% 1-year  
L. Zhang et al. 
(2011) 
Diabetes Sum of days of supply for 
all fills of medication in 
calendar year 2009/ total 
number of calendar days in 
2009 
PDC MPR ≥ 80% 1-year  
Adeyemi et al. 
(2012) 
Diabetes Sum of total days’ supply 
for all medication fills/ 
number of days (365) in the 
observation period 
MPR MPR ≥ 80% 1-year  





Number of days of supply 
dispensed per year/ number 
of days observed in the year 
(365) truncated at 1 











Formula that the authors 
used 
Term  Term based 
on formula 
presented 





Sum of the days covered/ 
365 (the number of follow-
up days) 
PDC MPR ≥ 80% 1-year  








(Sum of the days that 
recipient possessed disease-
related medication during 
the study year/365)×100 
Not reported MPR ≥ 80% 1-year 
Oladapo et al. 
(2012) 
Diabetes (Sum of total days’ supply 
for all fills/number of days 
in the study period) 
truncated at 1 
MPR PDC 80–100% ≥ 6-month 
Sharma and Taylor 
(2012) 
Diabetes Total days supplied in 365 
day period starting from the 
index date 








Summary of 61 Included Studies of Patients with Other Diagnoses: Formulas, Terms, Definitions of Pharmacy Refill Medication 
Adherence and Measurement interval 





Formula that the authors 
used 
Term Term based 
on formula 
presented 
R. W. Grant et al. 
(2005) 
Hypertension [(Total number of days of 
medication dispensed-final 
prescription)/total number 
of days between the first 







Continuous Not reported 
Bramley et al. 
(2006) 
Hypertension [(Supply of medication in 
days/total number of days in 
the study period)×100] 
truncated at 1 
MPR PDC 80–100% Not reported 
Siegel et al. (2007) Hypertension [Sum of days dispensed 
(except for the prescription 
dispensed on the finish 
date)/number of days 
elapsed from index date to 
finish date] 




≥ 80% Not described 
Heisler et al. (2008) Hypertension Total number of days on 
which patient did not have 
medications available/total 
number of days the patient 
























Formula that the authors 
used 
Term Term based 
on formula 
presented 
Nabi et al. (2008) Hypertension Number of days of supply 
of prescribed drugs filled 
during the survey year 
Not reported MPR 100% 1-year 
Schneider et al. 
(2008) 
Hypertension (Sum of the day’s supply for 
all prescriptions received 
during the study-last 
refilling of the 
prescription)/number of 
days between the dates of 




Continuous Not reported 
Vincze et al. (2008) Hypertension (Days supplied/number of 
days between the dates of 
the first and last prescription 




truncated at 1 
Continuous Not reported 
W. D. Lynch et al. 
(2009) 
Hypertension Number of days each 
employee had a supply of 
medication 
available/number of days in 
the measurement year 
(not allows overlaps) 
PDC PDC Continuous 1-year 
J. E. Bailey et al. 
(2010) 
Hypertension Total days’ supply for all 
qualifying drug classes/total 
number of days from the 
first to the last fill in the 







truncated at 1 
80–100% ≥ 6-month 
Pittman et al. 
(2010) 
Hypertension (Total days of medication 
supplied/ total days in a 
period) truncated at 1 











Formula that the authors 
used 
Term Term based 
on formula 
presented 
Shin et al. (2010) Hypertension Total number of days of 
medication dispensed 
(excluding the final 
prescription)/total number 
of days between the first 






≥ 80% Not reported 
Wu et al. (2010) Hypertension Number of days supplied 
with filled prescriptions/ 
total days of each patient’s 
observation period 
PDC MPR ≥ 80% Not reported 
Zedler et al. (2011) Hypertension 1) Total days’ supply 
excluding the last fill/ total 
calendar days between the 
index date and the final 
refill dispensing date 
 
2) Total days’ supply/ 
number of days in the 
observation period (360) 
(did not adjust (truncate) the 
total days’ supply value for 
oversupply extending 










≥ 80% 360-day 
Hope et al. (2004) Congestive heart 
failure 
(Number of pills received 
for all-last refill)/ number of 
pills prescribed in the same 
period 
Not described Compliance 
Ratio (CR) 











Formula that the authors 
used 
Term Term based 
on formula 
presented 
Sun et al. (2008) Heart failure or 
myocardial 
infarction 
Total number of days’ 
supply of the medication a 
patient received/number of 
days in the study period. 
MPR MPR ≥ 80% 1-year 
Chang et al. (2011) Myocardial 
infarction 
Days of medication supplied 
to each patient from all 
filled prescriptions for these 
medications during the 
interval 
(patients who used the 
medication before their 
index admission were 
credited with their excess 
supply in the first 3 months) 
PDC MPR ≥ 80% 3-month 
Dunlay et al. (2011) Heart failure Number of the days in the 
measurement period 
covered by prescription 
claims for the same 
medication or another in its 
therapeutic class  
PDC Unable to 
determine 
≥ 80% 6-month 
Patterson et al. 
(2011) 
Heart failure (Cumulative days of 
medication supply/ 
cumulative number of 
calendar days over any 
particular follow-up year) 
truncated at 1 











Formula that the authors 
used 
Term Term based 
on formula 
presented 




Days supplied over the 
same period adjusting for 
prescription overlap/ 
duration from the first 
prescription fill date within 
the measurement period 










Number of days supplied 
over the observation time 
interval, which will be 365 
days. 
MPR MPR ≥ 80% 1-year  
Huser et al. (2005) Hyperlipidemia Sum of the days’ supply for 
all claims during a defined 
period/the number of days 
elapsed during that period 
(1 indicates perfect 
adherence) 
MPR PDC Continuous 1-month  
Evans et al. (2009) Hyperlipidemia Total number of tablets 
dispensed/ total number of 
days of observation. 
Not reported MPR ≥ 80% 1-year 
Stacy et al. (2009) Hyperlipidemia Days’ supply associated 
with the total number of 
separate pharmacy claims 
over the 180-day follow-up 
observation period 











Formula that the authors 
used 
Term Term based 
on formula 
presented 
Burton et al. (2010) Hyperlipidemia Summed days with a 
medication supply/total 
number of days from the 
date of the first prescription 
until the examination date 
MPR MPR ≥ 80% 1-year 
Wiegand et al. 
(2012) 
Hyperlipidemia (Days’ supply of medication 
dispensed in the first year 
following the index date/ 
365 days)×100 
PDC MPR ≥ 80% 1-year  
S. V. Kane et al. 
(2001) 
Ulcerative colitis (Sum of days’ supply 







≥ 80% ≥ 6-month 
S. Kane et al. 
(2003) 
Ulcerative colitis (Sum of days’ supply 
dispensed/ sum of days in 
refill intervals)×100 
Not reported Refill 
Compliance 
Rate (RCR) 
≥80% ≥ 6-month 
Oliva-Hemker et al. 
(2007) 
Crohn’s disease (Cumulative days of 
medication dispensed 
during the study period/total 
days in the study 
period)×100 
Not reported MPR ≥ 80% 6-month 
Cross and 
Finkelstein (2009) 
Ulcerative colitis Total number of pills 
consumed/ total number 
prescribed 
Not reported Unable to 
determine 
80–120% 1-year 




(The amount of medication 
















Formula that the authors 
used 
Term Term based 
on formula 
presented 
Dolder et al. (2002) Mental illness 1)[(Total number of days in 
the study period-total 
number of days that 
medication was 
available)/total number of 
days in the study 
period]×100 
 
2) (Number of adherence 















2) Unable to 
determine 
20–120% 1-year 




Days of medication supply 
that patients received in the 
one-year period /number of 
days that patients were 
outpatients during the year 
MPR MPR ≥ 80% ≥ 1-year 
Gianfrancesco et al. 
(2008) 
Bipolar disorder (Number of days’ supply of 
a medication that the 
individual actually received, 
as indicated on prescription 
claims/number of days’ 
supply of a medication that 
the individual should have 
received if the prescription 
was filled correctly) 
truncated at 1 











Formula that the authors 
used 
Term Term based 
on formula 
presented 
Gilmer et al. (2009) Schizophrenia Number of days that 
medications were available 
for consumption/number of 
days that adults were 
eligible for Medi-Cal 
MPR Unable to 
determine 
80–110% 1-year 






(Sum of the days’ supply 
obtained over a series of 
intervals/ total days from 
the beginning to end of the 
time period) truncated at 1 
MPR PDC 80–100% 1-year  
 
Koneru et al. (2007) Systemic lupus 
erythematosus 
(Total number of 
medication doses 





MPR ≥ 80% Not described 
Koneru et al. (2008) Systemic lupus 
erythematosus 
Number of medication 
doses taken/number of 
doses prescribed for the 
time between the study visit 
and the refill date of the 
medication 
Not reported Unable to 
determine 
≥ 80% Not reported 
Ting et al. (2012) Systemic lupus 
erythematosus 
Number of doses dispensed/ 
number of doses prescribed 
for the period of time 
between study visits and 
pharmacy refill dates 
Not reported Unable to 
determine 











Formula that the authors 
used 
Term Term based 
on formula 
presented 




Sum of days’ supply for all 
fills during the post 
period/number of days of 
therapy between the first fill 
and the last fill during the 
post period plus the days’ 
supply for the last fill 
MPR MPRm Continuous Not reported 




Number of days of any 
available medication/24- 
month study period  
MPR MPR ≥ 80% 2-year  




Sum of days’ supply for all 
fills during the post-
identification period/240 
days 
PDC MPR Continuous 8-month 





(Total days’ supply 
obtained/number of days in 
the evaluation period)×100 
Not reported MPR Continuous 1-year 
Menckeberg et al. 
(2008) 
Asthma (Days’ supply were 
summed/total number of 
days from the beginning to 
the end of the time 
period)×100 






















Formula that the authors 
used 
Term Term based 
on formula 
presented 




Sum of the number of days’ 
supply of each prescription 
in a study period/total 
number of days during a 
study period 
MPR MPR Continuous 1-year 
Villar et al. (2009) Severe 
obstructive sleep 
apnea 
[(Days’ supply obtained-last 
refill)/days between first 
and last dispensing 
date]×100 truncated at 1 
MPR MPRm 
truncated at 1 
80–100% ≥ 2-year 




Actual proportion of days 
that medications were 
available 
MPR MPR ≥ 80% Not reported 




Proportion of medication in 
possession during a 90-day 
period 
Not reported MPR ≥ 80% 3-month  
Hankin et al. (2012) Allergic rhinitis Number of days of supply/ 
the total number of days 
between the first and last 
fills plus the last fill’s days 
of supply 
MPR MPRm Continuous 6-month  
Bautista et al. 
(2011) 
Epilepsy Number of days between 
prescription refills (30 days 
for our patient population)/ 
actual number of days 
between prescription refills 
MPR Unable to 
determine 











Formula that the authors 
used 






Epilepsy Number of days between 
prescription refills (30 days 
for our patient population)/ 
actual number of days 
between prescription refills 
MPR Unable to 
determine 
Continuous Not reported 





Days of prescription supply 
dispensed/number of days 





Continuous 1-year  
Sears et al. (2010) Overactive 
bladder 
Total days of medication 
dispensed except for the last 
refill/number of days 
between the first dispense 
date and the last refill date 
MPR Compliance 
Ratio (CR) 
≥ 80% Not reported 
A. Lee et al. (2011) End stage renal 
disease 
Number of days covered by 
prescription/ number of 
days during the 12-month 
post-index time period 
MPR MPR ≥ 80% ≥ 6-month 
Eakin et al. (2011) Cystic fibrosis (Sum of all days of 
medication supply received/ 
number of days the 
medication was prescribed 
for chronic use during the 
study period) truncated at 1 
MPR PDC Continuous Not reported 
Patel et al. (2010) Sickle cell 
disease 
Number of expected days 
between refills periods/ 
observed days between refill 
periods for the patient 
MPR Unable to 
determine 











Formula that the authors 
used 
Term Term based 
on formula 
presented 
Muir et al. (2012) Glaucoma 1) Difference between the 
number of days medication 
was available to the subject 
according to the pharmacy 
records and the prescribed 
dosing and the number of 
days that medication was 
required over the study 
period 
 
2) Number of days that the 
medication was available/ 
number of days that 
medication was required 











Park et al. (2012) Gout Number of days during the 
study period (365 days) that 
the patient had at least 1 
medication on hand 
PDC MPR ≥ 80% 1-year  
Wade et al. (2012) Osteoporosis (Sum of days’ supply 
dispensed for the 
medication/ number of days 
in the observation period) 
truncated at 1 











Formula that the authors 
used 
Term Term based 
on formula 
presented 




Number of days in which 
the medication was not 
available (gap) between 
each prescription 
fill/number of days between 
the first and last medication 








< 20% 6-month 
Warren et al. (2011) Chronic 
condition, not 
specified 
Percent of days a patient is 
in supply of a medication  
MPR MPR ≥ 80% 1-year  




[Total number of days 
covered by the member’s 
index medication 
therapeutic class between 
January 1, 2011, and August 
31, 2011/ total number of 
days in the measurement 
period (242 days)] 
truncated at 1 




Systematic Review 2: Barriers to and Facilitators of Diabetes Medication Adherence in 
Adult Diabetes Patients 
The second systematic review was conducted to synthesize the evidence related to 
barriers to and facilitators of medication adherence in adults with diabetes and categorize the 
identified factors into four categories—patient, medication characteristics, health system, and 
provider factors—within an adapted Gellad, Grenard, and McGlynn (2009)’s conceptual 
framework4. The results of this review were used to identify the predictive factors that need to be 
considered as covariates when examining the relationship between out-of-pocket pharmacy costs 
and medication adherence in adults with diabetes. The specific review questions were as follows. 
Review question: What factors affect adherence to oral diabetes medication or insulin 
therapy in adult diabetes patients? 
Specific review question 1: What are the barriers of adherence to oral diabetes 
medication or insulin therapy in adult diabetes patients? 
Specific review question 2: What are the facilitators of adherence to oral diabetes 
medication or insulin therapy in adult diabetes patients? 
Inclusion criteria. 
Included studies met the following criteria. The target population was 1) adults (age ≥ 19) 
with 2) either type 1 or type 2 diabetes; and 3) the outcome of interest was medication adherence 
to oral diabetes medications or insulin therapy. In addition, 4) the study results were presented as 
quantitative data including the direction and/or magnitude of an association between the 
                                                 
4 The original framework from Gellad et al. (2009) consists of the following three main constructs: patient, health 
system, and provider factors. In the adapted framework, the concept of medication characteristics is separated from 




predicting factors and medication adherence; and 5) the article was original research published in 
a peer reviewed journal; 6) in the English language. 
Exclusion criteria. 
A study was excluded if (1) study subjects with other diseases were mixed with subjects 
with diabetes, and the results were not reported separately; (2) measurement of medication 
adherence was not clearly described; (3) the study focused on adherence to medications other 
than diabetes medications; (4) the study was a randomized or non-randomized controlled trial, as 
these intervention studies usually control all other covariates to examine only the effects of 
intervention; (5) the study was conducted on animals; or (6) the information was presented as an 
editorial, letter, expert opinion, commentary, conference proceeding, thesis, book, or web page. 
Search strategy.  
Four databases—MEDLINE, PubMed, PsycINFO, and Scopus—were searched to select 
studies, beginning in November 2012, and the last searches were done in December 2012 for 
updates of literature made after the initial searches. 
Because PubMed is the most inclusive sources of healthcare research, the researcher 
began the search using PubMed, entering the following search terms: diabetes, medication 
adherence, predict*, determin*, barrier*, and facilitat*. 
The words “predict*,” “determin*,” “barrier*,” and “facilitat*” were combined by 
placing “OR” between them, and articles that included a combination of the phrases “diabetes,” 
“medication adherence,” and “predict* OR determin* OR barrier* OR facilitat*,” which were 
derived by placing “AND” between these phrases were extracted. The results produced were 




The search procedure developed for PubMed was carefully replicated as similarly as 
possible to retrieve studies from MEDLINE, PsycINFO, and Scopus. As setting a limit of 
“humans,” “English,” and “age + 19 years” was not possible in Scopus, further assessment was 
required to exclude the studies that did not meet these three criteria. The complete lists of 
strategies conducted on each database are listed in Appendix C. 
Study selection process. 
Using EndNote X5, all of the studies in the reference list were collected. Duplicate 
articles were then carefully eliminated from the list. In order to identify studies meeting all 
inclusion and exclusion criteria, a two stage process was employed: 1) title and abstract 
screening and 2) full-text assessment. The list of articles and reasons for exclusion were saved as 
an Excel file for future updates. 
Data extraction. 
Data were extracted from all studies meeting inclusion and exclusion criteria using a data 
extraction tool (Appendix D) developed by the researcher. The following information was 
collected from the included studies: authors’ names; publication year; country and/or area in 
which the study was conducted; number of study subjects; diabetes type; gender and age of 
participants; study design; group description; the definition and measurement of medication 
adherence; and non-modifiable and modifiable barriers and/or facilitators of diabetes medication 
adherence. 
Quality assessment: Risk of bias. 
The Health Evidence Bulletins—Wales for Observational Studies (2004) was used to 




items for case-control or cross-sectional studies to assess validity, reliability, and 
generalizability. This quality-assessment tool has four main sections: “A. What is this paper 
about?”; “B. Do I trust it?”; “C. What did they find?” and “D. Are the results relevant locally?” 
Since all studies were required to satisfy all items in section A to be included in the review, the 
results of section A were not included as part of quality appraisal. Each section included two to 
four questions, and the articles were assessed as “yes,” “no,” or “can’t tell” for each question. 
Higher numbers of “yes” answers indicated a lower risk of bias. Question 13 in section D was 
marked as “yes” if the study had at least 7 out of 10 “yes” answers including two specific items 
in each section; which refers to acceptable evidence for further use. Following were the specific 
questions that need to be satisfied: questions 5 and 6 in section B; questions 8 and 9 in section C; 
and questions 10 and 11 in section D. The instrument is included as Appendix E. 
Result of study selection. 
In total, the search identified 403 studies: 119 from MEDLINE, 112 from PubMed, 87 
from Scopus, and 85 from PsycINFO. Duplicate articles (n = 201) were then carefully eliminated 
from the list. Following this step, 202 studies were available for title and abstract review. Figure 






Figure 2.2. Flow diagram of the process of study selection for systematic review 2. 
403 records identified through 
 
MEDLINE: n = 119 
PubMed: n = 112 
Scopus: n = 87 
PsycINFO: n = 85 
 
Titles and abstracts 
screened 
(n = 202) 
Records excluded, with reasons (n = 113) 
 
 Not diabetes patients: 21 
 Medication adherence was not a variable of interest: 8 
 Medication adherence was an independent variable: 12 
 Not diabetes medication adherence: 13 
 Scale development: 15 
 Study design: review article: 7; intervention study: 28; 
qualitative research: 3 
 The relationships between the factors and medication 
adherence not assessed: 1 
 Publication type: book: 4; dissertation: 1 
 Full-text articles 
assessed for eligibility 
(n = 89) 
Full-text articles excluded, with reasons (n = 23) 
 
Measure of medication adherence unclear: 4 
Medication adherence was not a variable of interest: 1 
Medication adherence was an independent variable: 5 
 The relationships between the factors and medication 
adherence not assessed: 11 
Results combined with other diseases: 2 
 
Studies included in 
synthesis 
(n = 66) 
Duplicates 




Stage 1: Title and abstract screening. 
During title and abstract screening, 113 articles were excluded, and 89 studies remained 
for full-text assessment. The reasons for exclusion were: (1) the target population did not include 
adults with type 1 or 2 diabetes (n = 21); (2) medication adherence was not a variable of interest 
(n = 8) or (3) considered as an independent variable (n = 12); (4) the medication was not diabetes 
medication (n = 13); (5) the study purpose was scale development (n = 15); the article was (6) a 
review (n = 7), (7) an intervention study (n = 28), or (8) a qualitative study (n = 3); (9) the 
relationships between the factors and medication adherence was not assessed (n = 1); the study 
was published as (10) a book (n = 4) or (11) a dissertation (n = 1). 
Stage 2: Full-text assessment. 
The 89 remaining studies underwent full-text assessment and the reasons for excluding 
articles were recorded. Twenty-three articles were excluded because: (1) the measure of 
medication adherence was unclearly described or not described (n = 4); (2) medication adherence 
was not a variable of interest (n = 1) or (3) considered as an independent variable (n = 5); (4) the 
relationships between the factors and medication adherence was not assessed (n = 11); (5) the 
results for participants other than those with diabetes were not reported separately (n = 2). 





Table 2.4 summarizes the characteristics of the 66 studies. All included studies were 
published after 2000. The majority of studies (n = 57; 86.4%) were conducted in the United 
States (Albright, Parchman, & Burge, 2001; G. R. Bailey et al., 2012; Balkrishnan et al., 2006; 
Balkrishnan et al., 2003; Balkrishnan et al., 2004; Bell et al., 2010; Chao, Nau, & Aikens, 2007; 
Chao, Nau, Aikens, & Taylor, 2005; Cheong et al., 2008; Chernew et al., 2008; Colby, Wang, 
Chhabra, & Perez-Escamilla, 2012; Colombi, Yu-Isenberg, & Priest, 2008; Duru et al., 2010; 
Egede et al., 2011; Fisher, Glasgow, & Strycker, 2010; Gibson et al., 2010; Gonzalez et al., 
2007; Gonzalez et al., 2008; Gu et al., 2010; Heisler, Cole, Weir, Kerr, & Hayward, 2007; 
Hernandez-Tejada et al., 2012; Kaissi & Parchman, 2009; Kalsekar, Sheehan, & Peak, 2007; 
Katon et al., 2009; Kilbourne, Reynolds, et al., 2005; Kocarnik et al., 2012; Kreyenbuhl et al., 
2010; Kreyenbuhl et al., 2011; W. C. Lee et al., 2006; Lin et al., 2004; Mackey et al., 2012; 
Mann, Ponieman, Leventhal, & Halm, 2009; Mayberry & Osborn, 2012; Nau, Aikens, & 
Pacholski, 2007; Nau, Chao, & Aikens, 2005; Ngo-Metzger, Sorkin, Billimek, Greenfield, & 
Kaplan, 2012; Oladapo et al., 2012; Osborn et al., 2011; Osborn & Egede, 2012; Parada, Horton, 
Cherrington, Ibarra, & Ayala, 2012; Parchman, Zeber, & Palmer, 2010; Patel et al., 2010; M. 
Pawaskar et al., 2010; M.  Pawaskar et al., 2007; Piette, Heisler, Krein, & Kerr, 2005; Raebel et 
al., 2012; Rozenfeld et al., 2008; Sarkar, Fisher, & Schillinger, 2006; Schoenthaler, Schwartz, 
Wood, & Stewart, 2012; Scollan-Koliopoulos, O'Connell, & Walker, 2007; Shenolikar, 
Balkrishnan, Camacho, Whitmire, & Anderson, 2006a; Shenolikar et al., 2006b; Sherman, 
Sekili, Prakash, & Rausch, 2011; Smalls et al., 2012; Walker et al., 2012; Williams et al., 2009; 
Yang et al., 2009). Approximately half of the included studies (n = 36; 54.5%) employed a cross-




2012; Bell et al., 2010; Chao et al., 2007; Chao et al., 2005; Colby et al., 2012; Duru et al., 2010; 
Fisher et al., 2010; Gibson et al., 2010; Gonzalez et al., 2007; Hanko et al., 2007; Heisler et al., 
2007; Hernandez-Tejada et al., 2012; Jamous et al., 2011; Kaissi & Parchman, 2009; Kreyenbuhl 
et al., 2011; Lin et al., 2004; Mackey et al., 2012; Mann et al., 2009; Mayberry & Osborn, 2012; 
Munir, Randall, Yarker, & Nielsen, 2009; Nau et al., 2007; Ngo-Metzger et al., 2012; Osborn et 
al., 2011; Osborn & Egede, 2012; Parada et al., 2012; Piette et al., 2005; Sarkar et al., 2006; 
Schoenthaler et al., 2012; Scollan-Koliopoulos et al., 2007; Smalls et al., 2012; Tiv et al., 2012; 
Walker et al., 2012; Williams et al., 2009). The remaining studies were either retrospective 
(n=22; 33.3%) (Balkrishnan et al., 2006; Balkrishnan et al., 2004; Cheong et al., 2008; Chernew 
et al., 2008; Colombi et al., 2008; Donnan, MacDonald, & Morris, 2002; Gu et al., 2010; 
Kalsekar et al., 2007; Kocarnik et al., 2012; Kreyenbuhl et al., 2010; W. C. Lee et al., 2006; Nau 
et al., 2005; Oladapo et al., 2012; Patel et al., 2010; M. Pawaskar et al., 2010; M.  Pawaskar et 
al., 2007; Raebel et al., 2012; Rozenfeld et al., 2008; Shenolikar et al., 2006a, 2006b; Sherman et 
al., 2011; Yang et al., 2009) or prospective cohort studies (n = 8; 12.1%) (Balkrishnan et al., 
2003; Dirmaier et al., 2010; Egede et al., 2011; Gonzalez et al., 2008; Katon et al., 2009; 
Kilbourne, Reynolds, et al., 2005; Parchman et al., 2010; White et al., 2012). Study samples 
included patients from primary care clinics (n = 16; 24.2%) (Gonzalez et al., 2007; Gonzalez et 
al., 2008; Hernandez-Tejada et al., 2012; Kaissi & Parchman, 2009; Katon et al., 2009; 
Kilbourne, Reynolds, et al., 2005; Kocarnik et al., 2012; Mackey et al., 2012; Mann et al., 2009; 
Ngo-Metzger et al., 2012; Osborn et al., 2011; Parchman et al., 2010; Rozenfeld et al., 2008; 
Sarkar et al., 2006; Smalls et al., 2012; Walker et al., 2012), Medicare/Medicaid enrollees (n=13; 
19.7%) (Balkrishnan et al., 2006; Balkrishnan et al., 2003; Balkrishnan et al., 2004; Cheong et 




Pawaskar et al., 2010; M.  Pawaskar et al., 2007; Shenolikar et al., 2006a, 2006b; Yang et al., 
2009) data from state-level databases and health maintenance organizations or managed care 
organizations enrollee data (n = 6; 9.1%) (Chao et al., 2007; Chao et al., 2005; Lin et al., 2004; 
Nau et al., 2007; Nau et al., 2005; Williams et al., 2009), and military settings (n = 5; 7.6%) 
(Jamous et al., 2011; Kilbourne, Reynolds Iii, et al., 2005; Kocarnik et al., 2012; Kreyenbuhl et 
al., 2010; Piette et al., 2005). 
Most studies (n = 53; 80.3%) restricted their sample to adults with type 2 diabetes 
(Aflakseir, 2012; Al-Qazaz et al., 2011; Albright et al., 2001; Balkrishnan et al., 2006; 
Balkrishnan et al., 2003; Balkrishnan et al., 2004; Bell et al., 2010; Chao et al., 2007; Chao et al., 
2005; Cheong et al., 2008; Chernew et al., 2008; Colombi et al., 2008; Dirmaier et al., 2010; 
Donnan et al., 2002; Egede et al., 2011; Fisher et al., 2010; Gibson et al., 2010; Gonzalez et al., 
2007; Gonzalez et al., 2008; Hanko et al., 2007; Hernandez-Tejada et al., 2012; Jamous et al., 
2011; Kaissi & Parchman, 2009; Kalsekar et al., 2007; Kilbourne, Reynolds, et al., 2005; 
Kocarnik et al., 2012; Kreyenbuhl et al., 2010; Kreyenbuhl et al., 2011; W. C. Lee et al., 2006; 
Mackey et al., 2012; Mann et al., 2009; Mayberry & Osborn, 2012; Nau et al., 2007; Nau et al., 
2005; Ngo-Metzger et al., 2012; Oladapo et al., 2012; Osborn & Egede, 2012; Parada et al., 
2012; Parchman et al., 2010; Patel et al., 2010; M. Pawaskar et al., 2010; M.  Pawaskar et al., 
2007; Rozenfeld et al., 2008; Sarkar et al., 2006; Schoenthaler et al., 2012; Scollan-Koliopoulos 
et al., 2007; Shenolikar et al., 2006a, 2006b; Smalls et al., 2012; Tiv et al., 2012; Walker et al., 
2012; White et al., 2012; Williams et al., 2009), only 3 studies (4.5%) included those with type 1 
and 2 diabetes (Katon et al., 2009; Lin et al., 2004; Osborn et al., 2011). The remaining studies 
(n = 10; 15.2%) did not specify type of diabetes (G. R. Bailey et al., 2012; Colby et al., 2012; 




Wagner, 2004; Raebel et al., 2012; Sherman et al., 2011; Yang et al., 2009). All studies included 
both males and females. Study sample sizes ranged from 59 to 1,888,682. The total number of 
participants in all included studies totaled 3,191,935 and includes 1,259,489 type 2 diabetes, 
8,963 type 1 and 2 diabetes, and 1,923,483 unspecified diabetes patients. Over half of the studies 
(n = 43; 65.2%) included participants with mean ages of 50 to 70 (Al-Qazaz et al., 2011; 
Albright et al., 2001; G. R. Bailey et al., 2012; Chao et al., 2007; Chao et al., 2005; Cheong et 
al., 2008; Chernew et al., 2008; Colby et al., 2012; Colombi et al., 2008; Dirmaier et al., 2010; 
Donnan et al., 2002; Duru et al., 2010; Egede et al., 2011; Fisher et al., 2010; Gibson et al., 2010; 
Gonzalez et al., 2007; Gonzalez et al., 2008; Hanko et al., 2007; Heisler et al., 2007; Jamous et 
al., 2011; Kaissi & Parchman, 2009; Katon et al., 2009; Kilbourne, Reynolds, et al., 2005; 
Kocarnik et al., 2012; Kreyenbuhl et al., 2010; Kreyenbuhl et al., 2011; Lin et al., 2004; Mackey 
et al., 2012; Mann et al., 2009; Mayberry & Osborn, 2012; Nau et al., 2007; Nau et al., 2005; 
Oladapo et al., 2012; Osborn et al., 2011; Osborn & Egede, 2012; Parada et al., 2012; Parchman 
et al., 2010; M.  Pawaskar et al., 2007; Rozenfeld et al., 2008; Sarkar et al., 2006; Schoenthaler 
et al., 2012; Sherman et al., 2011; Williams et al., 2009). 
Measurements of medication adherence. 
Electronic lids on medication containers. 
Only 2 studies (3.0%) utilized electronic lid adherence (Kilbourne, Reynolds Iii, et al., 
2005; White et al., 2012). 
Patient self-reports. 
Self-report instruments were used to measure medication adherence in 37 studies. 
Morisky’s tool was the most frequently utilized instrument (n = 13; 35.1%) (Al-Qazaz et al., 




2012; Jamous et al., 2011; Mackey et al., 2012; Mann et al., 2009; Osborn & Egede, 2012; 
Parada et al., 2012; Parchman et al., 2010; Smalls et al., 2012; Walker et al., 2012), followed by 
the Summary of Diabetes Self-Care Activities scale (SDSCA) (n = 6; 16.2%) (Bell et al., 2010; 
Gonzalez et al., 2007; Gonzalez et al., 2008; Osborn et al., 2011; Sarkar et al., 2006; Scollan-
Koliopoulos et al., 2007), and Horne’s scale (n = 3; 8.1%) (Chao et al., 2007; Chao et al., 2005; 
Nau et al., 2007). 
Prescription refill records. 
Prescription refill data were used in 33 studies as the source of information from which 
medication adherence was estimated. Five different approaches to measurement were used: 
medication proportion ratio (MPR), proportion of days covered (PDC), continuous measure of 
medication gaps (CMG), medication proportion ratio modified (MPRm), and compliance refill 
(CR). 
MPR was the most frequently used method (n = 12; 36.4%) (Balkrishnan et al., 2006; 
Chernew et al., 2008; Donnan et al., 2002; Kilbourne, Reynolds, et al., 2005; Kocarnik et al., 
2012; Kreyenbuhl et al., 2010; Nau et al., 2005; Patel et al., 2010; M. Pawaskar et al., 2010; M.  
Pawaskar et al., 2007; Schoenthaler et al., 2012; Shenolikar et al., 2006b). The second prominent 
measurement of pharmacy refill adherence was PDC including MPR truncated at 1, which is 
equivalent to PDC (n = 11; 33.3%) (Balkrishnan et al., 2003; Balkrishnan et al., 2004; Colombi 
et al., 2008; Egede et al., 2011; Gibson et al., 2010; Gu et al., 2010; Oladapo et al., 2012; Raebel 
et al., 2012; Shenolikar et al., 2006a; Sherman et al., 2011; Yang et al., 2009). PDC and MPR are 
identical only when oversupply of MPR is truncated at 100% (Hess et al., 2006). CMG, an 
inverse ratio of PDC (Karve et al., 2008), was the third most identified pharmacy refill measure 




al., 2009), followed by MPRm truncated at 1 (n = 2; 6.13%) (Cheong et al., 2008; W. C. Lee et 
al., 2006), MPRm (n = 1; 3.0%) (Kalsekar et al., 2007), and CR (n = 1; 3.0%) (Rozenfeld et al., 
2008). 
Definitions of medication adherence. 
 Approximately 40% of the studies reported a cut-off point (n = 27; 40.9%) that defined 
adherence as occurring if patients took or purchased medications (G. R. Bailey et al., 2012; 
Cheong et al., 2008; Chernew et al., 2008; Colby et al., 2012; Colombi et al., 2008; Donnan et 
al., 2002; Duru et al., 2010; Egede et al., 2011; Gibson et al., 2010; Gonzalez et al., 2007; 
Gonzalez et al., 2008; Gu et al., 2010; Jamous et al., 2011; Katon et al., 2009; Kocarnik et al., 
2012; Kreyenbuhl et al., 2010; Kreyenbuhl et al., 2011; W. C. Lee et al., 2006; Mann et al., 
2009; Oladapo et al., 2012; Parada et al., 2012; M. Pawaskar et al., 2010; Piette et al., 2004; 
Rozenfeld et al., 2008; Sarkar et al., 2006; Tiv et al., 2012; Yang et al., 2009). Of 37 studies that 
used self-report measures, most (n = 9; 24.3%) used a cut-off point of 100% (Colby et al., 2012; 
Gonzalez et al., 2007; Gonzalez et al., 2008; Jamous et al., 2011; Kreyenbuhl et al., 2011; Parada 
et al., 2012; Piette et al., 2005; Sarkar et al., 2006; Tiv et al., 2012), whereas approximately 40% 
of the studies that used prescription refill records (n = 13; 39.4%) utilized “≥ 80%” including 
“≥80%,” “80–100%,” and “80–120%.” (Cheong et al., 2008; Chernew et al., 2008; Colombi et 
al., 2008; Egede et al., 2011; Gibson et al., 2010; Gu et al., 2010; Kocarnik et al., 2012; 
Kreyenbuhl et al., 2010; W. C. Lee et al., 2006; Oladapo et al., 2012; M. Pawaskar et al., 2010; 
Rozenfeld et al., 2008; Yang et al., 2009) Only two studies used “≥ 90%.” (n = 2; 8.7%) (Donnan 
et al., 2002; White et al., 2012) Non-adherence measure such as CMG, an inverse ratio of 
adherence measures, used a cut-off point of < 20%, (n = 2; 50.0%) (Duru et al., 2010; Katon et 




(Lin et al., 2004; Williams et al., 2009). 
One fourth of the included studies (n = 16; 24.2%) considered adherence as a continuous 
variable (Balkrishnan et al., 2006; Balkrishnan et al., 2003; Balkrishnan et al., 2004; Chao et al., 
2005; Kalsekar et al., 2007; Kilbourne, Reynolds, et al., 2005; Lin et al., 2004; Nau et al., 2005; 
Patel et al., 2010; M.  Pawaskar et al., 2007; Raebel et al., 2012; Schoenthaler et al., 2012; 
Shenolikar et al., 2006a, 2006b; Sherman et al., 2011; Williams et al., 2009). Of these, all but 
one study (Chao et al., 2005) employed prescription refill records measures. One third of the 
studies (n = 22; 33.3%) did not provide information on how they defined medication adherence 
or whether it was treated as a continuous or dichotomous variable (Aflakseir, 2012; Al-Qazaz et 
al., 2011; Albright et al., 2001; Bell et al., 2010; Chao et al., 2007; Dirmaier et al., 2010; Fisher 
et al., 2010; Hanko et al., 2007; Heisler et al., 2007; Hernandez-Tejada et al., 2012; Kaissi & 
Parchman, 2009; Mackey et al., 2012; Mayberry & Osborn, 2012; Munir et al., 2009; Nau et al., 
2007; Ngo-Metzger et al., 2012; Osborn et al., 2011; Osborn & Egede, 2012; Parchman et al., 







Characteristics of 66 Included Studies concerning Adult Diabetes Patients: Definitions, Measurements, Barriers, and Facilitators of 
Medication Adherence  
Author (year) Setting 
Country/Area 
Sample size (n) 
Diabetes type 
Gender (%) 
Age (mean ±SD) 
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versus Metformin  
 90% MPR Modifiable:  









                                                 
5 Study design: CS=Cross-sectional; PC=Prospective cohort; RC=Retrospective cohort 
6 Follow-up duration: only for cohort studies 
7 Measurement of medication adherence:  
Pharmacy refills: CMG=Continuous measure of medication gaps; MPR=Medication possession ratio; PDC=Proportion of days covered; 
MPRm=Medication proportion ratio, modified; CR=Compliance refill  
Self-report: ARMS=Adherence Refills and Medication Scale; BMQ=Brief Medication Questionnaire; SDSCA=Summary of Diabetes Self-Care 
Activities questionnaire 
Other abbreviations: DM=Diabetes mellitus; FDCT=Fixed-dose combination therapy; HMO=Health maintenance organization;  







Author (year) Setting 
Country/Area 
Sample size (n) 
Diabetes type 
Gender (%) 
Age (mean ±SD) 















Mean age 68 
yrs. 
-Higher number of 
daily 
tablets/medications;   
Both groups: 














N = 775 
Type 2 DM &  













(Charlson index)  
-Poor access to care 







use (versus insulin 
use)) 






N = 3,483 
Type 2 DM &  





Mean age 48.6 
yrs. 











-Black race (versus 
white race) 
-Other race (versus 













N = 4,463 






Grouped by:  














Author (year) Setting 
Country/Area 
Sample size (n) 
Diabetes type 
Gender (%) 
Age (mean ±SD) 



















N = 445 








scale (4 items) 
 












cognitive barriers to 





















at an urban 
VA  
N = 203 
Type 2 DM 
ODM users 
Veterans 
% Gender not 
reported 
Age 67.0 10.0 
yrs. 
PC (1 year) 
Grouped by:  






1) % days (of 




















Nau et al. (2005) USA 
Midwestern 
United States 
N = 1,454 
















Author (year) Setting 
Country/Area 
Sample size (n) 
Diabetes type 
Gender (%) 
Age (mean ±SD) 
























use or no use) 
Piette et al. (2005) USA 
5 VA 
N = 912 
DM (type not 
specified) 






Grouped by:  
High versus low 
physician trust 

























N = 4,710 
Type 2 DM 




Mean age 48.6 
yrs. 








-Poor access to care 
(Higher emergency 








-Black race (versus 
white race) 












N = 1,156 
Type 2 DM 
RC (2½  years) 
 
80–100% MPRm 











Author (year) Setting 
Country/Area 
Sample size (n) 
Diabetes type 
Gender (%) 
Age (mean ±SD) 



























Sarkar et al. (2006) USA 
San Francisco 
2 primary care 
clinics 
N = 408 
Type 2 DM &  
age > 30 
English or 
Spanish speakers 













efficacy scores not 
related to 
adherence  






N = 1,073 















race (versus all other 
race) not associated 
with non-adherence  
Modifiable: 
-Higher number of 
prescription refills 
not associated with 
adherence  
 






N = 3,169 
Type 2 DM 




Age 18–65 yrs. 
RC (3 years) 





















Author (year) Setting 
Country/Area 
Sample size (n) 
Diabetes type 
Gender (%) 
Age (mean ±SD) 



















race (versus white 
race) 




N = 445 



























N = 879 










Hanko et al. (2007) Hungary 
14 community 
pharmacies 
N = 142 







claim data of 
drug purchasing  
 















-Higher quality of 







Author (year) Setting 
Country/Area 
Sample size (n) 
Diabetes type 
Gender (%) 
Age (mean ±SD) 

















Heisler et al. (2007) USA 
 
N = 1,588 










tool (5 domains) 














N = 2,696 
New Type 2 DM 
& age < 65 




Mean age 48.0 
yrs. 

















N = 391 







depression status  
Not 
defined 















N = 168  
Type 2 DM 

















Author (year) Setting 
Country/Area 
Sample size (n) 
Diabetes type 
Gender (%) 
Age (mean ±SD) 
















Koliopoulos et al. 
(2007) 
USA 




N = 123 


























N = 22,332 

















-Higher number of 
tablets/medications 












N = 29,764 



















N = 2,052 
Type 2 DM 
Pittsburgh Plate 
Glass industries 
RC (2 years) 
Grouped by 
copayment level: 















Author (year) Setting 
Country/Area 
Sample size (n) 
Diabetes type 
Gender (%) 
Age (mean ±SD) 

























low or medium 
copayments)) 
 
of ODMs (versus 
new users of 
ODMs)) 












N = 208 




PC (9 months) 100% SDSCA 
(modified)  
 















N = 2,741 




RC (18 months) ≥ 80% CR  
 
Modifiable: 
















care clinics  
N = 617 




















Author (year) Setting 
Country/Area 
Sample size (n) 
Diabetes type 
Gender (%) 
Age (mean ±SD) 




































care clinics  
N = 4,117 





PC (5 years) 
Grouped by: 
depression status  











N = 151 

















about diabetes  






barriers to taking 
medication (Feeling 
medicines are hard 














N = 80 


































Author (year) Setting 
Country/Area 
Sample size (n) 
Diabetes type 
Gender (%) 
Age (mean ±SD) 




















- Older age 








N = 2,973 








2) Self-report (2 
items) 
 



























-Higher quality of 
life 
Yang et al. (2009) USA 
AL, CA, FL, 
MS, NY, and 
OH  
 
N = 1,888,682 
DM (type not 
specified) 
Medicare Part D 
enrollees 
















Author (year) Setting 
Country/Area 
Sample size (n) 
Diabetes type 
Gender (%) 
Age (mean ±SD) 























Hispanic, and other 
race (versus white 
race) 
-Female gender 




N = 696 
Type 2 DM 
Rural elderly 
ethnic minorities 
living below the 
poverty level 
49.3% Female 

















Dirmaier et al. 
(2010) 
Germany N = 866 
Type 2 DM 
48.8% Female 
Mean age 66.4 
yrs. 























N = 13,922 





Age 62.0 ±11.9 
yrs. 












Fisher et al. (2010) USA N = 463 

















Author (year) Setting 
Country/Area 
Sample size (n) 
Diabetes type 
Gender (%) 
Age (mean ±SD) 

















Gibson et al. (2010) USA 
 
N = 152,090 






Mean age 52.6 
yrs. 
CS 
Grouped by:  
ODM with or 






pocket costs (Higher 
level of prescription 
drug cost sharing, 
Higher cost sharing 

















Gu et al. (2010) USA N = 12,881 
DM (type not 
specified) 














only versus full 
coverage 
80–100% PDC Modifiable: 
-Higher out-of-
pocket costs (No 
coverage in donut 
hole (versus full 
coverage in donut 
hole), Generic drug 
coverage only in 
donut hole (versus 











N = 22,014 
Type 2 DM 
3.6% Female  
RC (18 months) 
Grouped by: 
80–120% MPR Modifiable: 
-Depression 
Modifiable: 







Author (year) Setting 
Country/Area 
Sample size (n) 
Diabetes type 
Gender (%) 
Age (mean ±SD) 















Mean age 60.4 
yrs. 








-Homelessness ≤ 1 
year 
Non-modifiable: 











of ODM delivery 
by mail (versus 
≤50% of ODM 
mailed)) 
-Higher number of 
tablets/medications 
( 3 different 










5 primary care 
practices  
N = 141 




















N = 3,169 
Type 2 DM 




RC  Continuous 
variable 
MPR Modifiable: 
-Higher number of 
comorbidities 














Author (year) Setting 
Country/Area 
Sample size (n) 
Diabetes type 
Gender (%) 
Age (mean ±SD) 






































N = 8,581 
Type 2 DM 
Medicaid 
enrollees 









Fee for service 
 80% MPR Modifiable: 
-Lack of health 




fee for service)) 
-Poor access to care 






-Black race (versus 
all other races) 
Non-modifiable: 
-Older age  





diabetes clinic  
N = 540 
Type 2 DM ≥ 1 
yr. 
ODM treatment 





















Author (year) Setting 
Country/Area 
Sample size (n) 
Diabetes type 
Gender (%) 
Age (mean ±SD) 















Egede et al. (2011) USA 
 
N = 690,968 



















Jamous et al. (2011) Palestine 
Military 
Medical clinic  
N = 131 
Type 2 DM 















not associated with 
adherence 
Modifiable: 















6 public and 
private mental 
health clinics 
N = 74 
Type 2 DM &  
age ≤ 65 
English speakers  
55.4% Female 












-Having a serious 
mental illness 







N = 383 





























Author (year) Setting 
Country/Area 
Sample size (n) 
Diabetes type 
Gender (%) 
Age (mean ±SD) 

























N = 3,777 
DM (type not 
specified) 
47.4% Female 
Mean age 58.8 
yrs. 






























N = 102 










-Perceived harms of 
medications 
(Concerns about the 
potential negative 
effects of medicines) 
Modifiable: 
-The belief that 
diabetes would last 
a long time (versus 
acute)  
G. R. Bailey et al. 
(2012) 
USA 









N = 59 















pocket costs for 
medications  







Colby et al. (2012) USA 
CT 
N = 61 













Author (year) Setting 
Country/Area 
Sample size (n) 
Diabetes type 
Gender (%) 
Age (mean ±SD) 

















age > 21 




-Benefits (receipt of 






-Higher number of 
tablets/medications  
Hernandez-Tejada 







N = 378 




















care clinics  
N = 280,603 





















N = 1,823 























USA N = 61 



























Author (year) Setting 
Country/Area 
Sample size (n) 
Diabetes type 
Gender (%) 
Age (mean ±SD) 















Ngo-Metzger et al. 
(2012) 
USA 




N = 1,135 






Age 55-64 yrs.: 
62.8% 










pocket costs (Higher 
medication cost, 
Presence of financial 
barriers to medical 
care, Perceived 
financial burden of 
diabetes) 
-No health insurance  
 





N = 4,277 























insulin use (versus 
insulin use)) 

















N = 139 

























Author (year) Setting 
Country/Area 
Sample size (n) 
Diabetes type 
Gender (%) 
Age (mean ±SD) 















Parada et al. (2012) USA 
 
N = 302 




















Raebel et al. (2012) USA 
 
N = 1,521 
DM (type not 
specified) 
New medication 
users (any type)  
47.3% Female 














-Higher number of 
physician 
visits/contacts (≥ 5 
ambulatory 
healthcare contacts 
≤ 6 months (versus 
< 5 visits)) 






based clinics  
N = 608 











(ODM and Insulin 
users (versus ODM 
only)) 
Non-modifiable: 
-Longer duration of 













Smalls et al. (2012) USA 
Southeastern 
United States  
2 primary care 
clinics  
N = 378 



















Author (year) Setting 
Country/Area 
Sample size (n) 
Diabetes type 
Gender (%) 
Age (mean ±SD) 
























N = 3,637 












































by physician only, 
and by physician 
and patient (versus 












confidence in the 
future) 
Non-modifiable: 







Author (year) Setting 
Country/Area 
Sample size (n) 
Diabetes type 
Gender (%) 
Age (mean ±SD) 















treatment (versus no 
need)) 
Walker et al. (2012) USA 
Southeastern 
United States  
2 primary care 
clinics  
N = 378 



















N = 60 
Type 2 DM 
33.0% Female 
Mean age 70 
yrs.  




1) % of days the 
prescribed 
number of doses 
was taken 
 







control (Higher prior 
HbA1c)  
-Higher number of 
daily 
tablets/medications 







5 Study design: CS=Cross-sectional; PC=Prospective cohort; RC=Retrospective cohort 
6 Follow-up duration: only for cohort studies 
7 Measurement of medication adherence:  
Pharmacy refills: CMG=Continuous measure of medication gaps; MPR=Medication possession ratio; PDC=Proportion of days covered; 
MPRm=Medication proportion ratio, modified; CR=Compliance refill  
Self-report: ARMS=Adherence Refills and Medication Scale; BMQ=Brief Medication Questionnaire; SDSCA=Summary of Diabetes Self-Care 
Activities questionnaire 
Other abbreviations: DM=Diabetes mellitus; FDCT=Fixed-dose combination therapy; HMO=Health maintenance organization;  




Risk of bias across studies. 
Of the 30 cohort studies included in the review, approximately half (n = 14, 46.7%) had a 
follow-up period of 2 or more years, a time sufficient to examine adherence over time 
(Balkrishnan et al., 2006; Balkrishnan et al., 2003; Balkrishnan et al., 2004; Cheong et al., 2008; 
Chernew et al., 2008; Colombi et al., 2008; Donnan et al., 2002; Egede et al., 2011; Kalsekar et 
al., 2007; Katon et al., 2009; W. C. Lee et al., 2006; M.  Pawaskar et al., 2007; Shenolikar et al., 
2006a, 2006b). In most studies (n = 49; 74.2%) the researchers controlled for confounders and 
biases using statistical methods, such as multivariate regression analysis (Aflakseir, 2012; Al-
Qazaz et al., 2011; Albright et al., 2001; Balkrishnan et al., 2006; Balkrishnan et al., 2003; 
Balkrishnan et al., 2004; Bell et al., 2010; Chao et al., 2007; Cheong et al., 2008; Chernew et al., 
2008; Colby et al., 2012; Colombi et al., 2008; Dirmaier et al., 2010; Donnan et al., 2002; Duru 
et al., 2010; Egede et al., 2011; Gibson et al., 2010; Gonzalez et al., 2007; Gonzalez et al., 2008; 
Gu et al., 2010; Heisler et al., 2007; Hernandez-Tejada et al., 2012; Katon et al., 2009; 
Kilbourne, Reynolds, et al., 2005; Kreyenbuhl et al., 2010; Kreyenbuhl et al., 2011; W. C. Lee et 
al., 2006; Lin et al., 2004; Munir et al., 2009; Nau et al., 2007; Ngo-Metzger et al., 2012; 
Oladapo et al., 2012; Osborn et al., 2011; Osborn & Egede, 2012; Parada et al., 2012; Parchman 
et al., 2010; M. Pawaskar et al., 2010; M.  Pawaskar et al., 2007; Piette et al., 2005; Raebel et al., 
2012; Rozenfeld et al., 2008; Sarkar et al., 2006; Schoenthaler et al., 2012; Shenolikar et al., 
2006b; Smalls et al., 2012; Tiv et al., 2012; Walker et al., 2012; White et al., 2012; Yang et al., 
2009). However, two thirds of the studies (n = 42; 63.6%) used convenience sampling or lacked 
a control group that was comparable on important confounding factors (Aflakseir, 2012; Al-
Qazaz et al., 2011; Albright et al., 2001; G. R. Bailey et al., 2012; Balkrishnan et al., 2003; Chao 




Fisher et al., 2010; Gonzalez et al., 2007; Gonzalez et al., 2008; Hanko et al., 2007; Hernandez-
Tejada et al., 2012; Jamous et al., 2011; Kaissi & Parchman, 2009; Katon et al., 2009; 
Kreyenbuhl et al., 2010; Mackey et al., 2012; Mann et al., 2009; Mayberry & Osborn, 2012; 
Munir et al., 2009; Nau et al., 2005; Ngo-Metzger et al., 2012; Oladapo et al., 2012; Osborn et 
al., 2011; Osborn & Egede, 2012; Parada et al., 2012; Parchman et al., 2010; Patel et al., 2010; 
Rozenfeld et al., 2008; Sarkar et al., 2006; Schoenthaler et al., 2012; Scollan-Koliopoulos et al., 
2007; Sherman et al., 2011; Smalls et al., 2012; Tiv et al., 2012; Walker et al., 2012; White et al., 
2012; Williams et al., 2009; Yang et al., 2009). 
The majority of studies (n = 54; 81.8%) utilized appropriate statistical methods 
(Aflakseir, 2012; Al-Qazaz et al., 2011; Albright et al., 2001; Balkrishnan et al., 2006; 
Balkrishnan et al., 2003; Balkrishnan et al., 2004; Basu, Yin, & Alexander, 2010; Cheong et al., 
2008; Colby et al., 2012; Colombi et al., 2008; Dirmaier et al., 2010; Donnan et al., 2002; Duru 
et al., 2010; Egede et al., 2011; Gibson et al., 2010; Gonzalez et al., 2007; Gonzalez et al., 2008; 
Gu et al., 2010; Hanko et al., 2007; Heisler et al., 2007; Hernandez-Tejada et al., 2012; Jamous 
et al., 2011; Kalsekar et al., 2007; Katon et al., 2009; Kilbourne, Reynolds, et al., 2005; Kocarnik 
et al., 2012; Kreyenbuhl et al., 2010; Kreyenbuhl et al., 2011; W. C. Lee et al., 2006; Lin et al., 
2004; Mackey et al., 2012; Mann et al., 2009; Muir et al., 2012; Ngo-Metzger et al., 2012; 
Oladapo et al., 2012; Osborn et al., 2011; Osborn & Egede, 2012; Parada et al., 2012; M. 
Pawaskar et al., 2010; M.  Pawaskar et al., 2007; Piette et al., 2005; Raebel et al., 2012; 
Rozenfeld et al., 2008; Sarkar et al., 2006; Schoenthaler et al., 2012; Scollan-Koliopoulos et al., 
2007; Shenolikar et al., 2006a, 2006b; Smalls et al., 2012; Tiv et al., 2012; Walker et al., 2012; 
White et al., 2012; Williams et al., 2009; Yang et al., 2009), and the researcher’s conclusions 




et al., 2011; G. R. Bailey et al., 2012; Balkrishnan et al., 2006; Balkrishnan et al., 2003; 
Balkrishnan et al., 2004; Bell et al., 2010; Chao et al., 2007; Chao et al., 2005; Cheong et al., 
2008; Colby et al., 2012; Colombi et al., 2008; Dirmaier et al., 2010; Donnan et al., 2002; Duru 
et al., 2010; Egede et al., 2011; Gibson et al., 2010; Gonzalez et al., 2007; Gonzalez et al., 2008; 
Gu et al., 2010; Hanko et al., 2007; Heisler et al., 2007; Hernandez-Tejada et al., 2012; Jamous 
et al., 2011; Kaissi & Parchman, 2009; Kalsekar et al., 2007; Katon et al., 2009; Kilbourne, 
Reynolds, et al., 2005; Kocarnik et al., 2012; Kreyenbuhl et al., 2010; Kreyenbuhl et al., 2011; 
W. C. Lee et al., 2006; Lin et al., 2004; Mackey et al., 2012; Mayberry & Osborn, 2012; Munir 
et al., 2009; Ngo-Metzger et al., 2012; Oladapo et al., 2012; Osborn et al., 2011; Osborn & 
Egede, 2012; Parada et al., 2012; Parchman et al., 2010; Patel et al., 2010; M. Pawaskar et al., 
2010; M.  Pawaskar et al., 2007; Piette et al., 2005; Raebel et al., 2012; Sarkar et al., 2006; 
Schoenthaler et al., 2012; Shenolikar et al., 2006b; Sherman et al., 2011; Smalls et al., 2012; Tiv 
et al., 2012; Walker et al., 2012; White et al., 2012; Williams et al., 2009; Yang et al., 2009). 
One third of the studies (n = 24; 36.4%) did not provide sufficient detail about the sample in 
terms of age, gender, and race/ethnicity to allow for generalizability of study findings (Aflakseir, 
2012; Albright et al., 2001; Balkrishnan et al., 2003; Cheong et al., 2008; Chernew et al., 2008; 
Colombi et al., 2008; Dirmaier et al., 2010; Donnan et al., 2002; Gibson et al., 2010; Gu et al., 
2010; Hanko et al., 2007; Jamous et al., 2011; Kilbourne, Reynolds, et al., 2005; W. C. Lee et al., 
2006; Munir et al., 2009; Nau et al., 2005; Oladapo et al., 2012; Parada et al., 2012; Rozenfeld et 
al., 2008; Sarkar et al., 2006; Schoenthaler et al., 2012; Tiv et al., 2012; White et al., 2012). 
Figure 2.3 synthesizes results of the quality appraisal, and Appendix G provides results of 




the included studies (n = 47, 71.2%) satisfy at least 7 out of 10 “yes” items including two 
specific items in each section indicating acceptable evidence for further use  
(Aflakseir, 2012; Balkrishnan et al., 2006; Balkrishnan et al., 2003; Balkrishnan et al., 2004; Bell 
et al., 2010; Cheong et al., 2008; Colby et al., 2012; Colombi et al., 2008; Dirmaier et al., 2010; 
Donnan et al., 2002; Duru et al., 2010; Egede et al., 2011; Gibson et al., 2010; Gonzalez et al., 
2007; Gonzalez et al., 2008; Gu et al., 2010; Heisler et al., 2007; Hernandez-Tejada et al., 2012; 
Kalsekar et al., 2007; Katon et al., 2009; Kilbourne, Reynolds, et al., 2005; Kocarnik et al., 2012; 
Kreyenbuhl et al., 2010; Kreyenbuhl et al., 2011; W. C. Lee et al., 2006; Lin et al., 2004; 
Mackey et al., 2012; Ngo-Metzger et al., 2012; Oladapo et al., 2012; Osborn et al., 2011; Osborn 
& Egede, 2012; Parada et al., 2012; Parchman et al., 2010; M. Pawaskar et al., 2010; M.  
Pawaskar et al., 2007; Piette et al., 2005; Raebel et al., 2012; Sarkar et al., 2006; Schoenthaler et 
al., 2012; Shenolikar et al., 2006b; Sherman et al., 2011; Smalls et al., 2012; Tiv et al., 2012; 








Figure 2.3. Quality assessment summary for systematic review 2.
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Quality Assessment Summary: Overall






Synthesis of the results of included studies. 
Figures 2.4 and 2.5 present the barriers to and facilitators of diabetes medication 
adherence organized by the adapted conceptual framework constructs from Gellad et al. (2009): 
patient, medication characteristics, health system, and provider factors. Barriers are presented as 
black bars and facilitators are presented as white bars. Dotted bars denote that the barrier or 
facilitator was identified in at least one study in which the mean age of the sample was over 60. 
The length of the bar represents the number of studies reporting a similar finding. Some factors 
were consistently reported as facilitators or barriers whereas others were reported inconsistently 










Figure 2.4. Barriers to and facilitators of diabetes medication adherence by patient factors identified in 66 studies of adults with 
diabetes. 
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Barriers to and Facilitators of Diabetes Medication Adherence by Patient Factors




















Figure 2.5. Barriers to and facilitators of diabetes medication adherence by medication characteristics, health system, and provider 
factors identified in 66 studies of adults with diabetes.
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Barriers to and Facilitators of Diabetes Medication Adherence 
by Medication Characteristics, Health system, and Provider Factors
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The majority of studies (n = 55; 83.3%) examined the relationship between patient 
factors and medication adherence (Aflakseir, 2012; Al-Qazaz et al., 2011; Albright et al., 2001; 
G. R. Bailey et al., 2012; Balkrishnan et al., 2006; Balkrishnan et al., 2004; Bell et al., 2010; 
Chao et al., 2007; Chao et al., 2005; Cheong et al., 2008; Chernew et al., 2008; Dirmaier et al., 
2010; Donnan et al., 2002; Egede et al., 2011; Fisher et al., 2010; Gibson et al., 2010; Gonzalez 
et al., 2007; Gonzalez et al., 2008; Gu et al., 2010; Hanko et al., 2007; Hernandez-Tejada et al., 
2012; Jamous et al., 2011; Kaissi & Parchman, 2009; Katon et al., 2009; Kilbourne, Reynolds, et 
al., 2005; Kreyenbuhl et al., 2010; Kreyenbuhl et al., 2011; Lin et al., 2004; Mann et al., 2009; 
Mayberry & Osborn, 2012; Munir et al., 2009; Nau et al., 2007; Nau et al., 2005; Ngo-Metzger 
et al., 2012; Osborn et al., 2011; Osborn & Egede, 2012; Parada et al., 2012; Patel et al., 2010; 
M. Pawaskar et al., 2010; M.  Pawaskar et al., 2007; Piette et al., 2005; Raebel et al., 2012; 
Rozenfeld et al., 2008; Sarkar et al., 2006; Schoenthaler et al., 2012; Scollan-Koliopoulos et al., 
2007; Shenolikar et al., 2006a, 2006b; Sherman et al., 2011; Smalls et al., 2012; Tiv et al., 2012; 
Walker et al., 2012; White et al., 2012; Williams et al., 2009; Yang et al., 2009). The most 
frequent barriers consistently identified significant to diabetes medication adherence among 
patient factors were depression/depressive symptoms (n = 15; 27.3%) (Chao et al., 2007; Chao et 
al., 2005; Dirmaier et al., 2010; Fisher et al., 2010; Gonzalez et al., 2007; Gonzalez et al., 2008; 
Katon et al., 2009; Kilbourne, Reynolds, et al., 2005; Kreyenbuhl et al., 2010; Lin et al., 2004; 






Some factors were consistently identified as either a barrier to or facilitator of medication 
adherence across the studies. Regarding race/ethnicity groups, those of black or African-
American race were more likely to not adhere to medications compared to non-Hispanic whites 
(n = 9) (Balkrishnan et al., 2006; Balkrishnan et al., 2004; Egede et al., 2011; Kreyenbuhl et al., 
2010; Osborn et al., 2011; Patel et al., 2010; M. Pawaskar et al., 2010; Shenolikar et al., 2006b; 
Yang et al., 2009). Patients who are not married (n = 1) (Egede et al., 2011), homeless (n = 1) 
(Kreyenbuhl et al., 2010), of low income (n = 2) (Chernew et al., 2008; Ngo-Metzger et al., 
2012), employed (n = 2) (Munir et al., 2009; Tiv et al., 2012), and had poor diabetes control 
(n=2) (Tiv et al., 2012; White et al., 2012) were less likely to adhere to their diabetes 
medications. In contrast, those reporting higher quality of life (n = 2) (Hanko et al., 2007; 
Williams et al., 2009) and higher health literacy (n = 1) (Osborn et al., 2011) were more likely to 
be more adherent to medications. 
However, findings were inconsistent for other factors. Twenty-three of the 66 studies 
identified older age as a significant determinant of diabetes medication adherence, with 17 
studies reporting that older people were more likely to adhere to instructions for taking diabetes 
medications (Balkrishnan et al., 2004; Chao et al., 2007; Cheong et al., 2008; Chernew et al., 
2008; Fisher et al., 2010; Gibson et al., 2010; Jamous et al., 2011; Kaissi & Parchman, 2009; 
Oladapo et al., 2012; Patel et al., 2010; M. Pawaskar et al., 2010; Rozenfeld et al., 2008; 
Shenolikar et al., 2006b; Sherman et al., 2011; Tiv et al., 2012; White et al., 2012; Yang et al., 
2009), and others reporting (n = 6) that older age makes people less likely to adhere to 
medications (Albright et al., 2001; Donnan et al., 2002; Egede et al., 2011; Gu et al., 2010; 
Munir et al., 2009; M.  Pawaskar et al., 2007). Although the findings from the studies were 




Studies more frequently reported that patients who had higher self-efficacy were more likely to 
adhere to diabetes medications (n = 7) (Chao et al., 2005; Hernandez-Tejada et al., 2012; Mann 
et al., 2009; Munir et al., 2009; Scollan-Koliopoulos et al., 2007; Tiv et al., 2012; Williams et al., 
2009) rather than non-adhere to those medications (n = 1) (Munir et al., 2009). Patients who 
received higher family/social support were also likely to have higher medication adherence (n=7) 
(Albright et al., 2001; Donnan et al., 2002; Kaissi & Parchman, 2009; Mayberry & Osborn, 
2012; Osborn & Egede, 2012; Scollan-Koliopoulos et al., 2007; Tiv et al., 2012) rather than poor 
adherence to their medications (n = 1) (Kaissi & Parchman, 2009). Most studies identified that 
females were more likely to have poorer diabetes medication adherence compared to males (n=8) 
(Balkrishnan et al., 2006; Chernew et al., 2008; Egede et al., 2011; Gibson et al., 2010; Gu et al., 
2010; Patel et al., 2010; M. Pawaskar et al., 2010; Yang et al., 2009), and only one study 
reported that females were more likely to be adherent to their medications (n = 1) (Parada et al., 
2012). 
Coexisting illnesses. 
Fifteen studies consistently reported that those with diabetes with depression or 
depressive symptoms are less likely to adhere to diabetes medications compared to those without 
depression (n = 15) (Chao et al., 2007; Chao et al., 2005; Dirmaier et al., 2010; Fisher et al., 
2010; Gonzalez et al., 2007; Gonzalez et al., 2008; Katon et al., 2009; Kilbourne, Reynolds, et 
al., 2005; Kreyenbuhl et al., 2010; Lin et al., 2004; Nau et al., 2007; Nau et al., 2005; Osborn & 
Egede, 2012; Parada et al., 2012; Piette et al., 2005). 
However, some factors did not demonstrate a consistent and clear barrier or facilitator 
relationship with diabetes medication adherence. For example, a higher number/severity of 




al., 2008) was reported as a facilitator to medication adherence, whereas the factor found to be a 
barrier in six studies (Balkrishnan et al., 2003; Kreyenbuhl et al., 2010; Patel et al., 2010; 
Shenolikar et al., 2006b; Tiv et al., 2012; Yang et al., 2009). 
Cognitive function. 
Only one article examined a cognitive function related concept. Smalls et al. (2012) 
reported that emotional processing—active attempts to acknowledge, explore, and come to 
understand one’s stressor-related emotions—was associated with adherence to diabetes 
medications (n = 1) and no studies examined cognitive impairment. 
Illness representation. 
The most frequently identified illness representation barrier to adherence was patient 
perception that the prescribed medication was harmful (n = 4) (Aflakseir, 2012; Chao et al., 
2007; Chao et al., 2005; Mann et al., 2009). Patients who perceived their prescribed medications 
to be harmful were more likely to be non-adherent to the medication. In contrast, patient 
perception that medication was beneficial was found to be a facilitator (n = 2) (Chao et al., 2005; 
Schoenthaler et al., 2012). Poor knowledge about diabetes was more frequently found to be a 
barrier (n = 3) (Al-Qazaz et al., 2011; Mann et al., 2009; Tiv et al., 2012) rather than a facilitator 
(n = 1) (Schoenthaler et al., 2012). Other illness representation factors identified as barriers were 
diabetes distress (n = 1) (Fisher et al., 2010), and diabetes fatalism (n = 1) (Walker et al., 2012). 
Belief that diabetes is a chronic disease (n = 1) (Aflakseir, 2012) and perceived fear about 
complications (n = 1) (Chao et al., 2005) were also facilitators of medication adherence. 




G. R. Bailey et al. (2012) found that patients who perceived their health status as poor 
were less likely to adhere to their diabetes medications (n = 1). 
Health behavior. 
Alcohol/substance use was associated with non-adherence to diabetes medications (n = 1) 
(Kreyenbuhl et al., 2010). However, smoking did not show a consistent barrier or facilitator 
relationship with diabetes medication adherence; one study found smoking to be a facilitator 
(n=1) (Raebel et al., 2012) whereas the other study found smoking patients were less likely to be 
adherent to diabetes medications (n = 1) (Hanko et al., 2007). 
Medication characteristics. 
The most common barriers were perceived emotional/cognitive barriers/difficulty taking 
medications (n = 3) (Chao et al., 2005; Mann et al., 2009; Tiv et al., 2012) and Metformin 
treatment (versus Sulfonylurea) (n = 3) (Balkrishnan et al., 2006; Patel et al., 2010; Shenolikar et 
al., 2006b). 
Convenient administration of medication (n = 3) (Balkrishnan et al., 2003; W. C. Lee et 
al., 2006; Oladapo et al., 2012) was the most frequently reported facilitators across all studies, 
followed by familiarity with regimens (n = 1) (Colombi et al., 2008). 
Higher number of daily tablets/medications and more complex medication regimens had 
inconsistent results. Some studies determined that patients who had higher number of daily 
tablets/medications were less likely to adhere to their diabetes medications (n = 4) (Donnan et 
al., 2002; Oladapo et al., 2012; Shenolikar et al., 2006b; White et al., 2012) whereas other studies 
found that patients who had higher number of daily tablets/medications were more likely to be 
adherent (n = 6) (Cheong et al., 2008; Colby et al., 2012; Kreyenbuhl et al., 2010; Oladapo et al., 




identified as both a barrier (n = 1) (Schoenthaler et al., 2012) and a facilitator (n = 1) 
(Kreyenbuhl et al., 2010). 
Health system factors. 
The most frequently and consistently reported health system factors related to non-
adherence to diabetes medication were poor access to care (n = 4) (G. R. Bailey et al., 2012; 
Balkrishnan et al., 2006; Balkrishnan et al., 2003; M. Pawaskar et al., 2010), lack of health 
insurance (n = 2) (Ngo-Metzger et al., 2012; M. Pawaskar et al., 2010), and receipt of state or 
federal subsidies (n = 1) (Colby et al., 2012). 
Higher out-of-pocket cost was the only factor that showed inconsistent results among 
health system factors. Although higher out-of-pocket costs showed inconsistent results across the 
studies, the majority reported that patients who spent higher out-of-pocket costs for their 
medications were less likely to be adherent (n = 8) (G. R. Bailey et al., 2012; Colombi et al., 
2008; Gibson et al., 2010; Gu et al., 2010; Mackey et al., 2012; Ngo-Metzger et al., 2012; Piette 
et al., 2005; Tiv et al., 2012) with only two studies (Gibson et al., 2010; Patel et al., 2010) 
identifying higher cost as a facilitator. 
The most common facilitator of diabetes medication adherence was higher rates of mail-
order/independent pharmacy use (n = 5) (Duru et al., 2010; Gibson et al., 2010; Kalsekar et al., 
2007; Kreyenbuhl et al., 2010; Sherman et al., 2011). Diabetes patients who often used mail-
order or independent pharmacies were more likely to adhere to their medication compared to 
those who used retail pharmacies or shopped at chain pharmacies. Active patient engagement 
(n=3) (Parada et al., 2012; Parchman et al., 2010; Williams et al., 2009), and higher employer 






Six studies examined the relationship between provider support and adherence and 
consistently reported that patients who perceived higher support from health professionals were 
more likely to adhere to instructions concerning taking diabetes medications (Colby et al., 2012; 
Hanko et al., 2007; Heisler et al., 2007; Mackey et al., 2012; Tiv et al., 2012; Williams et al., 
2009). Patients who felt satisfied with their providers were also more likely to adhere to their 
diabetes medications (n = 1) (Schoenthaler et al., 2012). Frequent physician visits/contacts 
showed inconsistent results as either a barrier (n = 1) (Patel et al., 2010) or a facilitator (n = 2) 
(Kreyenbuhl et al., 2010; Raebel et al., 2012). 
Discussion. 
Across the studies in this review, the most frequently and consistently reported barrier for 
diabetes medication adherence was depression or depressive symptoms, a patient factor. This 
result was consistent with a previous systematic review and a meta-analysis that had examined 
the effects of depression on patient adherence (DiMatteo, Lepper, & Croghan, 2000; Eze-Nliam, 
Thombs, Lima, Smith, & Ziegelstein, 2010; Grenard et al., 2011). Patients with depression were 
approximately two to three times more likely to be non-adherent to their medications compared 
to patients without depression (DiMatteo et al., 2000; Grenard et al., 2011). This might be 
explained by considering that depression may discourage patients’ willingness to take their 
medications because depression often coexists with social isolation from individuals who could 
provide emotional support (DiMatteo et al., 2000). 
The most frequently identified facilitator of adherence was higher support from health 
professionals. This finding was also consistent with conclusions from previous studies focusing 




(Brookhart et al., 2007; Schoenthaler et al., 2009; van Servellen & Lombardi, 2005).  
Studies in which the mean age of the patient sample was over 60 years old also 
demonstrated consistent findings. Depression or depressive symptoms (n = 9) was the most 
frequently identified barrier among the studies with a mean age of 60 years and older (Dirmaier 
et al., 2010; Gonzalez et al., 2007; Gonzalez et al., 2008; Katon et al., 2009; Kilbourne, 
Reynolds, et al., 2005; Kreyenbuhl et al., 2010; Lin et al., 2004; Parada et al., 2012; Piette et al., 
2005), followed by higher out-of-pocket costs (n = 4) (Colombi et al., 2008; Gu et al., 2010; 
Piette et al., 2005; Tiv et al., 2012), and higher number/severity of comorbidity (n = 4) 
(Balkrishnan et al., 2003; Kreyenbuhl et al., 2010; Tiv et al., 2012; Yang et al., 2009). The most 
commonly reported facilitator in the elderly was higher support from health professionals (n = 4) 
(Hanko et al., 2007; Heisler et al., 2007; Tiv et al., 2012; Williams et al., 2009), followed by 
higher family/social support (n = 3) (Donnan et al., 2002; Osborn & Egede, 2012; Tiv et al., 
2012), higher (diabetes) self-efficacy (n = 2) (Tiv et al., 2012; Williams et al., 2009), higher 
quality of life (n = 2) (Hanko et al., 2007; Williams et al., 2009), and mail-order/independent 
pharmacy use (n = 2) (Duru et al., 2010; Kreyenbuhl et al., 2010). 
Several factors demonstrated inconsistent results across the studies: age, gender, self-
efficacy, family/social support, number/severity of comorbid conditions, duration of illness, 
knowledge about diabetes, smoking, complexity of medication regimens, number of daily 
tablets/medications, out-of-pocket costs, and number of physician visits/contacts. 
Some factors were prominent (≥ 5 studies) barriers or facilitators even within or without 
those discrepancies: age, gender, race/ethnicity, depression or depressive symptoms, diabetes 
self-efficacy, family/social support, mail-order pharmacy use, support from health professionals, 




studies (n = 7) (Chao et al., 2005; Hernandez-Tejada et al., 2012; Mann et al., 2009; Munir et al., 
2009; Scollan-Koliopoulos et al., 2007; Tiv et al., 2012; Williams et al., 2009) rather than a 
barrier (n = 1) (Munir et al., 2009). 
Interestingly, some of the factors that have showed inconsistent results in all adult age 
groups demonstrated clear barrier or facilitator relationships among the mean age of 60 years and 
older groups: gender, self-efficacy, family/social support, smoking, out-of-pocket costs, and 
number of physician visits/contacts. 
One factor that showed inconsistent findings across all age group studies but not among 
the studies with a mean age of 60 years and older was out-of-pocket costs. In all age group 
studies, eight studies reported higher out-of-pocket costs to be a barrier (G. R. Bailey et al., 
2012; Colombi et al., 2008; Gibson et al., 2010; Gu et al., 2010; Mackey et al., 2012; Ngo-
Metzger et al., 2012; Piette et al., 2005; Tiv et al., 2012) while only one study identified this 
factor was associated with higher medication adherence (Patel et al., 2010). However, in the 
elderly population studies, higher out-of-pocket costs acted as a barrier (n = 4) (Colombi et al., 
2008; Gu et al., 2010; Piette et al., 2005; Tiv et al., 2012). This finding was consistent with those 
of previous studies (Briesacher et al., 2007; Mojtabai & Olfson, 2003; Piette et al., 2004). Piette 
et al. (2004) stated that there is a relationship between out-of-pocket costs and treatment 
adherence. A previous systematic review about cost-related medication non-adherence showed 
that there was a consistent association between financial burden and medication non-adherence 
(Briesacher et al., 2007). Mojtabai and Olfson (2003) also made the case that elderly Medicare 
beneficiaries are not able to adhere to their prescribed medicines due to costs and recommended 
that Medicare prescription drug benefit legislation be enacted. 




et al., 2002; Kreyenbuhl et al., 2010; White et al., 2012), showed a huge inconsistency across all 
adult age group studies as well as studies with mean age of 60 years and older. 
Summary. 
The majority of the factors related to medication adherence are potentially modifiable. 
The findings from this review suggest that the control of depression, the convenient ordering of 
medication and support from health professionals may improve medication adherence in adults 
with diabetes. 
In order to examine the relationship between various factors and medication adherence, 
future research needs to ensure inclusion of all of the factors that affect medication adherence 
identified in this review to control the effects of any confounding variables. In addition, further 
study is essential to gain deeper understanding of the processes involved in the factors which 




Impact of Medicare Part D and Its Coverage Gap 
Medicare Part D was enacted on January 1, 2006 in an effort to reduce prescription drug 
cost burdens for the elderly (O'Sullivan, 2008). However, Medicare Part D has a coverage gap 
between the initial coverage limit and the catastrophic coverage threshold. As part of healthcare 
reform, the Patient Protection and Affordable Care Act of 2010 enacted provisions to reduce the 
coverage gap through gradual reduction and the gap will be completely closed by the year 2020. 
Among those lacking prescription drug coverage, low-income, chronic illness patients 
had high cost-related non-adherence rates (Safran et al., 2010). After implementation of 
Medicare Part D, the majority of the patients who lacked prescription coverage had obtained 
drug coverage mainly through voluntary enrollment in Medicare Part D (Safran et al., 2010). 
Those who enrolled in Medicare Part D were likely to have higher out-of-pocket expenditures 
and utilization compared with Medicare Part D eligible non-enrollees (Yin et al., 2008). After the 
implementation of Medicare Part D, drug utilization was increased and out-of-pocket costs 
decreased (Lau & Stubbings, 2012; Mott, Thorpe, Thorpe, Kreling, & Gadkari, 2010; Polinski, 
Kilabuk, Schneeweiss, Brennan, & Shrank, 2010; Safran et al., 2010; Stubbings & Lau, 2013; 
Yin et al., 2008; Y. Zhang, Donohue, Lave, O'Donnell, & Newhouse, 2009) even though the 
effect of Medicare Part D varied in subgroups of beneficiaries such as sick and poor beneficiaries 
without Medicaid (Briesacher et al., 2011; Stubbings & Lau, 2013). In addition to improving 
access to essential medication use, Medicare Part D drug coverage also increased use of 
inappropriate or overused medications (Polinski, Donohue, Kilabuk, & Shrank, 2011). 
However, the impact of the coverage gap on drug use and expenses were mixed (Polinski 
et al., 2010). About a quarter of beneficiaries reached the coverage gap in 2006 (Nair et al., 




et al., 2011). Drug expenditures of beneficiaries who did not enter the gap remained unchanged 
(Schmittdiel et al., 2009), but those exposed to the coverage gap had increased costs (Nair et al., 
2011; Polinski et al., 2010) and discontinued medications (Polinski et al., 2010). Although 
beneficiaries who reached the coverage gap were twice as likely to discontinue essential 
medications (Polinski et al., 2010; Polinski, Shrank, et al., 2011), entering the threshold did not 
lead to switching to other affordable and therapeutically interchangeable medications (Polinski, 
Shrank, et al., 2011); chronically ill beneficiaries generally continue to take brand-name 
medications while in the gap (Nair et al., 2011). For Medicare’s dual-eligible beneficiaries, 
however, drug use (Polinski, Donohue, et al., 2011) and out-of-pocket costs (Basu et al., 2010) 
remained unchanged. 
Beneficiaries who have reached the catastrophic threshold were more likely to be older 
(Raebel, Delate, Ellis, & Bayliss, 2008), have greater morbidity (Bayliss, Ellis, Delate, Steiner, 
& Raebel, 2010; Daniel & Malone, 2007), receive more medications (Raebel et al., 2008), have 
higher prescription fill rates (Pedan, Lu, & Varasteh, 2009), have increased utilization (Bayliss et 
al., 2010; Daniel & Malone, 2007), have more medical office visits (Raebel et al., 2008), and 
have limited access to generic medications (Bayliss et al., 2010) compared to beneficiaries who 
did not reach the threshold. Those who used strategies to reduce costs such as using less of or 
discontinuing medications, or not filling a prescription were more likely to be younger, less 
healthy, highly educated, lacking drug coverage, and in a low income group (Cronk, Humphries, 
Delate, Clark, & Morris, 2008). 
Beneficiaries who entered the coverage gap were more likely to have lower subsequent 
monthly drug expenditures probably due to failure to renew their medication resulting in poorer 




was more prevalent for beneficiaries who reached the catastrophic threshold (Raebel et al., 
2008). When beneficiaries had increased out-of-pocket costs while in the gap, the rates of usage 
of essential and overused medications decreased (Polinski, Donohue, et al., 2011). 
Diabetes patients reach the drug coverage gap much more and sooner than those without 
diabetes (Nair et al., 2011; Schmittdiel et al., 2009). Approximately a quarter of the beneficiaries 





Summary of the Chapter and Gaps in Knowledge 
In this chapter, previous studies were reviewed focusing on four topics in order to 
synthesize current knowledge and to identify knowledge gaps in these areas. These topics are: 1) 
a comparison of three different types of medication adherence measures, 2) the most common 
methods to calculate and to define medication adherence using pharmacy claims data, 3) barriers 
to and facilitators of adherence to diabetes medications in adult diabetes patients, and 4) the 
impact of Medicare Part D on out-of-pocket pharmacy expenditures and medication adherence. 
First, three methods of measuring medication adherence were compared: patient self-
reports, electronic lids on medication containers, and pharmacy claims data. The patient self-
report is a simple and cost-effective method, but it has a high recall bias and social desirability 
issues. The medication adherence assessed by electronic lids on medication containers is often 
considered the gold standard of measuring medication adherence but can be expensive and 
impractical. The method of calculating medication adherence using pharmacy claims data has 
better congruence with the electronic lid adherence measure compared to the self-reported 
medication adherence in all age groups and can be an alternative method of measuring 
medication adherence for research purposes. 
Second, a systematic review focusing on the studies that measured medication adherence 
using pharmacy claims data was conducted to determine the most common measure of pharmacy 
claims-based medication adherence as well as to identify the most common criteria to define 
adherence to medication for this study. Ninety-four studies were reviewed. The most frequently 
utilized method of medication adherence measured by pharmacy refill records in diabetes 
patients was MPR, followed by PDC. Over half of the studies defined adherence to medication 




pharmacy refill records, while the remainder of the studies used a 6-month period. These 
measures, the criteria, and the measurement periods of medication adherence using pharmacy 
claims data were used to measure and define medication adherence for this study. 
Third, a systematic review was conducted to identify barriers to and facilitators of 
medication adherence among adult diabetes patients. A total of 66 studies were reviewed. In all 
adult age groups as well as for adults with a mean age of 60 years and older, depression was the 
most frequently and consistently identified factor associated with poor diabetes medication 
adherence, whereas higher support from health professionals is associated with improved 
medication adherence. The impact of out-of-pocket costs showed inconsistent findings across 
studies examining all age groups, but were clearly identified as a barrier to medication adherence 
across the studies with a mean age of 60 years and older. Further research is necessary regarding 
factors where findings have been inconsistent and factors that have not yet been studied, such as 
cognitive function, particularly as they relate to the steadily increasing population of elderly 
individuals with diabetes.  
Lastly, the impact of Medicare Part D on out-of-pocket pharmacy expenditures and 
medication adherence was reviewed. Most studies found that drug utilization increased and out-
of-pocket costs decreased after Medicare Part D became effective. Compared to those without 
diabetes, diabetes patients tended to enter the drug coverage gap more frequently and earlier in 
the coverage year. Approximately 25% of Medicare Part D beneficiaries with diabetes reached 
the coverage gap or catastrophic coverage level. Beneficiaries who reached the coverage gap 
tended to have lower drug expenditures in the following month, likely due to failure to refill their 
medication. Poor adherence to medication was more prevalent for beneficiaries who reached the 




impact of Medicare Part D using data from prior to 2010 and have not considered current efforts 
to reduce the financial burden of the coverage gap. Evidence is still lacking on the impact of 
recent efforts to close the coverage gap on lowering the proportion of out-of-pocket pharmacy 
costs among elderly diabetes patients. 
The findings from four reviews in this chapter informed the methodology, which 
described in Chapter 3. Having evaluated the various measures of medication adherence, it was 
determined that measurement of medication adherence using prescription refill records was 
appropriate for this study. From the findings from the systematic review of the common methods 
of pharmacy claims-based medication adherence, either MPR or PDC can be used to calculate 
medication adherence when using prescription refill records. The pharmacy claims-based 
medication adherence was measured over one year and defined with an 80% cut-off point for this 
study. The factors identified in the second systematic review were included as covariates to 
examine the relationship with medication adherence in the analysis for Aim 1 of this study to 
identify independent predictors of medication adherence in adults with diabetes. Based on the 
findings from the last review on Medicare Part D, the data years from 2010 were also included as 
a part of the analysis in order to examine the impact of current policy efforts through the 




Chapter III: Methodology 
This chapter presents the study design and information on the Medical Expenditure Panel 
Survey (MEPS), the data source for this study, including sample descriptions, information on 
survey components, and data collection procedures. In addition, the conceptual framework that 
guides this study, study variables including their operational definitions and data sources within 
the MEPS, as well as the plan for statistical analyses, are described. Lastly, investigator training 
and human subjects protection plan are presented. 
Study Design 
In this study, a cross-sectional and an interrupted time series design were employed for 
Aims 1 and 2, respectively. The MEPS, a large-scale dataset provided by the Agency for 
Healthcare Research and Quality (AHRQ) was used as the data source. First, characteristics of 
adult diabetes patients who were adherent were compared to those who were non-adherent to 
their diabetes medications and the independent predictors of medication adherence in adult 
diabetes patients were identified. In addition, the impact of Medicare Part D on out-of-pocket 
pharmacy costs for Medicare beneficiaries with diabetes was evaluated by examining the trend 
and comparing the proportion of out-of-pocket pharmacy costs for a sample of elderly patients 
with diabetes before (data years 2000–2005) and after (data years 2006–2011) implementation of 
Medicare Part D. 
Data Source and Sample 
The MEPS sample is a part of the National Health Interview Survey (NHIS), sponsored 
by the National Center for Health Statistics, which enables the generation of national- and 




civilians. Each year, a new sample, called a panel, is selected from households that responded to 
the previous year’s NHIS, based on a complex stratified multi-stage design. The U.S. is 
partitioned into primary sampling units (PSUs)—a county or group of adjacent counties—and 
roughly half of the PSUs sampled for NHIS are used to identify participants for the MEPS 
sample. Each sampled PSU is divided into second-stage units (SSUs), a cluster of housing units 
such as census blocks or tracts. The final-stage unit is a sample of households from each selected 
SSU. All family members living in selected households are included in the sample. Since the 
MEPS survey recruits only non-institutionalized people in the U.S., patients in long-term care 
facilities and military personnel not living in the same household are not included. Although new 
households are selected each year, the same PSUs and SSUs are used for approximately 10 years 
unless the sampling frame of the NHIS has been redesigned. Subpopulations of interest, 
including Asians, Blacks, Hispanics, and cancer patients (2011 panel) are oversampled to 
produce reliable estimates. 
Survey Components  
The MEPS consists of three components: household, medical provider, and insurance. 
The household component (HC) provides annual data for approximately 14,000 households 
regarding demographic characteristics, health conditions, health status, use of medical care 
services, charges and payments, access to care, satisfaction with care, health insurance coverage, 
and income. The medical provider component (MPC) is not available as part of the dataset 
available to the public. MPC data are collected from providers regarding dates of visits/services, 
use of medical care services, charges and sources of payments, and diagnosis and procedure 
codes for medical visits/encounters to supplement or replace respondent self-reported 




component is restricted for reasons of confidentiality; therefore, only select researchers whose 
projects have been approved by AHRQ data center can access data either at the AHRQ data 
center in Rockville, Maryland or at one of the U.S. Census Bureau Research Data Centers. The 
insurance component (IC) is a separate survey, not linked to the HC survey, of private and public 
sector employers that provides data on employer-based health insurance, including the number 
and types of private insurance plans offered (if any), premiums, contributions by employers and 
employees, eligibility requirements, benefits associated with these plans, and employer 
characteristics. 
Data from the HC (for Aims 1 and 2) and MPC (for Aim 1) was used for this study. HC 
variables including demographics, health conditions and status, charges and payments, access to 
care, satisfaction with care, and health insurance coverage will be used. Since medication 
adherence is the outcome of interest in the proposed study, a MPC variable, pharmacy refill 
dates, is needed to calculate adherence rates. Of note, the days supplied variable, essential for 
calculating medication adherence, was first collected in 2010. This is described in further detail 
in the variables of interest section. 
Data Collection Procedures  
In the MEPS, a panel is selected each year and followed up over two calendar years with 
five rounds of in-person interviews. The data are collected in rounds 1, 2, and 3 during the first 
year and rounds 3, 4, and 5 during the second year; round 3 is designed to overlap both calendar 
years. As such, every year has an overlap of two panels. Figure 3.1 illustrates the MEPS panel 





Figure 3.1. The MEPS panel design: data reference periods. Adapted from “MEPS-HC Panel 
Design and Data Collection Process,” by Agency for Healthcare Research and Quality, 
Rockville, MD. Retrieved October 15, 2013 from 
http://www.meps.ahrq.gov/survey_comp/hc_data_collection.jsp 
Each interview lasts an average of 90 minutes with a range of 1 to 4 hours. In each round, 
the core interview includes data regarding demographics, charge payment including total 
charges, copayments, out-of-pocket payments, insurance payments, and other sources of 
payment for medical events etc., medical conditions, employment, health status, health 
insurance, and healthcare utilization. Rounds 2 and 4 interviews collect data on access to care, 
child preventive health, and satisfaction with health plans and providers. Preventive care and 




members’ real estate, businesses, vehicles, investments, and debts are collected only in round 5. 
Details on the survey contents are described in Appendix F. 
Conceptual Framework or Rationale 
 To guide Aim 1 of this study, the conceptual framework was adapted from the model 
presented in Gellad et al. (2009). The ideas presented in Gellad et al. (2009) were originally 
developed to explore policy options in order to improve medication adherence (Gellad et al., 
2009). The adapted framework is presented in Figure 3.2. 
 
Figure 3.2. Conceptual framework of medication adherence adapted for Aim 1. 
 The adapted framework used for Aim 1 illustrates the interactions among patient, health 




construct was not included due to limited data availability. The primary outcome variable for this 
model is medication adherence. Patient factors include demographics, coexisting illness, 
cognitive function, illness representation, perceived health status, and health behavior. 
Demographics include age, gender, race/ethnicity, education level, family support, and poverty. 
Coexisting illness includes presence of depression, number of major comorbid conditions and 
diabetes duration. Cognitive function involves cognitive limitations that include comprehension 
and memory function. Illness representation includes knowledge about illness and confidence in 
self-care. Perceived health status includes self-report of physical and mental health status. Health 
behavior includes smoking. Health system factors include out-of-pocket pharmacy costs, type of 
health insurance, and access to care such as timely usual care. Provider factors include patient 
satisfaction with their providers such as time spent discussing treatment. 
Variables of Interest 
 In this study, patient, health system, and provider factors were examined to identify 
factors associated with medication adherence in adults with diabetes. Tables 3.1 and 3.2 provide 
details regarding outcome and independent variables, and their operational definitions and 
references within the MEPS for Aims 1 and 2, respectively. The variables are organized by 














Categories/ranges or unit Level of 
data 
The MEPS variable name 
(Questionnaire section and 
number based on data year 
2011)  
An asterisk (*) indicates restricted data 





operational definition of 
Proportion of Days 
Covered (PDC) 
(see text for details) 
Adherent (annual PDC ≥ 
80%); non-adherent 
Categorical Date Filled* (PM Q1) 
RXDAYSUP (PM Q4) 
 
Independent variables     
Patient factors     
Demographics     
Age Age (last time eligible) 19‒44; 45‒64; ≥ 65 years Categorical AGELAST (RE 12, 57–66) 
Gender Self-reported gender  Female; Male Categorical SEX (RE 12, 57, 61) 




Hispanic; other race 
Categorical RACEX (RE 101A) 
HISPANX (RE 98A‒101A) 
Education level Highest degree when first 
entered the MEPS  
≤ High school; ≥ college; 
other degrees 
Categorical HIDEG (RE 103‒105) 
Family support Living alone or with 
family members as of 
12/31/2011 
Living alone; living with 
family members 
Categorical FAMSZEYR (Constructed) 












Categories/ranges or unit Level of 
data 
The MEPS variable name 
(Questionnaire section and 
number based on data year 
2011)  
An asterisk (*) indicates restricted data 
Poverty Ever have Medicaid 
during 2011 
Poor (yes); not poor Categorical MCDEV11 (constructed) 
Coexisting illness     
Diabetes Self-reported diabetes 
diagnosis (CCS 
code#=49 or 50) 
Diabetes; no diabetes Categorical CCCODEX (Constructed) 
Diabetes duration Years living with 
diabetes=person’s age 
(AGELAST) - age of 
diagnosis of diabetes 
(DIABAGED)  
Years Continuous AGELAST (AGE11X, 
AGE42X, AGE31X) 
DIABAGED (PE27) 
Depressive symptoms Patient Health 
Questionnaire (PHQ-2) ≥ 
3, self-reported 
depressive mood and 
decreased interest in 
usual activities during the 
past two weeks 
Depressive (PHQ-2≥ 3); 
not depressive 












Categories/ranges or unit Level of 
data 
The MEPS variable name 
(Questionnaire section and 
number based on data year 
2011)  
An asterisk (*) indicates restricted data 
Severity of comorbid 
conditions  
D'Hoore, Bouckaert, and 
Tilquin (1996)’s 
Charlson comorbidity 
index score of the self-
reported comorbid 
conditions listed below: 
 
Myocardial infarct; 





disease; connective tissue 
disease; ulcer disease; 
mild liver disease; 
hemiplegia; moderate or 
severe renal disease; any 
tumor; leukemia; 
lymphoma; moderate to 
severe liver disease; 
metastatic solid tumor 
(not including diabetes) 
0–28 Continuous ICD9CODX (CE05, HS04, 
ER04, OP09, MV09, HH05, 
PM09 (Edited)) 












Categories/ranges or unit Level of 
data 
The MEPS variable name 
(Questionnaire section and 
number based on data year 
2011)  
An asterisk (*) indicates restricted data 
Cognitive limitation (1) Experienced 
confusion or memory 
loss; or (2) have 
problems making 
decisions; or (3) require 
supervision for their own 
safety 
Diminished; normal 
cognitive function  
Categorical COGLIM31, COGLIM53 (HE 
24–25) 
Illness representation     
Source of knowledge 
about diabetes self-care  
Number of diabetes self-
care knowledge source 
(provider/ reading 
internet/ taking class) 
None; 1; 2; 3 Categorical DSCPCP53, DSCNPC53, 
DSCPHN53, DSCINT53, 
DSCGRP53 (DCS12, DCS 13) 
 
Diabetes self-efficacy Confidence taking care 
of diabetes 
Not confident; confident Categorical DSCONF53 (DCS 14) 
Perceived health status     
Physical health status Score from physical 
component summary SF-
12V2 
Poor (PCS42 < 50); good Categorical PCS42 (SAQ Q18–Q29) 
Mental health status  Score from mental 
component summary SF-
12V2 
Poor (MCS42 < 50); 
good 
Categorical MCS42 (SAQ Q18–Q29) 
Health behavior     












Categories/ranges or unit Level of 
data 
The MEPS variable name 
(Questionnaire section and 
number based on data year 
2011)  
An asterisk (*) indicates restricted data 
Diabetes-related routine 
check-ups (A1c, foot, 
eye) 
(1) Times tested for A1c; 
(2) had feet checked; (3) 
had dilated eye exam 
(1): number of times 
tested 













DSEYNV53 (DCS 4) 
Other preventive efforts 
(routine BP, cholesterol 
check-up, flu 
vaccination) 
(1) Time since last blood 
pressure check; (2) how 
long cholesterol last 
check; (3) how long last 
routine checkup; (4) how 
long last flu vaccination 
Within past year; more 
than 2 years ago or never 








costs (amount paid by 
self or family) at 
pharmacies (RXSLF11) 
divided by annual total 
pharmacy expenditures 
(RXEXP11)  














Categories/ranges or unit Level of 
data 
The MEPS variable name 
(Questionnaire section and 
number based on data year 
2011)  
An asterisk (*) indicates restricted data 
Type of health insurance Type of health insurance Private; Medicare; 
Medicaid; Medicare & 
Medicaid; other public; 
or uninsured 




Access to care 
-Timely usual care 
 
 
(1) Having usual care 
provider; (2) difficulty 
getting usual care 
provider 
(1): Yes; no  
(2): Difficult; not 
difficult  
Categorical HAVEUS42 (AC05) 
DFTOUS42 (AC14) 
Provider factors     
Satisfaction with 
providers 
(1) Doctor listened to 
you; (2) doctor explained 
so understood; (3) doctor 
showed respect; (4) 
doctor spent enough time 
with you 



















Categories/ranges or unit Level of 
data 
The MEPS variable name 
(Questionnaire section and 
number based on data year 
2011) 




costs (amount paid by 
self or family) at 
pharmacies (RXSLF11) 
divided by annual total 
pharmacy expenditures 
(RXEXP11)  




for Aim 2-1 
    
Group Group classified by age Non-elderly (50–60 
years); Elderly (≥ 65 
years) 
Categorical AGE31X (RE 12, 57–66) 
Time Year Years from 2000 to 2011 Continuous Constructed 
Policy Medicare Part D policy 
implementation status 
Pre-Part D (2000–2005); 
Post-Part D (2006–2011) 
Categorical Constructed 
Time_post Year after Part D 
implementation 
Years from 2006 to 2011 Continuous Constructed 
Medicare Part D Medicare Part D 
enrollment status 
Medicare beneficiaries 
with Part D coverage; 
without Part D coverage 













Categories/ranges or unit Level of 
data 
The MEPS variable name 
(Questionnaire section and 
number based on data year 
2011) 
Independent variables 
for Aim 2-2 
    
Group Group classified by age Non-elderly (50–60 
years); Elderly (≥ 65 
years) 
Categorical AGE31X (RE 12, 57–66) 
Policy Medicare Part D policy 
implementation status 
Pre-Part D (2000–2005); 




    
Patient factors     
Demographics     
Age Age 50–60; ≥ 65 years Categorical AGE31X (RE 12, 57–66) 
Gender Self-reported gender  Female; Male Categorical SEX (RE 12, 57, 61) 




Hispanic; other race 
Categorical RACEX (RE 101A) 
HISPANX (RE 98A‒101A) 
Coexisting illness     
Severity of comorbid 
conditions  
D'Hoore et al. (1996)’s 
Charlson comorbidity 
index score of the self-
reported comorbid 
conditions 
0–28 Continuous ICD9CODX (CE05, HS04, 
ER04, OP09, MV09, HH05, 
PM09 (Edited)) 
Diabetes Self-reported diabetes 
diagnosis (CCS 
code#=49 or 50) 












Categories/ranges or unit Level of 
data 
The MEPS variable name 
(Questionnaire section and 
number based on data year 
2011) 
Health system factors     
Type of health insurance Type of health insurance Private; Medicare; 
Medicaid; Medicare & 
Medicaid; other public; 
or uninsured 




Access to care (1) Problems with access 
to prescribed medicines; 
(2) delays in getting 
prescribed medicines 
Yes; no  
 
Categorical PMUNAB42 (AC48A, AC48, 
AC49) 





Plan for Statistical Analyses 
All statistical analyses were performed using SAS 9.2 and 9.4 versions for Aim 1 and 
Aim 2, respectively. The distribution of each continuous variable was assessed using histograms 
prior to the analysis of the data. Descriptive statistics were used to describe the characteristics of 
the sample. For continuous variables, the means and standard errors were reported while for 
categorical variables, the percentages of each variable were calculated. 
Since the MEPS data were collected using a complex stratified multi-stage design, SAS 
procedure statements for survey sampling such as “proc surveyreg” and “proc surveylogistic” 
were used in order to obtain the correct standard errors and p-values. In order to correct unequal 
probability sampling bias and non-response bias, the appropriate sampling weights were used in 
all analyses. The level of significance of each test was set to an alpha of .05. 
Target population and sample. 
The target population of this study was non-institutionalized U.S. residents with a 
diagnosis of diabetes and were prescribed one or more diabetes medications, whether oral or 
injected, or both. The MEPS participants aged 19 years and older who reported a diagnosis of 
diabetes and had at least two prescription records of diabetes medication(s) met inclusion criteria 
for the study sample for Aim 1. For Aim 2, the sample was limited to the MEPS participants 
aged 65 years and older who reported a diagnosis of diabetes and had been prescribed at least 
one diabetes medication. 
 Using the clinical classification software (CCS) code variable in the MEPS, self-reported 
diabetes diagnosis (CCS code=49 or 50) was identified. Diabetes medications were identified 
using the Multum Lexicon therapeutic classification variable, TC1S1 = 99 (antidiabetic agents), 




sub-therapeutic classes: (1) sulfonylurea (TC1S1_1 = 213), (2) biguanide (TC1S1_1 = 214), (3) 
insulin (TC1S1_1 = 215), (4) alpha-glucosidase inhibitor (TC1S1_1 = 216), (5) 
thiazolidinediones (TC1S1_1 = 271), (6) meglitinides (TC1S1_1 = 282), (7) antidiabetic 
combinations (TC1S1_1 = 314), (8) dipeptidyl peptidase 4 inhibitors (TC1S1_1=371), (9) 
amylin analogs (TC1S1_1 = 372), (10) incretin mimetics (TC1S1_1 = 373). 
Definition and measurement of outcome variables. 
Aim 1: Medication adherence. 
Medication adherence was the outcome variable of Aim 1. For this study, prescribed 
medicine file records of the MEPS data were used to calculate the variable of interest, 
medication adherence. The MPR and PDC have been the most commonly used methods of 
calculation of adherence using pharmacy refill data based on the literature review (Chapter 2). 
However, MPR tends to overestimate the true rate of medication adherence since this is the 
simple summation of “days of supply” when patients refill their medications earlier than 
prescribed (Martin et al., 2009; Wang, 2013). In contrast, PDC measures “the number of days 
“covered” by a prescription and divides by the number of days in the measurement 
period,”(Wang, 2013) and provides a more conservative estimate of medication adherence when 
the patient uses more than one drug in a class (Martin et al., 2009). In an effort to endorse a 
standardized measurement of medication adherence, the Pharmacy Quality Alliance (PQA) 
examined existing measures of medication adherence, and selected PDC as a preferred method 
(Nau, u.d.). 
Multiple prescribed medications for a single condition is common for patients with 
chronic diseases (Choudhry et al., 2009). However, the measurements of prescription refill 




medications (Choudhry et al., 2009). For concurrent adherence to multiple related medications, 
Choudhry et al. (2009) suggested the following 3 distinct ways for each of the prescription-based 
(each fill) and interval-based (study period) methods using patients with diabetes prescribed two 
or more classes of oral diabetes medications: (1) average PDC, (2) proportion of days with ≥ one 
drug available, and (3) proportion of patients with PDC ≥ 80% for all drugs. Prescription-based 
methods are unable to differentiate different drug-taking patterns such as new users (not having 
used any oral diabetes medication of any class in the 12 months before their earliest index date) 
versus discontinuers (patients who did not fill any prescriptions for oral diabetes medications in 
the last 6 months), as well as overestimates medication adherence compared to interval-based 
methods (Choudhry et al., 2009). Among three different methods of calculation of the 
simultaneous adherence to multiple medications for each patient, most patients were defined as 
adherent when using the measurement of “proportion of days with ≥ one drug available”, 
whereas “PDC ≥ 80% for all drugs” results in most patients were not adherent (Choudhry et al., 
2009). Based on this, “interval-based average PDC” was used for this study. 
For this study, a modified operational definition of PDC provided by PQA (Nau, u.d.), 
appropriate for measuring adherence to multiple medications based on Choudhry et al. (2009)’s 
methods was used as follows: (1) determine the patient’s measurement period, defined as the 
index prescription date to the end of the calendar year, disenrollment, or death; (2) within the 
measurement period, count the days the patients was covered by at least one drug in the same 
therapeutic class based on the prescription fill date and days of supply. If prescription fills for the 
same drug overlap, then adjust the prescription start date to be the day after the previous fill had 
ended; (3) divided the number of covered days found in [step (2)] by the number of days found 




as a percentage for each patient. 
PDC = 
Number of days covered by at least one drug within the same therapeutic class
Number of days from the index prescription date to the end of the calendar year
 
Adherence to medications was defined as an annual average PDC of 80% or higher. 
There are several underlying assumptions for calculating PDC. When a patient refilled 
medications before the previous medications should have run out, new medication was assumed 
to take the day after the end of the old dispensing (Choudhry et al., 2009). If a patient 
accumulated medications more than a study period, the accumulated supply was truncated at a 
study period (Choudhry et al., 2009). The detailed methods used for this study were along with 
SAS program codes by Wang (2013). 
Aim 2: The proportion of out-of-pocket pharmacy costs. 
The outcome variable of Aims 2 was the proportion of out-of-pocket costs for 
prescription drugs, which was defined as out-of-pocket costs at pharmacies divided by total 
pharmacy expenses. The MEPS obtains information on out-of-pocket pharmacy expenditures 
directly from pharmacies in order to reduce survey participant recall bias due to self-report. Out-
of-pocket pharmacy costs were measured as actual dollar values of the total amount of payments 
by patients or family for prescription drugs during five rounds. Imputed out-of-pocket pharmacy 
costs expenditures were used for this study since AHRQ provides only imputed versions of the 
out-of-pocket pharmacy expenditure variables. 
Statistical analysis plan for Aim 1. 
A cross-sectional study design was employed for Aim 1. The outcome variable of Aim 1 
was medication adherence. To measure medication adherence, an annual PDC in 2011 was used 




into adherent (PDC ≥ 80%) and non-adherent (< 80%). If the sample achieved 80% or greater of 
PDC, they were defined as adherent and vice versa. 
For Aim 1-1, the sample, adult diabetes patients aged 19 years and older who were 
prescribed diabetes medications, was dichotomized based on medication adherence (≥ 80%: 
adherent, < 80%: non-adherent) and the variables of patient, health system, and provider factors 
were compared using a Wald chi-square test and a simple logistic regression for categorical and 
continuous variables, respectively. Variables that achieved a p-value of ≤ 0.05 were eligible for 
entry into the multivariate logistic regression models in Aim 1-2. 
Aim 1-2 aimed to identify a subset of independent predictors of medication adherence. 
All variables that met the p-value criteria in the previous analyses from Aim 1-1 were entered 
into the regression model. In addition, variables that were consistently (≥ 5 studies) related to 
adherence to diabetes medications in the literature review (age, gender, race/ethnicity, depressive 
symptoms, out-of-pocket pharmacy costs, diabetes self-efficacy, and family support) were added 
and remained in the regression model regardless of the p-values. Based on the results from each 
test, variables that did not meet the p-value criteria of < .05 were excluded from the model. In 
addition, known predictors in the literature review were retained in the model regardless of their 
p-values. This step was repeated until a full model for adherence to diabetes medication was 
identified. All possible interaction terms were also explored. 
Statistical analysis plan for Aim 2. 
An interrupted time series design was employed for Aim 2-1 to examine the trends of the 
proportion of out-of-pocket costs for prescription drugs in elderly compared to non-elderly adults 
with diabetes. In addition, difference-in-difference analyses were performed to answer Aim 2-2 




proportion of out-of-pocket costs for prescription drugs in both groups prior to and subsequent to 
Part D. The variable of interest for Aim 2 was the proportion of out-of-pocket costs for 
prescription drugs. This was defined as out-of-pocket costs for prescription drugs (the amount 
paid by family or by participants themselves) at pharmacies divided by total pharmacy expenses, 
and ranged from 0 to 100%. The sample for Aim 2 consisted of adults who were aged 65 years 
and older with diabetes and who had been prescribed diabetes medications (target group), 
including Medicare Part D beneficiaries and non-beneficiaries in addition to a comparison group 
selected from among non-elderly adults with diabetes aged 50−60 years. The comparison group 
did not include those who were 61−64 years old because each MEPS panel was followed for two 
years, and therefore, a minimum 3-year age gap between the target and comparison groups was 
necessary to avoid the overlap of the target and comparison groups (e.g., adults aged 64 years old 
in the comparison group will turn 65 after their birth day this current year). 
First, the characteristics of the target and comparison groups were compared. Within the 
target group, the characteristics of Medicare Part D beneficiaries were compared to those of non-
beneficiaries. 
In addition, the proportion of Part D beneficiaries with diabetes who fell into the coverage gap 
and catastrophic coverage from 2006 to 2011 was examined based on the Part D design of each 
year. Table 3.3 presents the changes in actual dollar values of each parameter in Medicare Part D 
design by year, from 2006 to 2011. Because of being based on the original dollar values of each 





Changes in Medicare Part D Plan Parameters from 2006 to 2011 
 2006 2007 2008 2009 2010 2011 
Deductible $250 $265 $275 $295 $310 $310 
Initial coverage limit $2,250 $2,400 $2,510 $2,700 $2,830 $2,840 
Catastrophic threshold $3,600 $3,850 $4,050 $4,350 $4,550 $4,550 
 
For the segmented regression of interrupted time series and difference-in-difference 
analyses, however, all dollar values of each year were adjusted to 2011 U.S. dollars because 
actual dollar values for several years (2000−2011) were compared over time. These adjustments 
were in accordance with the inflation rate using the Consumer Price Index and based on the 
recommendation by AHRQ (Medical Expenditure Panel Survey, 2013). 
For Aim 2-1, a segmented regression of interrupted time series analysis was used to 
examine the impact of Medicare Part D on the proportion of out-of-pocket pharmacy 
expenditures over the 12 year period by estimating changes in the slope over time as well as 
comparing 6 years of yearly out-of-pocket pharmacy expenditures before the initiation of 
Medicare Part D (2000–2005) and after Medicare Part D was implemented (2006–2011). Since 
sample size varied by year, weights were adjusted by race/ethnicity using the 2010 U.S. Census 
data (non-Hispanic whites = 63.7%; non-Hispanic blacks = 12.2%; Hispanics = 16.3%; and other 
races = 7.8%) in order to treat each year’s data equally and make weighted sample size 
statistically equivalent year to year. 
The research design diagram for three groups, Medicare Part D beneficiaries, non-




O2, O3, O4, O5, O6), initiation of Medicare Part D (X), followed by post-Medicare Part D period 
(O7, O8, O9, O10, O11, O12). 
O1  O2  O3  O4  O5  O6  X  O7  O8  O9  O10  O11  O12 
O1  O2  O3  O4  O5  O6 (X) O7  O8  O9  O10  O11  O12 
O1  O2  O3  O4  O5  O6       O7  O8  O9  O10  O11  O12 
The following estimated models of the outcome variable, y, the yearly race/ethnicity-
adjusted mean proportion of out-of-pocket pharmacy expenditures were used for three groups: 
y= β0 + βtime • xtime + βpolicy • xpolicy + βtime_post • xtime_post + βMedicare_PartD • xMedicare_PartD+ ε 
 
 Figure 3.3. Graphical illustration of interrupted time series. 
Figure 3.3 depicts a graphical illustration of the interrupted time series. Each coefficient 
has the following interpretation. 
 β0: Intercept. The average proportion of out-of-pocket pharmacy costs in 2000. 
 βtime: Pre-Part D slope. The initial yearly rate of the proportion of out-of-pocket 




 βpolicy: Change in level after the implementation of Part D. Change in the mean 
proportion of out-of-pocket pharmacy costs after the implementation of Medicare 
Part D (2006−2011). 
 βtime_post: Change in slope between pre- and post-Part D. Immediate yearly change 
of the mean proportion of out-of-pocket pharmacy costs between pre- and post-
Part D. 
 βMedicare_PartD: Difference in level between Part D beneficiaries and non-
beneficiaries. Difference in the mean proportion of out-of-pocket pharmacy costs 
between Part D beneficiaries and non-beneficiaries. 
The xtime is the design variable for time, and designates each year from 1 to 12 (e.g., year 
2000=1, year 2001=2…year 2010=11, year 2011=12). The xpolicy is the design variable for 
Medicare Part D implementation (e.g., before Medicare Part D=0 and after Medicare Part D=1). 
The xtime_post is the design variable for time after Part D implementation, assigned 0 to the period 
of pre-Part D and designates each year during post-Part D from 0 to 6 (e.g., year 2006=1, year 
2007=2…year 2011=6). The xMedicare_PartD is the design variable for Medicare Part D enrollment 
status (e.g., Part D non-enrollees=0, Medicare Part D enrollees=1). 
For Aim 2-2, a difference-in-difference analysis was used to estimate causal effects of 
Medicare Part D on the mean proportion of out-of-pocket pharmacy costs by comparing average 
change in the two time periods [pre- (2000−2005) and post-Part D phases (2006−2011)] for the 
target group to the comparison group. This analysis enables to eliminate the effect of potential 
confounding factors by comparing pre- and post- Part D between the target and comparison 
group. 




Opre  X  Opost 
Opre       Opost 
The outcome variable (y), the race/ethnicity-adjusted mean proportion of out-of-pocket 
pharmacy expenditures, is modeled by the following equation: 
y= β0 + βgroup • xgroup + βpolicy • xpolicy + βgroup*policy (xgroup • xpolicy)+ ε 
 
Figure 3.4. Graphical illustration of difference-in-difference. 
Figure 3.4 depicts a graphical illustration of the difference-in-difference. The βgroup is the 
group specific effect, βpolicy is the effect of Medicare Part D for both groups, and βgroup*policy is the 
true Part D effect. The  xgroup is the design variable indexed by group where 0 indicates those 
aged 50‒60 years with diabetes who were prescribed one or more diabetes medications (i.e., 
comparison group) and 1 indicates those aged 65 years and older with diabetes who were 
prescribed one or more diabetes medications (i.e., target group). The xpolicy was indexed by time 
periods xpolicy =0, 1 where 0 designates a time period before Medicare Part went into effect (i.e., 





Prior to developing the dissertation proposal, the investigator completed all required 
online training for human subjects protection. These included modules on the Human Insurance 
Portability and Accountability Act (HIPAA) and required human subjects protection courses 
offered through the Collaborative Institutional Training Initiative (CITI) using Rascal system 
(https://www.rascal.columbia.edu). In addition, the investigator attended the AHRQ MEPS data 
users’ workshops in September 2012, May 2013, and May 2014 as well as the AHRQ Center for 
Financing, Access, and Cost Trends (CFACT) seminar on the impact of financial burdens on 
medication adherence in diabetes using 2005–2009 data. The investigator also participated in a 
SAS workshop offered at the SAS training center in Rockville, Maryland on June 25–27, 2013 to 
gain further knowledge about advanced survey procedures, which are crucial for making 
statistically valid estimates from samples using a complex survey design. 
Human Subjects Protection 
Prior to study initiation, an institutional review board (IRB) application was submitted to 
Columbia University Medical Center (CUMC) in accordance with CUMC IRB policies and 
approved. Following approval by the CUMC IRB, the study protocol was also submitted to 
AHRQ for approval to use a restricted variable, dates on which prescriptions were filled, which 
is restricted for reasons of confidentiality. Following approval by AHRQ, the MEPS data were 
accessed at an approved AHRQ data center in accordance with the AHRQ data center and the 
MEPS confidentiality agreement. For this project, all analyses using restricted data only (Aim 1) 
were performed in a secured room at the Data Center in Rockville, Maryland. According to 




only results that pass the review were taken from the Data Center. Data were only used for 







Chapter IV: Research Findings/Results 
This chapter provides study results for Aim 1 and 2. First, the characteristics of adult 
diabetes patients who adhere to their medications are compared to those who do not, and the 
independent predictors of medication adherence in this population are identified. In addition, 
study findings regarding the trend and comparisons of the average proportions of out-of-pocket 
expenses of total pharmacy expenditures by Medicare Part D coverage over time before (2000‒
2005) and after (2006‒2011) the implementation of Medicare Part D between diabetes patients 
aged 65 years and older (target group) and those aged 50−60 years (comparison group) are 
presented. 
Results for Aim 1 
To compare the characteristics of adherent patients [medication adherence (PDC) ≥ 80%] 
with non-adherent patients, data were limited to the MEPS 2011 datasets for Aim 1 because of 
availability and completeness of data. The variable days’ supply, which is essential for the 
calculation of medication adherence, was first collected in 2010. Although the variable was also 
available in 2010, the MEPS 2010 datasets were not included because most of the restricted 
variable (date refilled prescriptions by pharmacy) and other variables from the restricted MEPS 
dataset in 2010 had missing values, making impossible to match the restricted variable with the 
public use files. 
Data extraction process. 
For Aim 1, data were extracted from the following three public use files from 2011 Full 
Year Consolidated Data File (HC-147), 2011 Medical Conditions File (HC-146), and 2011 







prescriptions) in the 2011 Prescribed Medicine File, which was only accessible at the AHRQ data 
center, was extracted. Figure 4.1 illustrates the data extraction process for Aim 1. 
 
 
Figure 4.1. Data extraction from the MEPS data files for Aim 1. 
Study sample selection. 
The final sample for Aim 1 was adults with diabetes aged 19 years and older who 
completed the supplemental diabetes care survey and filled at least two prescriptions of diabetes 
medication during 2011 to calculate medication adherence. In the analyses for Aim 1, the sample 
was not limited to the elderly (≥ 65 years) as limiting the data to the elderly reduced the sample 
size and the power to detect a significant statistical effect. To calculate medication adherence, at 
least 2 prescription records were needed to determine the period that the medication was supplied 
or covered. Figure 4.2 depicts the process of sample selection from the MEPS in 2011 for Aim 1. 
Restricted use 
: Only accessible   
at the AHRQ Data Center 
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2011 Full Year 
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(HC-147) 


















Figure 4.2. Sample selection process for Aim 1. 
Descriptive characteristics of the study sample. 
Table 4.1 summarizes the descriptive characteristics of the total study sample for Aim 1. 
The final sample for Aim 1 consisted of 992 adults with diabetes who had prescribed diabetes 
medicine records in the 2011 MEPS datasets, including 833 who adhered to their medications 
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represent approximately 10,818,003 non-institutionalized adult diabetes patients in the U.S. 
(9,216,939 adherent; 1,601,064 non-adherent). 
The majority of the subjects in the total sample was either middle-aged or elderly (46.4% 
and 41.2%, respectively). Gender distribution (51.9% male and 48.1% female, respectively) was 
similar. Most of the sample reported their race/ethnicity as non-Hispanic white (67.2%). Nearly 
three-fourths of the total sample reported having a high school education or less (76.0%), and 
were living with family members (77.2%). Approximately 17% of the total sample reported 
having Medicaid coverage during 2011 as either their only form of health insurance or 
concurrently with Medicare coverage. 
On average, subjects in the study sample had lived with diabetes for about 11 years. 
Regarding comorbid conditions, the proportion of subjects who reported depressive symptoms 
was 16.9%. Approximately 13.3% of the sample reported difficulty seeing; of these, about one-
third of them reported being blind (4.8%), while 16.9% reported having a cognitive limitation. 
The majority of the sample had used either one or two ways (55.0% and 35.3%, 
respectively) to acquire diabetes knowledge and 26.0% expressed lack of confidence in their 
diabetes self-care ability. Nearly three-fourths of the sample perceived their physical health as 
poor (74.3%) whereas one-half (46.8%) of the subjects perceived their mental health as poorer 
than that of average Americans. 
Approximately 14.0% of the sample reported currently smoking. The proportion of 
subjects who reported having had screenings within the past year for complications of diabetes, 
including those of the foot and eye, were 35.7% and 28.4%, respectively. On average, subjects in 
this study had an A1c test approximately 7 times within the past year. Nearly all subjects 







cholesterol (99.2%) had been tested in the past year. A majority (77.1%) of the subjects reported 
that they had received flu vaccine within the past year. 
Although most (96.5%) subjects reported having a usual source of care provider, almost 
one-fourth (25.9%) had difficulties getting to usual care provider. The majority of the sample 
(58.8%) was covered by private health insurance. On average, the proportion of out-of-pocket 
costs for prescription drugs was 40%. 
Most subjects expressed satisfaction with their providers; they reported that their doctor 
always listened to them (68.3%), provided clearly understood explanations (64.0%), showed 
respect (69.4%), and spent sufficient time with them (58.5%). 
Findings of Aim 1-1. 
Aim 1-1 of this study was to compare the characteristics of adherent and non-adherent 
adult diabetes patients to identify the variables meeting criteria (p ≤ .05) for entry into an initial 
regression model. Adults with diabetes who were adherent to medications prescribed for 
treatment of diabetes were more likely to be older (p = .002), male (p = .01), and non-Hispanic 
white (p = .02) compared with adults who were non-adherent. Adult diabetes patients who 
adhered to their medications differed from those who did not, as evidenced by their longer 
duration of time with diabetes (p < .0001), undergoing more HbA1c tests (p < .0001), having 
private health insurance, Medicare only, or Medicare and Medicaid (p = .01), having a lower 
proportion of out-of-pocket costs for prescription drug expenditures (p < .0001), and always 
getting comprehensive explanations from their providers (p = .05). Table 4.1 presents the 










Table 4.1  
Comparison of Patient, Health system, and Provider Characteristics of Adherent (≥80%) and Non-adherent Adult Diabetes Patients 
 Total Adherent Non-adherent p - value 
Weighted n (weighted %) 
   Variable                 
10,818,003 9,216,939 (85.2)  1,601,064 (14.8)   
      Categories                Weighted % Weighted % Weighted %  
Patient factors     
Demographics     
   Age 









      45‒64 46.4 45.5 51.8  
      65+ 41.2 43.8 25.9  
   Gender 








.01     
   Race/ethnicity  









      Non-Hispanic black 15.1 14.2 19.9  
      Hispanic 12.1 11.1 18.2  
      Other races 5.6 5.3 7.6  
   Education level  

















 Total Adherent Non-adherent p - value 
Weighted n (weighted %) 
   Variable                 
10,818,003 9,216,939 (85.2)  1,601,064 (14.8)   
      Categories                Weighted % Weighted % Weighted %  
      ≥ College 16.0 16.0 16.0  
      Other degrees 8.0 7.4 11.8  
   Family support  









   Poverty 17.3 17.2 17.6 .91 
Coexisting illness     
   Diabetes duration,  




12.1 ± 0.2 
 
10.0 ± 0.3 
 
< .0001 
   D’Hoore’s Charlson comorbidity index,  




0.9 ± 0.04 
 
0.8 ± 0.06 
 
.09 
   Depressive symptoms (PHQ-2 ≥ 3) 16.9 16.7 18.2 .68 
   Difficulty seeing  13.3 13.3 13.0 .93 
   Blind  4.8 4.9 4.2 .88 
Cognitive function     
   Cognitive limitation  16.9 17.1 15.7 .72 
Illness representation     
   Source of diabetes knowledge  

















 Total Adherent Non-adherent p - value 
Weighted n (weighted %) 
   Variable                 
10,818,003 9,216,939 (85.2)  1,601,064 (14.8)   
      Categories                Weighted % Weighted % Weighted %  
      None 1.8 2.0 0.8 .14 
      1 55.0 55.5 52.4  
      2  35.3 35.0 37.0  
      3 7.9 7.5 9.8  
   Diabetes self-efficacy  









   Perceived health status     
      Poor physical health  









      Poor mental health 









Health behavior     
   Current smoker 14.0 14.4 11.7 .41 
   HbA1c test in past year,  
   mean ±SE (times) 
6.9 7.1 ± 0.4 5.5 ± 0.2 < .0001 
   Foot check in past year 35.7 36.0 33.8 .70 
   Eye check in past year 28.4 28.6 26.8 .71 









 Total Adherent Non-adherent p - value 
Weighted n (weighted %) 
   Variable                 
10,818,003 9,216,939 (85.2)  1,601,064 (14.8)   
      Categories                Weighted % Weighted % Weighted %  
   Cholesterol check in past year 99.1 99.1 99.5 .5 
   Regular checkup in past year 98.6 98.6 98.8 .89 
   Flu vaccine in past year 77.1 78.3 69.5 .12 
Health system factors     
Access to care     
   Having usual care provider 96.5 96.3 97.2 .5 
   Difficulty getting to usual care provider 26.0 26.6 22.3 .28 
Type of health insurance     
   Type of health insurance     
      Private 58.8 60.3 50.5 .01 
      Medicare only 16.6 17.0 14.2  
      Medicaid only 8.4 7.7 12.2  
      Medicare & Medicaid 7.7 8.3 4.5  
      Other public 0.3 0.3 0.5  
      Uninsured 8.2 6.4 18.1  
Out-of-pocket costs     
   Proportion of out-of-pocket costs 




30.0 ± 1.0 
 











 Total Adherent Non-adherent p - value 
Weighted n (weighted %) 
   Variable                 
10,818,003 9,216,939 (85.2)  1,601,064 (14.8)   
      Categories                Weighted % Weighted % Weighted %  
Provider factors     
Satisfaction with providers     
   Always listened to you  68.3 69.1 64.0 .38 
   Always explained so understood 64.0 65.6 54.6 .05 
   Always showed respect  69.4 70.4 64.2 .26 






Findings of Aim 1-2. 
Table 4.2 describes the results from each step of model building for Aim 1-2 to identify 
independent predictors of adherence to diabetes medication among adult diabetes patients. Model 
1 estimated the effect of patient characteristics, health system, and provider factors on adherence 
to medication, controlling for other covariates. Candidates for entry into the first step of the 
model were variables that were different (p ≤ .05) between adherent and non-adherent diabetes 
patients and variables that were theoretically important as they had been identified as a barrier or 
facilitator to medication adherence in five or more studies included in the systematic review of 
literature (Chapter 2). Eleven variables met criteria for entry into Model 1; of these, 8 met the p-
value ≤ .05 criterion [age (p = .002), gender (p = .01), race/ethnicity (p = .02), diabetes duration 
(p < .0001), HbA1c test in 2011 (p < .0001), type of health insurance (p = .01), proportion of out-
of-pocket pharmacy costs of total expenditures for prescribed medicines (p <.0001), doctors’ 
explanations understood (p = .05)] and 3 for theoretical importance as either a barrier (depressive 
symptoms) or facilitator (family support, diabetes self-efficacy) in the systematic review. 
For Model 2, variables that did not satisfy both criterion of a p-value of .05 or less in 
Model 1 and variables did not show consistencies in a barrier/facilitator relationship with 
medication adherence (diabetes duration, number of HbA1c tests in 2011, and type of health 
insurance) were excluded from the model. Following this procedure, 8 variables (age, gender, 
race/ethnicity, family support, depressive symptoms, diabetes self-efficacy, ratio of out-of-
pocket pharmacy costs of total expenditures for prescribed medicines, and doctors’ explanations 
understood) remained in Model 2. Older patients were more likely to be adherent compared to 
younger patients [65+ years: OR= 3.64, 95% CI (1.76, 7.48); 45‒64 years: OR= 2.10, 95% CI 






0.52, 95% CI (0.32, 0.86)]. Non-Hispanic blacks [OR= 0.56, 95% CI (0.33, 0.96)] and Hispanics 
[OR= 0.55, 95% CI (0.33, 0.90)] were less likely to be adherent compared to non-Hispanic 
whites. In addition, patients who had providers who did not always provide understandable 






Table 4.2  
Model Building Steps: Predictors of Adherence to Diabetes Medication among Adult Diabetes 
Patients using Multivariate Logistic Regression Analyses 
Conceptual framework 
   Variable  
      Categories 
Model 1 
preliminary main effects 
Model 2  
main effects model 
OR (95% CL) OR (95% CL) 
Patient factors   
   Age* 





      45‒64 1.96 (0.93, 4.14) 2.10 (1.14, 3.86) 
      65+  2.94 (1.07, 8.11) 3.63 (1.76, 7.48) 
   Gender* 





      Female 0.61 (0.32, 1.15) 0.52 (0.32, 0.86) 
   Race/ethnicity* 





      Non-Hispanic black 0.48 (0.26, 0.90) 0.56 (0.33, 0.96) 
      Hispanic 0.46 (0.25, 0.85) 0.55 (0.33, 0.90) 
      Other races 0.65 (0.25, 1.68) 0.66 (0.27, 1.59) 
   Family support* 
      Living alone 
 
0.73 (0.36, 1.49) 
 
0.63 (0.38, 1.06) 
      Living with other family members 1 (reference) 1 (reference) 
   Depressive symptoms* 
      Yes 
 
1.34 (0.66, 2.75) 
 
1.23 (0.70, 2.15) 
      No 1 (reference) 1 (reference) 
   Diabetes duration (years) 1.01 (0.98, 1.04) Excluded 
   Diabetes self-efficacy* 
      Not Confident 
 
0.92 (0.52, 1.62) 
 
0.54 (0.27, 1.08) 
      Confident 1 (reference) 1 (reference) 







   Variable  
      Categories 
Model 1 
preliminary main effects 
Model 2  
main effects model 
OR (95% CL) OR (95% CL) 
Health system factors   
   Type of health insurance  





      Medicare only  1.14 (0.42, 3.12)  
      Medicaid only  0.71 (0.35, 1.44)  
      Medicare & Medicaid  1.94 (0.51, 7.36)  
      Other public 0.60 (0.04, 9.71)  
      Uninsured 0.54 (0.19, 1.52)  
   Proportion of out-of-pocket costs  
   for total pharmacy expenses* (%) 
0.76 (0.28, 2.04) 0.54 (0.27, 1.08) 
Provider factors   
   Doctor explained so understood 
      Not always 
 
0.53 (0.31, 0.90) 
 
0.61 (0.37, 0.98) 
      Always 1 (reference) 1 (reference) 
Note: An asterisk (*) indicates theoretically important variables that ≥ 5 studies identified the 






Several plausible interaction terms — race/ethnicity*depression, gender*depression, 
age*depression — were also tested, however, none were statistically significant at the p < .05 
level, and adding these interaction terms did not significantly improve the model. Figure 4.3 is a 
final conceptual framework for Aim 1. 
 







Results for Aim 2 
Study sample selection. 
Subjects 65 years of age and older with diabetes who were prescribed one or more 
diabetes medications during 2000 to 2011 were used as a target group for Aim 2. In the phase of 
the implementation of Medicare Part D, the year after 2006, the target group was classified as 
either Medicare Part D beneficiaries or non-beneficiaries (see Figure 4.4). A comparison group, 
adult diabetes patients who were aged 50‒60 years and prescribed one or more diabetes 
medication, was selected from the same period to identify the true effect of Medicare Part D by 








Figure 4.4. Sample selection process for Aim 2, before and after 2006. 
Descriptive characteristics of the study sample. 
Table 4.3 presents characteristics of the target group (≥ 65 years) compared to the 
comparison group (50‒60 years) by year. The target group consisted of 4,717 diabetes patients 
aged 65 years and older including both Part D beneficiaries and non-beneficiaries. The 
comparison group consisted of 3,459 adult diabetes patients who were aged 50‒60 years old. 
Both groups were similar in distribution of gender, race/ethnicity, and proportion of those who 















Medicare Part D 
beneficiaries
n = 1,558
Medicare Part D 
non-beneficiaries
n = 1,226










50‒60 years with diabetes 
& ≥ 1 diabetes medication
n = 3,459
Age not reported (n = 
2,811) or not met 







However, the comparison group was, on average, had less comorbidity (p-values ranged from 
< .0001 to .3), and had private health insurance, rather than public health insurance (p-values 
ranged from < .0001 to .002). 
Table 4.4 compares characteristics of Part D beneficiaries and non-beneficiaries within 
the target group. Medicare Part D beneficiaries were more likely to be female (p-values ranged 
from .01 to .1), black or Hispanic (p-values ranged from .0001 to .3), and have public health 










Comparison of Characteristics of Target (≥ 65 years) and Comparison Groups (50‒60 years) from 2000 to 2011 
Variable Group Year 
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 
Age, mean 
±SE (years) 

















































<.0001 <.0001 <.0001 <.0001 <.0001 <.0001 <.0001 <.0001 <.0001 <.0001 <.0001 <.0001 
Female 
(weighted %) 
≥ 65yrs 59.1 60.6 53.3 56.3 55.2 53.3 52.4 54.0 60.8 53.5 54.2 50.4 
50‒60yrs 58.8 39.6 44.7 53.3 49.7 48.7 51.4 44.1 44.5 46.3 52.5 48.2 












































































































p-value .03 .2 .01 .07 .6 .7 .06 .0006 .6 .05 .06 .01 
D’Hoore’s 
Charlson 


































































    
    

















































































.002 <.0001 <.0001 <.0001 <.0001 <.0001 <.0001 <.0001 <.0001 <.0001 <.0001 <.0001 
Problems 





≥ 65yrs NR NR NR NR NR 4.4 4.1 1.5 2.2 1.6 3.0 1.5 
50‒60yrs NR NR NR NR NR 4.2 9.2 4.9 6.0 2.8 4.6 6.6 







≥ 65yrs NR NR NR NR NR 8.4 9.2 3.2 3.2 4.4 4.9 3.6 
50‒60yrs NR NR NR NR NR 9.2 15.5 7.9 9.1 4.8 5.7 6.5 











Comparison of Characteristics of Part D Beneficiaries and Non-beneficiaries among Elderly with Diabetes from 2006 to 2011 
Variable Medicare Part D 
Enrollment Status 
 Year 
2006 2007 2008 2009 2010 2011 
Age, mean ±SE 
(years) 
Beneficiaries  74.7 ±0.5 72.8 ±0.4 75.2 ±0.7 73.4 ±0.5 75.1 ±0.5 73.4 ±0.3 
Non-beneficiaries  74.6 ±0.4 73.9 ±0.5 74.8 ±0.5 73.5 ±0.6 73.2 ±0.6 73.0 ±0.3 
p-value  .8 .2 .7 .9 .02 .5 
Female 
(Weighted %) 
Beneficiaries  61.3 60.5 66.8 57.5 58.3 54.3 
Non-beneficiaries  45.2 48.3 54.7 48.7 49.0 48.1 
p-value  .01 .02 .04 .1 .1 .1 
Race 
(Weighted %) 
Beneficiaries     White 
   Black 
   Hispanic 

























Non-beneficiaries    White 
   Black 
   Hispanic 

























p-value  .3 .0003 .0002 .003 .0001 .0001 
D’Hoore’s 
Charlson 
Beneficiaries  0.7 ±0.1 0.8 ±0.1 1.4 ±0.2 1.4 ±0.1 1.4 ±0.2 1.1 ±0.1 









Variable Medicare Part D 
Enrollment Status 
 Year 
2006 2007 2008 2009 2010 2011 
comorbidity 
index, mean ±SE 




    
Beneficiaries    Any private 
   (supplemental) 
   Public only 

























Non-beneficiaries    Any private 
   Public only 

























Beneficiaries  6.8 1.1 2.8 0.4 4.5 2.3 
Non-beneficiaries  1.2 1.3 1.7 2.6 0.2 0.9 
p-value  .02 .8 .5 .2 .02 .1 





Beneficiaries  11.9 4.4 4.4 5.6 6.3 4.8 
Non-beneficiaries  7.2 2.2 2.3 3.5 2.4 2.6 






Figure 4.5 shows the proportions of Part D beneficiaries and non-beneficiaries with 
diabetes from 2006 to 2011. The proportion of Part D beneficiaries with diabetes gradually 
increased from 45.3% in 2006 to 51.7% in 2011, whereas non-beneficiaries with diabetes 
showed a declining trend from 54.7% to 48.3% over the six year period. In addition, since 2008, 
the enrollment rate in Part D exceeded the proportion of non-beneficiaries among elderly 
diabetes patients who received prescribed diabetes medications. 
 
Figure 4.5. Proportions of Part D beneficiaries versus non-beneficiaries among elderly with 
diabetes from 2006 to 2011. 
Figure 4.6 illustrates the proportion of Part D beneficiaries with diabetes who had 
reached the initial coverage limit, coverage gap, and catastrophic coverage from 2006 to 2011. 
The proportion of diabetes patients who reached the catastrophic coverage (> catastrophic 
threshold) gradually increased from 39.9% to 56.1%. and overall proportion of Medicare Part D 
beneficiaries with diabetes who exceeded the initial coverage limit and were thus required to 
assume full responsibility for cost of their prescription drugs during the coverage gap period 
2006 2007 2008 2009 2010 2011
Beneficiaries 45.3% 48.9% 51.5% 50.3% 53.6% 51.7%








Proportions of Part D Beneficiaries versus Non-beneficiaries 






increased from 58.1% to 72.1% (see Figure 4.6). This is significantly higher than the rate 
reported in prior studies, which showed approximately 25% of Medicare Part D beneficiaries 
with diabetes enter the coverage gap (Schmittdiel et al., 2009). 
 
Figure 4.6. Proportions of those who had reached the initial coverage limit, coverage gap, and 
catastrophic coverage among Part D beneficiaries with diabetes from 2006 to 2011. 
Findings of Aim 2-1. 
To answer Aim 2-1, trend of the yearly race/ethnicity-adjusted proportion of out-of-
pocket costs for total pharmacy expenditures from 2000 to 2011 in the target group was 
compared with that of the comparison group using a segmented regression of interrupted time 
series analysis. 
41.9%
33.0% 28.2% 30.9% 34.4% 27.9%
18.2%
21.9% 24.7% 19.2% 18.8%
16.0%
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Result of a segmented regression of interrupted time series analysis. 
The regression model of the proportion of out-of-pocket pharmacy costs for the target 
group (≥ 65 years) (1) is presented below. The bolded coefficients in the regression model 
indicate they were significant at the p-value .05 level. 
y=56.3 -1.3xtime -13.5xpolicy +0.5xtime_post -5.5xMedicare_PartD. (1) 
Within the target group, a 1.3% yearly decreasing trend (SE = 0.6%, p < .0001) was 
observed in the proportion of out-of-pocket costs of total pharmacy expenditures during the 6 
years preceding Medicare Part D policy initiation. After the implementation of Medicare Part D, 
the yearly rate of decline of the proportion of out-of-pocket pharmacy costs decreased from 1.3% 
to 0.8% per year within the target group; however, the trend change of 0.5% was not statistically 
significant (SE = 0.7%, p = .48). The Medicare Part D policy had an impact on decreasing the 
proportion of out-of-pocket costs of total pharmacy expenditures by 13.5% (SE = 2.2%, p<.0001) 
for all (both Part D beneficiaries and non-beneficiaries) within the target group. However, when 
adjusted for race/ethnicity, Medicare Part D beneficiaries spent 5.5% less (SE = 1.2%, p < .0001) 
on out-of-pocket expenses for total pharmacy costs compared to Medicare Part D non-
beneficiaries. 
The regression models of the proportion of out-of-pocket pharmacy costs in the 
comparison group (50−60 years) (2) (3) are presented below:  
y=47.0 -1.6xtime +1.0xpolicy +0.7xtime_post, (2) 
y=45.1 -1.0xtime. (3) 
In the first step to build a regression model for the comparison group, design variables, 
xtime, xpolicy, and xtime_post were initially entered. The estimating equation in (2) describes the result 






significance level of p-value criterion of less than .05. The final model for the comparison group 
was the equation in (3). In the comparison group, the baseline proportion of out-of-pocket costs 
was 45.1% for total pharmacy expenses and that decreased 1.0% by year. Figure 4.7 depicts 
comparison of those trend lines of yearly race/ethnicity adjusted proportion of out-of-pocket 









Figure 4.7. Trend of yearly race/ethnicity-adjusted proportion of out-of-pocket pharmacy costs among adults with diabetes aged ≥ 65 












































Trend of Yearly Race/ethnicity-adjusted Proportion of Out-of-pocket Pharmacy Costs 
among Adults with Diabetes Aged ≥ 65 Years and 50−60 Years
Who Received One or More Diabetes Medications from 2000 to 2011
Mean proportion of out-of-pocket pharmacy 
costs (DM ≥ 65 yrs)
Mean proportion of out of-pocket pharmacy 
costs (DM 50‒60 yrs)
Trendline of DM ≥ 65 yrs
Trendline of Part D beneficiaries with DM ≥ 
65 yrs
Trendline of Part D non-beneficiaries with 
DM ≥ 65 yrs
Trendline of DM 50‒60 yrs
Medicare Part D
Policy implementation
Target group (≥ 65 years)






Findings of Aim 2-2. 
To answer Aim 2-2, the effect of the implementation of Medicare Part D on the 
proportion of out-of-pocket costs for prescription drugs for the target group was estimated using 
a difference-in-difference analysis by comparing changes in the proportion of out-of-pocket costs 
for prescription drugs prior to and subsequent to Part D in both groups. 
Result of a difference-in-difference analysis. 
 The regression model of race/ethnicity-adjusted mean proportion of out-of-pocket 
pharmacy expenditures is the following equation: 
y= 41.1 + 10.5xgroup - 5.7xpolicy – 16.2 (xgroup • xpolicy) 
Figure 4.8 and Table 4.5 present the results of difference-in-difference estimations 
graphically and in tabular form, respectively, of the mean proportion of out-of-pocket pharmacy 
costs before and after Medicare Part D implementation between the target and comparison 
groups. As demonstrated in Table 4.5, after Part D implementation the mean proportion of out-
of-pocket pharmacy costs significantly decreased by 16.2% in the target group compared to 







True Part D Effect: Difference-in-difference Estimates of the Mean Proportion of Out-of-pocket 
Pharmacy Costs after the Implementation of Medicare Part D between the Target (≥ 65 years) 





Mean proportion of out-of-pocket pharmacy costs 
β (SE) 
p-value 
Pre-Part D  
(2000‒2005) 
Post-Part D  
(2006‒2011) 
Difference 
Age 65 years and older 51.6 (0.9) 29.7 (0.5)  -21.9 (1.1) < .0001 
Age 50‒60 years 41.1 (1.0) 35.4 (0.8) -5.7 (1.3) < .0001 
True Part D effect 
(Δ Difference) 







Figure 4.8. True Part D effect: Comparison of change in the mean proportion of out-of-pocket 
pharmacy costs after the implementation of Medicare Part D between diabetes patients aged ≥ 65 









































True Part D Effect: Comparison of Change in the Mean 
Proportion of Out-of-pocket Pharmacy Costs after the 
Implementation of Medicare Part D between Diabetes 
Patients aged ≥ 65 years and Those aged 50‒60 years
Diabetes patients aged ≥ 65 
years (actual change under 
Part D)
Diabetes patients aged 
50‒60 years (actual change 
under Part D)
Diabetes patients aged ≥ 65 
years (assumed change 
without Part D)







Chapter V: Summary, Discussion, Conclusions, and Recommendations 
This chapter summarizes and interprets key study findings, compares findings of this 
study with pertinent past research, and provides possible explanations where finding may differ 
from past research. Limitations and methodological weaknesses of this study are also described. 
Lastly, based on the findings, implications for policy and practice are discussed and 
recommendations for future research are addressed. 
Summary and Discussion of Key Findings 
Predictors of medication adherence in adults with diabetes. 
This study explored patient, health system, and provider factors associated with 
medication adherence in adults with diabetes. Of 11 variables meeting criteria for model entry, 
only three patient level variables (age, gender, race/ethnicity) and one provider level variable 
(provider communication) were associated with medication adherence in this sample. Younger, 
female, non-Hispanic black and Hispanic adult diabetes patients and those who had providers 
who did not always provide comprehensive explanations regarding treatment and medications 
were less likely to adhere to their diabetes medications compared with the reference group. 
Despite their lack of statistical significance in relation to medication adherence in this study, the 
variables family support, depressive symptoms, diabetes self-efficacy, and the proportion of out-
of-pocket pharmacy costs were retained in the final model because of theoretical relevance as 
each has been consistently shown to be significantly associated with medication adherence in 
previous studies. 
The final model consisted of a dependent variable, medication adherence, and other 






diabetes self-efficacy), health system (out-of-pocket pharmacy costs), and provider factors 
(doctor’s comprehensive explanations). 
Patient factors. 
Age. 
In prior studies, the association between age and medication adherence has been 
inconsistent. Variations in this relationship seemed to be determined by the manner in which the 
researchers defined the age inclusion criteria for sampling (e.g., adults aged between 18 and 65 
years), and the way in which they classified age groups (e.g., some studies considered age as a 
continuous variable whereas others classified age into several groups, for example, 18−29, 
30−49, and 50−64 years). Although there was no conclusive association between age and 
medication adherence, a majority of prior studies have found that older patients were more likely 
to be adherent, rather than non-adherent (Balkrishnan et al., 2004; Chao et al., 2007; Cheong et 
al., 2008; Chernew et al., 2008; Fisher et al., 2010; Gibson et al., 2010; Jamous et al., 2011; 
Kaissi & Parchman, 2009; Oladapo et al., 2012; Patel et al., 2010; M. Pawaskar et al., 2010; 
Rozenfeld et al., 2008; Shenolikar et al., 2006b; Sherman et al., 2011; Tiv et al., 2012; White et 
al., 2012; Yang et al., 2009). Consistent with the majority of the studies examined in the review, 
in this study, older adult diabetes patients were more likely than younger patients to be adherent 
controlling for other covariates. 
The reasons for non-adherence may differ by age group (Okoronkwo, Okeke, 
Chinweuba, & Iheanacho, 2013). For example, Okoronkwo et al. (2013) found that younger 
patients (20‒29 years) who were non-adherent tended to overlook the negative consequences of 
non-adherence and did not feel the need to take medications, while middle-aged patients (40‒49 






The main reason for non-adherent in younger patients was based on their health beliefs, which 
might influence their health behaviors whereas non-adherence in middle-aged patients is usually 
unintentional because they simply forget to take their medications probably due to cognitive 
decline or their busy schedules (Okoronkwo et al., 2013). Therefore, non-adherence may be 
more challenging to address in younger patients. Providers may reinforce the negative 
consequences of non-adherence and to modify negative beliefs about medication especially for 
younger patients. 
Gender.  
Lower adherence in females has been widely shown in numerous studies examining the 
predictors of medication adherence in diabetes patients (Balkrishnan et al., 2006; Chernew et al., 
2008; Egede et al., 2011; Gibson et al., 2010; Gu et al., 2010; Patel et al., 2010; M. Pawaskar et 
al., 2010; Yang et al., 2009). Consistent with the previous findings, in this study, female gender 
was a significant factor associated with non-adherence among adults with diabetes controlling 
for other covariates. There are several plausible explanations for this finding. 
First, one of the common reasons for early discontinuation or poor adherence is side 
effects from medication. However, females are often underrepresented in clinical trials, 
particularly in Phase I and II experimental drug trials, despite legislative guidelines requiring the 
inclusion of women in clinical trials. Therefore, side effects in females remain unknown. 
Because there is limited research on the side effects of diabetes medications in females, it 
may be difficult for health providers to identify side effects and address management. Providers 
might not recognize gender-specific side effects of the medication and such symptoms are 
possibly ignored because clinical trials and post-marketing surveillance focused on gender-






medications than those experienced by males may not know how to report the adverse events to 
their providers. Rather than consulting with their providers and switching their treatment plans, 
females might want to avoid undesirable adverse reactions to drugs by discontinuing their 
medications. 
Additionally, it is plausible that gender disparity in medication adherence could be 
explained by depression or depressive symptoms. Depression or depressive symptoms are well-
known factors that are significantly related to medication non-adherence as shown in the review 
(Chapter 2). A recent systematic review found that females are more likely to be depressed than 
males among diabetes patients (Roy & Lloyd, 2012). Because the prevalence of depression in 
females is significantly higher than that in males across all age groups in the U.S. (Centers for 
Disease Control and Prevention, 2012), it may influence the higher non-adherence rates in 
females. 
Moreover, the role as a family caregiver may be related to lower adherence in females. 
Caregivers may suffer from various health problems because they feel stressed and are less 
focused on addressing their health. A majority of caregivers at home are females. 
Race/ethnicity. 
Non-Hispanic blacks and Hispanics were less likely to be adherent compared with non-
Hispanic whites controlling for other covariates. This finding is consistent with studies 
examining medication adherence among different races and ethnicities (Balkrishnan et al., 2006; 
Balkrishnan et al., 2004; Egede et al., 2011; Kreyenbuhl et al., 2010; Osborn et al., 2011; Patel et 
al., 2010; M. Pawaskar et al., 2010; Shenolikar et al., 2006b; Yang et al., 2009). Poor adherence 
in non-Hispanic blacks and Hispanics may be associated with health disparities in these 






including the lack of educational, social, and economic opportunities compared with whites, non-
Hispanic blacks and Hispanics are more likely to experience difficulties in obtaining and paying 
for health insurances and prescription medications. Additionally, poor health literacy in non-
Hispanic blacks and Hispanics (Osborn et al., 2011) may lead to a lack of faith in the efficacy of 
medications and a lack of trust in health care providers, which result in higher non-adherence 
rates. Educational efforts about the benefits of medication adherence may help lowering non-
adherence rates in these populations. 
Family support. 
Family members play a substantial role in adherence to medications by encouraging and 
reminding patients living with chronic diseases to take medications. A body of evidence exists 
that says that family support is associated with medication adherence (Albright et al., 2001; 
Mayberry & Osborn, 2012; Tiv et al., 2012). In this study, patients living with family members 
was used as a proxy for family support with the assumption that patients living with family 
members would receive more positive support than those living alone. Therefore, the non-
adherence rate would be higher among adult diabetes patients who were living alone compared 
with those living with family members. However, living with other family members does not 
necessarily equate to receiving positive support from them. Instead, someone living with family 
members may experience a family burden, rather than support, which may discourage adherence. 
Therefore, residing with family members does not adequately capture family support. In this 
study, family support was not associated with medication adherence. 
Depression/depressive symptoms. 
Inconsistent with the findings from other studies in the systematic review (Chao et al., 






Gonzalez et al., 2008; Katon et al., 2009; Kilbourne, Reynolds, et al., 2005; Kreyenbuhl et al., 
2010; Lin et al., 2004; Nau et al., 2007; Osborn & Egede, 2012; Parada et al., 2012; Piette et al., 
2005), this study failed to find any relationship between depressive symptoms and medication 
adherence controlling for other covariates. Bell et al. (2010) also found that depression was not 
associated with adherence. 
One plausible explanation for this conflicting finding might be due to the tool, the Patient 
Health Questionnaire-2 (PHQ-2), used for measuring depressive symptoms. Although the PHQ-2 
is a well-known tool to screen for depression, it may not be sensitive for detecting depression as 
PHQ-2 scores with a cutoff of 3 or higher had good specificity, but poor sensitivity (Arroll et al., 
2010). Furthermore, the instrument only measures the frequency of depressive moods during the 
previous two weeks, which would not capture depressive symptoms that occurred earlier. 
Because the PHQ-2 was administered once a year at round 4 for the previous year’s cohort or at 
round 2 for the current year’s cohort, depressive symptoms in the rest of the period, before or 
after that point of time, might be missed. 
Diabetes self-efficacy. 
Self-care is essential for diabetes management to prevent the negative consequences of 
poor glycemic control. Except for the findings of Sarkar et al. (2006), diabetes self-efficacy has 
been associated with better adherence to diabetes medication in other relevant studies (Chao et 
al., 2005; Hernandez-Tejada et al., 2012; Munir et al., 2009; Scollan-Koliopoulos et al., 2007; 
Tiv et al., 2012). 
In this study, however, no difference in diabetes self-efficacy was found between 
adherent and non-adherent patients controlling for other covariates. This finding might have 






efficacy. In other prior studies, researchers used either a validated diabetes self-efficacy scale 
(Hernandez-Tejada et al., 2012; Munir et al., 2009; Sarkar et al., 2006) or included one item 
associated with medication-specific self-efficacy (Chao et al., 2005). This study used a single 
item available in the MEPS to measure a patient’s confidence level in general diabetes self-care. 
However, this one item is not sufficient to capture self-efficacy nor validated. 
Health system factors: Out-of-pocket pharmacy costs. 
Previous researchers have found that higher out-of-pocket pharmacy costs were inversely 
related to better medication adherence among diabetes patients (G. R. Bailey et al., 2012; 
Colombi et al., 2008; Gibson et al., 2010; Gu et al., 2010; Mackey et al., 2012; Ngo-Metzger et 
al., 2012; Piette et al., 2005; Tiv et al., 2012). However, this study failed to find a correlation 
between the proportion of out-of-pocket costs of total pharmacy expenses and medication non-
adherence controlling for other covariates. There are two possible explanations for the lack of 
correlation. 
First, difficulty in distinguishing temporality between medication adherence and out-of-
pocket pharmacy costs may account for the insignificant result. Both variables, medication 
adherence and out-of-pocket pharmacy costs, were measured by the year. This study showed that 
the majority of elderly with diabetes exceeded the initial threshold limit of Medicare Part D and 
that they should pay the full cost of their medications during the coverage gap period. Therefore, 
patients may get discouraged and discontinue taking their medications when they have higher 
financial burdens of prescription drugs. Alternatively, if patient continue their drugs, they are 
more likely to have high drug spending. Thus, non-adherent patients could be either those who 






Furthermore, failure to identify an association between out-of-pocket pharmacy costs and 
medication adherence among adult diabetes patients may be because of the treatment fidelity in 
chronic disease patients. Higher out-of-pocket pharmacy costs may increase the risk of non-
adherence. However, the reasons for non-adherence were not just simply due to high out-of-
pocket pharmacy costs, as chronic disease patients have built long-term relationships with their 
providers and tend to follow their instructions well. 
Provider factors: Satisfaction with providers. 
Controlling for other covariates, diabetes patients who had providers who did not always 
provide comprehensive explanations were less likely to be adherent, which is consistent with the 
findings of previous studies (Colby et al., 2012; Hanko et al., 2007; Heisler et al., 2007; Mackey 
et al., 2012; Ratanawongsa et al., 2013; Tiv et al., 2012; Williams et al., 2009). Ratanawongsa et 
al. (2013) recently found that poor communication with providers was independently associated 
with medication adherence for oral diabetes medications. It is crucial for patients to understand 
their treatment to be adherent. Communication and rapport between patients and providers can 






The impact of Medicare Part D on the proportion of out-of-pocket costs of total 
pharmacy expenses.  
This study found that during the years 2000 to 2011 pharmacy out-of-pocket costs 
decreased for both beneficiaries and non-beneficiaries. It may be that insurance companies were 
preparing for initiation of the Medicare Part D benefit for seniors by redesigning their plans to be 
compatible with the Part D regulations. 
Following implementation of Part D, annual spending on out-of-pocket pharmacy costs 
was less for Part D beneficiaries compared to non-beneficiaries when adjusted for race and 
ethnicity. This finding indicates that Part D had a significant influence in lowering out-of-pocket 
drug spending in elderly with diabetes and this population could benefit from Part D. 
Findings of this study are consistent with other research (Briesacher et al., 2011; Millett, 
Everett, Matheson, Bindman, & Mainous, 2010; Mott et al., 2010; Safran et al., 2010; Yin et al., 
2008). Briesacher et al. (2011) found that Part D resulted in decreases in out-of-pocket pharmacy 
costs among general Part D beneficiaries, except in patients with poor health and low income 
beneficiaries without Medicaid. Similarly, Safran et al. (2010) and Millett et al. (2010) also 
found that Part D is beneficial in decreasing out-of-pocket prescription drug costs in particular 
for Medicare beneficiaries who previously had limited prescription drug coverage. Patients with 
higher previous out-of-pocket prescription drug spending were more likely to enroll in Part D 
compared to those with lower drug spending (Yin et al., 2008), and Part D beneficiaries who had 
higher initial out-of-pocket drug costs were more likely to experience greater reductions in their 
out-of-pocket drug spending after Part D enrollment, compared to beneficiaries with lower initial 
out-of-pocket pharmacy costs (Mott et al., 2010). Part D beneficiaries with no previous 






to those with stable drug coverage previously (Y. Zhang, Donohue, Lave, et al., 2009). Among 
dual Medicare and Medicaid beneficiaries, however, Part D did not have a significant change on 
out-of-pocket prescription drug spending (Basu et al., 2010; Millett et al., 2010). 
Consistent with the findings of other researchers, this study showed the evidence that Part 
D was successfully implemented to reduce financial burdens of out-of-pocket drug costs for the 
elderly and its effects have been observed to persist. Along with this successful achievement, the 
number of Part D beneficiaries exceeded that of non-beneficiaries among elderly diabetes 
patients starting in 2008. However, the proportion of Part D beneficiaries with diabetes who 
exceeded catastrophic threshold limit have continuously increased, and overall proportion of 
both coverage gap and catastrophic coverage groups considerably increased. 
Conclusion 
This study aimed to explore what factors related to patient adherence to diabetes 
medication among adults with diabetes and to evaluate the effect of Medicare Part D in reducing 
the financial burden of prescription drugs in elderly diabetes patients. In adult diabetes patients, 
adherence to diabetes medications was negatively associated with being younger, female, non-
Hispanic black or Hispanic compared with their respective reference groups. Having a provider 
who did not always provide comprehensive explanations of treatment and medications was also 
associated with lower adherence. Provider communication is the only factor that can be 
modifiable to improve adherence to medication; this data suggests that when providers 
effectively communicate with their patients and try to promote a comprehensive understanding 
about treatment and medications, patients have better medication adherence. 
Moreover, this study also demonstrated that implementation of the Medicare Part D 






expenses for Part D beneficiaries compared to non-beneficiaries, and provided access to 
prescriptions, especially in medically underserved populations including elderly, females, and 
racial/ethnic minorities. As shown in this study, enrollment rates in Part D gradually increased 
and the number of beneficiaries exceeded the number of non-beneficiaries after 2008 among 
elderly with diabetes receiving diabetes medications. Also, more females, non-Hispanic blacks 
and Hispanics were enrolling in Part D plans compared to males and non-Hispanic whites which 
might mitigate some cost-related non-adherence in these vulnerable populations. Furthermore, 
Part D has influenced the prescription drug insurance market regardless of Part D enrollment 
status because both beneficiaries and non-beneficiaries spent a lower proportion of out-of-pocket 
pharmacy costs after the implementation of Part D compared to before. 
Implications for practice. 
Adherence to medications is essential to improve health outcomes but still challenging 
for patients living with diabetes. Based on the findings of this study, health care providers can 
use several strategies to help patients reducing non-adherence to their medications. Findings of 
the systematic review of measurement of medication adherence (Chapter 2) found that there is 
lack of agreement regarding the gold standard for medication adherence and terminology was 
inconsistent with the formulas described; some researchers were largely mixed up using 
terminology and they use different terms for the same pharmacy measure. 
Health professionals need to consider ongoing evaluation of their patients’ medication 
adherence over time using a clearly defined medication adherence measure and adequately 







Further, the systematic review (Chapter 2) supports the routine screening and treatment 
of depression as part of their treatment plans in adult diabetes patients for better adherence to 
diabetes medications and minimize complex medication regimens treating the elderly with 
diabetes. Also, health care providers should understand the circumstances of medication non-
adherence and mitigate any factors associated with non-adherence, such as side-effects, when 
possible. 
In addition, all health care providers need to enhance their understanding of their 
patients’ prescription drug insurance coverage, and help identify best drug options for patients 
who need access to more affordable drugs. Cooperating with social workers, providers can 
implement treatment plans that reduce the risks of cost-related non-adherence for medically 
underserved populations as social workers can identify appropriate resources. This study found 
that racial and gender disparities exist in medication utilization and expenditures, and Medicare 
Part D may be one effective way of helping the elderly access their prescription drugs and lower 
the financial burden of medication. However, choosing an optimal Part D plan is challenging, 
even for physicians (Barnes et al., 2013; Hanoch, Miron-Shatz, Cole, Himmelstein, & Federman, 
2010). Since medical decision-making is often more difficult for patients with lower numeracy 
levels regardless of age (Hanoch et al., 2010; Hanoch, Wood, Barnes, Liu, & Rice, 2011), health 
professionals, as patient advocates, need to offer their patients the most affordable drug options 
depending on their prescription drug insurance, if equivalent drug options are available. 
Health professionals also encourage their patients to be involved in their treatment plans 
for better medication adherence. Ongoing communication between health care providers and 
patients is crucial to improving medication adherence. Health care providers can offer adequate 






comprehensive explanations about expected side effects of medications. Health professionals 
also need to emphasize negative health outcomes of the non-adherence to medications and to 
encourage patients to take their medications as prescribed. 
Implications for policy. 
Recent policies to decrease the cost burden of prescribed medication through the 
initiation of Medicare Part D in 2006, as well as the more recent plan for gradual closure of the 
Part D coverage gap through the Affordable Care Act, were implemented to reduce barriers to 
medication adherence for the elderly. The study provides several policy implications to minimize 
gender and racial disparities in non-adherence and increased access to prescribed drugs through 
the successful implementation of Medicare Part D. 
First of all, national legislative efforts, such as economic incentives or regulation to 
balance gender and racial/ethnic disparities in research, are necessary to better understanding the 
needs of underserved populations. This study found that non-adherence to diabetes medications 
is more prevalent in females, non-Hispanic blacks and Hispanics. In order to eliminate gender 
and racial/ethnic health disparities, targeted research in these populations is the first step to 
enhancing understanding of the underlying factors that affect gender and racial/ethnic disparities 
in health outcomes. Historically, females have been underrepresented in clinical trials, thus 
relatively little is known about the efficacy and side effects of medications in females. Increasing 
the participation of medically underserved populations in research is a starting point for 
understanding these populations, and ultimately will allow the development of targeted 
interventions to achieve better medication adherence. In an effort to eliminate gender and 
racial/ethnic disparities in research, such as increasing participation of females and minorities, 






minorities since 1993 according to the NIH revitalization Act of 1993 (PL 103-43) except when 
there is a compelling reason to exclude them. In September of 2014, the NIH announced its plan 
to invest an additional $10 million for gender balance in research. These measures are necessary 
to the success of adherence efforts in underserved groups. 
System-level efforts to eliminate health disparities in gender and racial/ethnic minorities, 
including the collaborative engagement of community partners, are crucial because these 
disparities in health outcomes may occur as a result of sociodemographic factors that affect the 
minorities, such as poverty, or differences in education, culture and language (Graham & 
Spengler, 2009). The U.S. Department of Health & Human Services (2008) published a report 
entitled “A Strategic Framework for Improving Racial/Ethnic Minority Health and Eliminating 
Racial/Ethnic Health Disparities” that emphasized using the system-level approach to improve 
minority health and reduce racial/ethnic health disparities. Policy makers can utilize this 
framework as a tool to develop implementation and evaluation plans of individual, community 
and national efforts to reduce health disparities in these populations (U.S. Department of Health 
& Human Services, 2008). 
Furthermore, policy makers must be aware of the practical problems that health care 
providers might face in improving care coordination among providers, and consider simplifying 
Part D to make it more comprehensible to the eligible elderly. Medicare Part D is obviously 
beneficial for underserved patients in increasing access to prescription drugs and reducing 
financial burden; however, the selection of a Part D plan is still challenging for the elderly 
because Part D has too many options that were difficult to understand even for physicians 
(Barnes et al., 2013; Hanoch et al., 2010). Furthermore, Part D may result threaten patients’ 






reimbursement for pharmacists. According to Goyal, Patel, and Sansgiry (2010), the delayed 
processing time for reimbursement is a major problem that is discouraging pharmacists. As such 
there is a possibility of pharmacies declining Medicare Part D beneficiaries, which would 
eventually lead to reduced access to their prescription drugs. 
Limitations and Strengths 
Although this study represents a new contribution to the body of knowledge, the findings 
reported herein must be interpreted within the context of the following main limitations. 
First, the findings and interpretations of Aim 1 have limited generalizability. In 
particular, the subjects in Aim 1 were limited to those who had a restricted variable, i.e., the date 
of refill records by pharmacies, on more than two prescriptions of diabetes medication as date of 
refill was necessary for the calculation of medication adherence. The MEPS collected the date of 
refill records of participants who signed the Medical Provider Component Authorization Forms 
that allows contacting their medical providers and pharmacies to release their patients’ medical 
information. Further, pharmacies were limited to those (usually large pharmacy chains such as 
CVS) that agreed to complete the MEPS Medical Provider Component Data Form for 
Pharmacies. As not all participants provided this information, the results from Aim 1 may be 
biased. Also, the findings from Aim 1 may not be generalizable to institutionalized U.S. people. 
Second, due to the cross-sectional nature of this study design, it was unclear to 
distinguish temporality between independent and dependent variables. For example, depressive 
symptoms can change over relatively short periods of time (e.g., one week). However, the MEPS 
collected data about depressive symptoms at only one time point (either round 2 or 4) and do not 
capture depressive symptoms over time. Depressive symptoms measured in this way therefore 






may be present if depressive symptoms were measured over then full year. Furthermore, the 
instruments used in this study might not adequately measure the concepts of interest because this 
study used secondary data, and as such the researcher was not able to control the collection of the 
data. For example, medication adherence estimated from prescription refill records may not 
perfectly reflect adherence behavior. However, the advantage of this method is that it avoids 
social desirability bias, which is a common issue with self-report. 
Third, for Aim 2, this study used different cohorts each year for 12 years rather than 
follow one cohort over time; therefore, the outcomes each year are likely partly due to the 
different characteristics of each cohort. It is unclear to distinguish whether Medicare Part D is 
effective in lowering patient’s spending, or higher out-of-pocket spending patients tended to 
enroll in other prescription drug insurance options rather than Medicare Part D. Further, only one 
modeling approach (linear regression) was employed and not verified using a logistic model or 
other statistical modeling options. 
Despite these limitations, this study contributes significant new evidence to the field. To 
our knowledge, this is the first study to evaluate medication adherence and identify significant 
factors related to medication adherence in adult diabetes patients using the MEPS, national data. 
Furthermore, using interrupted time series analyses, this study assessed the trends in maturation 
over time before the Part D began, to avoid being misled by the results. In addition, the causal 
effects of Medicare Part D on the target group (adults aged ≥ 65 years with diabetes) was 
estimated by using the comparison group (adults aged 50–60 years with diabetes). Finally, 
contrary to Aim 1, the findings from Aim 2 are generalizable to all non-institutionalized U.S. 
elderly with diabetes because data analysis for Aim 2 was performed using the public use files, 






findings of Aim 1 are less generalizable because it used the restricted variables collected from 
the limited sub-sample, survey participants who agreed to contact their pharmacy and whose 
pharmacists completed the survey form for pharmacies. 
Recommendations for Future Research 
Although this study presents several meaningful findings, due to its methodological 
limitations, the evidence regarding how out-of-pocket pharmacy costs affect patient’s non-
adherence to medications and regarding whether the closure of Part D coverage gap is effective 
is preliminary as closure of the Part D coverage gap will not be fully implemented until 2020. 
Further research is required with the following recommendations. 
First, a longitudinal study with multiple measures of the independent variables, such as 
depressive symptoms, would be better suited to answering the question and dealing with 
temporality issues. Even though this study studied factors previously reported to be associated 
with medication adherence, some factors failed to find relationships with medication adherence. 
One plausible explanation of these inconclusive findings might be that some of the concepts 
defined in this study were not appropriately due to the retrospective nature of the study. 
Furthermore, depressive symptoms needed to be measured multiple times due to their instability, 
and in order to be comparable with other independent factors in a relationship with an outcome 
variable. Prospective cohort studies are needed to demonstrate how out-of-pocket pharmacy 
costs affect patient’s behaviors related to medication adherence, and would determine whether 
higher out-of-pocket costs precede lower medication adherence by tracking patient’s out-of-
pocket costs per prescription, dates of prescription refill with the reasons of late refills. 
In addition, future research is required to examine the relationship of poorly studied 






factors that may affect medication adherence but were not included for this study due to limited 
data availability such as perceived risks and benefits of medication. 
Moreover, qualitative research using focus group or interviews is necessary to gain a 
better understanding of the reasons for non-adherence to medications by age, gender, and 
race/ethnicity. 
Finally, limited evidence is available regarding the impact of recent efforts to close the 
Medicare Part D coverage gap on reducing financial burden and improving medication 
adherence in Part D beneficiaries. Further investigation is needed to evaluate the impact of the 
closure of the Medicare Part D coverage gap over time through implementation of the Patient 
Protection and Affordable Care Act of 2010 on reducing the financial burden of prescription 
drugs for Part D beneficiaries. A comparison of baseline out-of-pocket spending at the time of 
enrollment of Part D beneficiaries and non-beneficiaries may be needed in order to prevent 
misinterpretation of the findings. In addition, further studies need to focus on the impact of 
lowering out-of-pocket pharmacy expenditures with the Affordable Care Act (2010) on 
enhancing actual medication utilization and medication adherence as well as short- (e.g., HbA1c 
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Appendix B. Complete Lists of Search Strategies for Systematic Review 1 
MEDLINE – 73 
 
Pharmacy refill.af./ 105 
Pharmacy records.af./ 633 
Pharmacy claim.af./ 121 
1 or 2 or 3/ 855 
Medication adherence.ab,ti./ 3152 
4 and 5/ 79 
limit 6 to (English language and humans)/ 73 
 
PubMed – 170 
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Note: An asterisk (*) indicates the questions that need to be satisfied for “yes” in question 13. 
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Appendix E. Risk of Bias Tool: Health Evidence Bulletins – Wales   
(For observational studies) 
 
Health Evidence Bulletins - Wales: Questions to assist with the critical appraisal of an observational study e.g. 
cohort, case-control, cross-sectional. (Type IV evidence) Sources used: Critical Appraisal Skills Programme (CASP, 
Anglia and Oxford RHA) questions and Polgar A, Thomas SA. Chapter 22. Critical evaluation of published research 
in Introduction to research in the health sciences. 3rd edition. Melbourne: Churchill Livingstone, 1995; Undertaking 
systematic reviews of research on effectiveness. University of York: NHS Centre for Reviews & Dissemination, 









A/ What is this paper about? 
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1. Is the study relevant to the needs of the 
Project? 
   
2. Does the paper address a clearly focused 
issue? 
in terms of  
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- are the aims of the investigation clearly 
stated? 
   
 
B/ Do I trust it? 
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3. Is the choice of study method appropriate?    
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*5. Is confounding and bias considered? 
- Have all possible explanations of the effects 
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- (cohort study) Were the assessors blind to 
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explain the effect?  
- (case-control study) How comparable are the 
cases and controls with respect to potential 
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- (case-control study) Were interventions and 
other exposures assessed in the same way for 
cases and controls?  
- (case-control study) Is it possible that 
overmatching has occurred in that cases and 
controls were matched on factors related to 
exposure? 
*6. (Cohort study) Was follow up for long 
enough? 
- Could all likely effects have appeared in the 
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- Could the effect be transitory?  
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C/ What did they find? 
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7. Are tables/graphs adequately labeled and 
understandable? 
   
*8. Are you confident with the authors' choice 
and use of statistical methods, if employed? 
   
*9. What are the results of this piece of 
research? 
- Are the authors' conclusions adequately 
supported by the information cited? 
   
 
D/ Are the results relevant locally? 
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*10. Can the results be applied to the local 
situation? 
- Consider differences between the local and 
study populations (e.g. cultural, geographical, 
ethical) which could affect the relevance of the 
study. 
   
11. Were all important outcomes/results 
considered? 
   
12. Is any cost-information provided?    
13. Accept for further use as Type IV 
evidence? 
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Appendix F. Survey Contents 
 
Core interviews (Each round) 
 Demographics: age, sex, race/ethnicity, marital status, education attainment, military 
service, poverty status 
 Charge payment: total charges, copayments, out-of-pocket payments, insurance 
payments, reimbursements, discounts, disallowed amounts, balance due, and other 
sources of payment for medical events reported in earlier sections 
 Conditions: physical, and mental health conditions identified through medical events or 
disability days 
 Employment: employment or self-employment status, type of business or industry, firm 
size, how long the person has worked at each job, whether health insurance was offered, 
hours worked, and job titles or main duties, periods of unpaid leave at their job, previous 
jobs and the reasons for not working 
 Health status: physical and mental health status includes limitations in activities of daily 
living (ADLs) and instrumental activities of daily living (IADLs), the use of health aids, 
physical limitations, activity limitations, mental impairments, vision impairments, and 
hearing difficulties 
 Health insurance: including private and public health insurance programs: type of plan, 
name of plan, nature of coverage, duration of coverage, and who pays various costs for 
the policy premiums 
 Utilization: each sample person at the event level: use and expenditures for office- and 







Round 2 and 4 
 Access to Care: identifies whether each household member has a medical provider who 
provides the usual source of care, reasons why members without a usual source of care, 
various aspects of satisfaction with usual care providers, and problems they may have 
experienced in obtaining needed health care 
 Child Preventive Health: general health status, special health care needs, potential 
behavioral problems, accessibility to health care, preventive care, height, and weight of 
any child in the family 
 Satisfaction with health plan and providers: (1) satisfaction information for private 
insurance, Medigap, Medicare managed care programs, Medicaid/SCHIP, and TRICARE 
insurance; (2) ease of access to medical care, need to seek approval for medical 
treatments and delays in care experienced while waiting for approval, ease of access to 
understandable plan information and repercussions of poor access, need to complete 
paperwork and problems filling out paperwork, and an overall rating of the health plan. 
 
Round 3 and 5  
 Preventive Care: any preventive care received, asks about frequency of dental and 
physical check-ups, flu shots, and other preventive health exams 
 Income: federal income tax filing status, specifically about itemized deductions for health 








 Assets: Real estate, businesses, vehicles, investments, other assets, and debts 
 
Supplemental Paper Questionnaires 
 Diabetes Care Survey: given once a year to each person identified as having diabetes; 
includes questions about diabetes related tests and managing diabetes 
 Adult SAQ: given once a year to each adult 18 years old or older; focuses on self-
reported opinions on one’s physical and mental health, other issues related to health care, 
and quality of care measures 
 Cancer SAQ: given only in panel 15 round 5 and panel 16 round 3 to each person 
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Author (year) Study design8 







3 4 *5 *6 7 *8 *9 *10 *11 12 13 
Albright et al. (2001) CS X X O - X O X ? O X X 
Donnan et al. (2002) RC O O O O X O O ? O X O 
Balkrishnan et al. (2003) PC O X O O O O O ? O O O 
Balkrishnan et al. (2004) RC O O O O O O O O O O O 
Lin et al. (2004) CS X O O - X O O O O X O 
Chao et al. (2005) CS X X X - X X O O O X X 
Kilbourne, Reynolds Iii, et al. (2005) PC O O O X O O O ? O X O 
Nau et al. (2005) RC O X X ? X X X ? X X X 
Piette et al. (2005) CS X O O - O O O O O O O 
Balkrishnan et al. (2006) RC O O O O O O O O O O O 
W. C. Lee et al. (2006) RC O O O O X O O ? O X O 
Sarkar et al. (2006) CS X X O - X O O ? O X O 
Shenolikar et al. (2006a) RC O O X O X O X O O O X 
Shenolikar et al. (2006b) RC O O O O O O O O O O O 
Chao et al. (2007) CS X X O - X X O O O X X 
Gonzalez et al. (2007) CS X X O - O O O O O X O 
Hanko et al. (2007)  CS X X X - X O O ? O X X 
Heisler et al. (2007) CS X O O - O O O O O X O 
Kalsekar et al. (2007) RC O O X O O O O O O X O 
Nau et al. (2007) CS X O O - X X X O O X X 
M.  Pawaskar et al. (2007) RC O O O O O O O O O O O 
                                                 
Note: O=Yes, X=No, ?=Can’t tell, -=Not applicable 
An asterisk (*) indicates the questions that need to be satisfied for “yes” in question 13. 
8 Study design: CS=cross-sectional, RC= retrospective cohort, PC=prospective cohort 
9 Quality assessment questions: 3=Is the choice of study method appropriate? 4=Is the population studied appropriate? 5=Is confounding and bias considered? 
6=(cohort study) Was follow up for long enough? 7=Are tables/graphs adequately labeled and understandable? 8=Are you confident with the authors’ choice and 
use of statistical methods if employed? 9=Are the authors’ conclusions adequately supported by the information cited? 10=Can the results be applied to the local 







Author (year) Study design8 







3 4 *5 *6 7 *8 *9 *10 *11 12 13 
Scollan-Koliopoulos et al. (2007) CS X X X - X O X O O X X 
Cheong et al. (2008) RC O O O O O O O ? O O O 
Chernew et al. (2008) RC O X O O X X X ? O O X 
Colombi et al. (2008) RC O O O O X O O ? O O O 
Gonzalez et al. (2008) PC O X O X X O O O O X O 
Rozenfeld et al. (2008) RC O X O X X O X ? O X X 
Kaissi and Parchman (2009) CS X X X - X X O O O X X 
Katon et al. (2009) PC O X O O X O O O O X O 
Mann et al. (2009) CS X X X - X O X O O X X 
Munir et al. (2009) CS X X O - X O O ? O X X 
Williams et al. (2009) CS X X X - O O O O O X O 
Yang et al. (2009) RC O X O X O O O O O X O 
Bell et al. (2010) CS X O O - O O O O O X O 
Dirmaier et al. (2010) PC O O O X O O O ? O X O 
Duru et al. (2010) CS X O O - O O O O O X O 
Fisher et al. (2010) CS X X X - X X X O O X X 
Gibson et al. (2010) CS X O O - X O O ? O O O 
Gu et al. (2010) RC O O O X O O O ? O O O 
Kreyenbuhl et al. (2010) RC O X O X O O O O O O O 
Parchman et al. (2010) PC O X O X X X O O O X O 
Patel et al. (2010) RC O X X ? O X O O O O X 
M. Pawaskar et al. (2010) RC O O O X O O O O O O O 
Al-Qazaz et al. (2011) CS X X O - X O O O O X X 
Egede et al. (2011) PC O X O O O O O O O X O 
Jamous et al. (2011) CS X X X - X O O ? O X X 
Kreyenbuhl et al. (2011) CS X O O - O O O O O X O 
Osborn et al. (2011) CS X X O - O O O O O X O 
Sherman et al. (2011) RC O X X X O X O O O O O 
Aflakseir (2012) CS X X O - O O O ? O X O 
G. R. Bailey et al. (2012) CS X X X - X X O O O O X 
Colby et al. (2012) CS X X O - X O O O O O O 
Hernandez-Tejada et al. (2012) CS X X O - O O O O O X O 







Author (year) Study design8 







3 4 *5 *6 7 *8 *9 *10 *11 12 13 
Mackey et al. (2012) CS X X X - X O O O O O O 
Mayberry and Osborn (2012) CS  X X X - O X O O O X X 
Ngo-Metzger et al. (2012) CS X X O - O O O O O O O 
Oladapo et al. (2012) RC O X O X O O O ? O X O 
Osborn and Egede (2012) CS X X O - O O O O O X O 
Parada et al. (2012) CS X X O - X O O ? O X O 
Raebel et al. (2012) RC O O O ? O O O O O O O 
Schoenthaler et al. (2012) CS X X O - O O O ? O X O 
Smalls et al. (2012) CS X X O - O O O O O X O 
Tiv et al. (2012) CS X X O - X O O ? O X O 
Walker et al. (2012) CS X X O - O O O O O X O 




Note: O=Yes, X=No, ?=Can’t tell, -=Not applicable 
An asterisk (*) indicates the questions that need to be satisfied for “yes” in question 13. 
8 Study design: CS=cross-sectional, RC= retrospective cohort, PC=prospective cohort 
9 Quality assessment questions: 3=Is the choice of study method appropriate? 4=Is the population studied appropriate? 5=Is confounding and bias considered? 
6=(cohort study) Was follow up for long enough? 7=Are tables/graphs adequately labeled and understandable? 8=Are you confident with the authors’ choice and 
use of statistical methods if employed? 9=Are the authors’ conclusions adequately supported by the information cited? 10=Can the results be applied to the local 
situation? 11=Were all important outcomes/results considered? 12=Is any cost-information provided? 13=Accept for further use as Type IV evidence 
